<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">96257</article-id><article-id pub-id-type="doi">10.7554/eLife.96257</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.96257.3</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Dual targeting of histone deacetylases and MYC as potential treatment strategy for H3-K27M pediatric gliomas</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Algranati</surname><given-names>Danielle</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Oren</surname><given-names>Roni</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1228-412X</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Dassa</surname><given-names>Bareket</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Fellus-Alyagor</surname><given-names>Liat</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Plotnikov</surname><given-names>Alexander</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Barr</surname><given-names>Haim</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Harmelin</surname><given-names>Alon</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>London</surname><given-names>Nir</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Ron</surname><given-names>Guy</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8129-7146</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Furth</surname><given-names>Noa</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8728-519X</contrib-id><email>noa.furth@weizmann.ac.il</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Shema</surname><given-names>Efrat</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3718-593X</contrib-id><email>efrat.shema@weizmann.ac.il</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0316ej306</institution-id><institution>Department of Immunology and Regenerative Biology, Weizmann Institute of Science</institution></institution-wrap><addr-line><named-content content-type="city">Rehovot</named-content></addr-line><country>Israel</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0316ej306</institution-id><institution>Department of Veterinary Resources, Weizmann Institute of Science</institution></institution-wrap><addr-line><named-content content-type="city">Rehovot</named-content></addr-line><country>Israel</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0316ej306</institution-id><institution>Bioinformatics Unit, Department of Life Sciences Core Facilities, Faculty of Biochemistry, Weizmann Institute of Science</institution></institution-wrap><addr-line><named-content content-type="city">Rehovot</named-content></addr-line><country>Israel</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0316ej306</institution-id><institution>Wohl Institute for Drug Discovery of the Nancy and Stephen Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science</institution></institution-wrap><addr-line><named-content content-type="city">Rehovot</named-content></addr-line><country>Israel</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0316ej306</institution-id><institution>Department of Chemical and Structural Biology, Weizmann Institute of Science</institution></institution-wrap><addr-line><named-content content-type="city">Rehovot</named-content></addr-line><country>Israel</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03qxff017</institution-id><institution>Racah Institute of Physics, Hebrew University</institution></institution-wrap><addr-line><named-content content-type="city">Jerusalem</named-content></addr-line><country>Israel</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Dalal</surname><given-names>Yamini</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/040gcmg81</institution-id><institution>National Cancer Institute</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Dalal</surname><given-names>Yamini</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/040gcmg81</institution-id><institution>National Cancer Institute</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>02</day><month>08</month><year>2024</year></pub-date><volume>13</volume><elocation-id>RP96257</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-02-05"><day>05</day><month>02</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-02-11"><day>11</day><month>02</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.02.05.578974"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-04-22"><day>22</day><month>04</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.96257.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-07-04"><day>04</day><month>07</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.96257.2"/></event></pub-history><permissions><copyright-statement>© 2024, Algranati, Oren et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Algranati, Oren et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-96257-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-96257-figures-v1.pdf"/><abstract><p>Diffuse midline gliomas (DMGs) are aggressive and fatal pediatric tumors of the central nervous system that are highly resistant to treatments. Lysine to methionine substitution of residue 27 on histone H3 (H3-K27M) is a driver mutation in DMGs, reshaping the epigenetic landscape of these cells to promote tumorigenesis. H3-K27M gliomas are characterized by deregulation of histone acetylation and methylation pathways, as well as the oncogenic MYC pathway. In search of effective treatment, we examined the therapeutic potential of dual targeting of histone deacetylases (HDACs) and MYC in these tumors. Treatment of H3-K27M patient-derived cells with Sulfopin, an inhibitor shown to block MYC-driven tumors in vivo, in combination with the HDAC inhibitor Vorinostat, resulted in substantial decrease in cell viability. Moreover, transcriptome and epigenome profiling revealed synergistic effect of this drug combination in downregulation of prominent oncogenic pathways such as mTOR. Finally, in vivo studies of patient-derived orthotopic xenograft models showed significant tumor growth reduction in mice treated with the drug combination. These results highlight the combined treatment with PIN1 and HDAC inhibitors as a promising therapeutic approach for these aggressive tumors.</p></abstract><abstract abstract-type="plain-language-summary"><title>eLife digest</title><p>Diffuse midline gliomas (DMGs) are among the most aggressive and fatal brain cancers in children. They are often associated with changes in histones, the proteins that control gene activity and give chromosomes their structure. Most children with DMGs, for example, share the same anomaly in their histone H3 protein (referred to as the H3-K27M mutation). This change affects how small chemical tags called methyl and acetyl groups can be added onto histone 3, which in turn alters the way the protein can switch genes on and off. As a result, tumours start to develop.</p><p>One potential therapeutic strategy against DMGs is to use histone deacetylase inhibitors (HDACi), a promising type of drugs which inhibits the enzymes that remove acetyl groups from histones. Patients can develop resistance to HDACi, however, highlighting the need to explore other approaches. One possibility is to treat patients with several types of drugs, each usually targeting a distinct biological process that contributes to the emergence of cancer. This combined approach can have multiple benefits; the drugs potentially amplify each other’s effect, for example, and it is also less likely for cells to become resistant to more than one compound at the time. In addition, each drug in the combination can be used in a lower dose to reduce side effects and benefit patients.</p><p>DMG tumour cells often feature higher activity levels of a protein known as MYC, which can contribute to the growth of the tumour. Algranati, Oren et al. therefore set out to test whether combining an HDACi known as Vorinostat with a drug that blocks MYC activity (Sulfopin) can act as an effective treatment for this cancer.</p><p>Tumour samples from eight DMG patients were treated with either Sulfopin alone, or Sulfopin in association with Vorinostat. Cells exposed to both drugs were less likely to survive, and additional genetic experiments showed that the combined treatment had resulted in pathways that promote tumour development being blocked. When both Sulfopin and Vorinostat were administered to mice made to grow human DMG tumors, the animals showed a greater reduction in tumor growth.</p><p>Treatment options for DMG are usually limited, with chemotherapy often being ineffective and surgery impossible. The work by Algranati, Oren et al. suggests that combining HDACi and drugs targeting the MYC pathway is a strategy that should be examined further to determine whether clinical applications are possible.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>DMG</kwd><kwd>epigenetics</kwd><kwd>oncogene</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000781</institution-id><institution>European Research Council</institution></institution-wrap></funding-source><award-id>ERC801655</award-id><principal-award-recipient><name><surname>Shema</surname><given-names>Efrat</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003977</institution-id><institution>The Israel Science Foundation</institution></institution-wrap></funding-source><award-id>1881/19</award-id><principal-award-recipient><name><surname>Shema</surname><given-names>Efrat</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100019329</institution-id><institution>Emerson Collective</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Shema</surname><given-names>Efrat</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001698</institution-id><institution>The Israeli Cancer Research Fund</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Shema</surname><given-names>Efrat</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Combined inhibition of oncogenic and epigenetic pathways results in a substantial decrease in the viability and growth of H3-K27M pediatric glioma models.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Diffuse midline gliomas (DMGs) are fatal tumors of the central nervous system that occur primarily in children (<xref ref-type="bibr" rid="bib47">Johung and Monje, 2017</xref>; <xref ref-type="bibr" rid="bib39">Hayden et al., 2021</xref>). Years of clinical trials have revealed that conventional chemotherapy is ineffective, and with no option for complete resection, DMG is now the leading cause of brain tumor-related death in children (<xref ref-type="bibr" rid="bib81">Ostrom et al., 2015</xref>; <xref ref-type="bibr" rid="bib104">Srikanthan et al., 2021</xref>). Sequencing studies showed that up to 80% of the diagnosed children exhibit a lysine 27 to methionine (H3-K27M) mutation in one of the genes encoding histone H3.3 and H3.1 (clinically classified as DMG, H3 K27M-mutant). Numerous subsequent studies revealed pronounced alterations in the epigenetic landscape driven by this histone mutation (<xref ref-type="bibr" rid="bib14">Castel et al., 2015</xref>; <xref ref-type="bibr" rid="bib32">Fontebasso et al., 2014</xref>; <xref ref-type="bibr" rid="bib97">Schwartzentruber et al., 2012</xref>; <xref ref-type="bibr" rid="bib120">Wu et al., 2012</xref>). Among these global epigenetic alterations are a drastic loss of H3 lysine 27 tri-methylation (H3K27me3), concomitant with an increase in H3 lysine 27 acetylation (H3K27ac). These epigenetic alterations were shown to affect transcriptional programs and support tumorigenesis (<xref ref-type="bibr" rid="bib7">Bender et al., 2013</xref>; <xref ref-type="bibr" rid="bib15">Chan et al., 2013</xref>; <xref ref-type="bibr" rid="bib63">Lewis et al., 2013</xref>; <xref ref-type="bibr" rid="bib56">Krug et al., 2019</xref>; <xref ref-type="bibr" rid="bib87">Piunti et al., 2017</xref>; <xref ref-type="bibr" rid="bib36">Harpaz et al., 2022</xref>).</p><p>Detailed characterization of the modes of chromatin deregulation in these tumors pointed toward targeting epigenetic pathways as a promising therapeutic approach (<xref ref-type="bibr" rid="bib29">Filbin and Monje, 2019</xref>). Specifically, pervasive H3K27 acetylation patterns observed in H3-K27M DMGs, along with enrichment of H3K27ac specifically on mutant nucleosomes (<xref ref-type="bibr" rid="bib63">Lewis et al., 2013</xref>; <xref ref-type="bibr" rid="bib56">Krug et al., 2019</xref>; <xref ref-type="bibr" rid="bib87">Piunti et al., 2017</xref>; <xref ref-type="bibr" rid="bib33">Furth et al., 2022</xref>), underscored the histone acetylation pathway as a potential drug target for this cancer. Indeed, pan-histone deacetylase inhibitors (HDACi), such as Vorinostat and Panobinostat, were found to inhibit growth and to restore gene expression alterations observed in H3-K27M malignant gliomas (<xref ref-type="bibr" rid="bib34">Grasso et al., 2015</xref>; <xref ref-type="bibr" rid="bib124">Yin et al., 2007</xref>; <xref ref-type="bibr" rid="bib106">Su et al., 2022</xref>). However, recent studies demonstrated that H3-K27M cells develop resistance to HDACi treatment (<xref ref-type="bibr" rid="bib34">Grasso et al., 2015</xref>; <xref ref-type="bibr" rid="bib106">Su et al., 2022</xref>), stressing the importance of identifying novel drug combinations to induce synergistic inhibition of oncogenic pathways.</p><p>The MYC oncogenic pathway is frequently deregulated in diverse cancers, and thus stands as a prominent therapeutic target (<xref ref-type="bibr" rid="bib16">Chen et al., 2018</xref>). High-level gene amplification of <italic>MYC</italic> is recurrently observed in pediatric high-grade gliomas (<xref ref-type="bibr" rid="bib12">Buczkowicz et al., 2014</xref>; <xref ref-type="bibr" rid="bib68">Mackay et al., 2017</xref>). H3-K27M gliomas show high expression of <italic>MYC</italic> and MYC target genes, due to both epigenetic alterations and structural variants, resulting in a viability dependency on MYC signaling (<xref ref-type="bibr" rid="bib56">Krug et al., 2019</xref>; <xref ref-type="bibr" rid="bib82">Pajovic et al., 2020</xref>; <xref ref-type="bibr" rid="bib23">Dubois et al., 2022</xref>). Unfortunately, directly targeting MYC in tumors is extremely challenging (<xref ref-type="bibr" rid="bib115">Wang et al., 2021</xref>). <xref ref-type="bibr" rid="bib22">Dubiella et al., 2021</xref> have recently developed a unique inhibitor targeting peptidyl-prolyl isomerase NIMA-interacting-1 (PIN1), an upstream regulator of MYC activation (). PIN1 itself is frequently upregulated in many types of cancers, resulting in sustained proliferative signaling and tumor growth (<xref ref-type="bibr" rid="bib25">Farrell et al., 2013</xref>; <xref ref-type="bibr" rid="bib19">D’Artista et al., 2016</xref>). The PIN1 inhibitor, Sulfopin, was shown to downregulate MYC target genes in vitro and to block MYC-driven tumors in murine models of neuroblastoma (<xref ref-type="bibr" rid="bib22">Dubiella et al., 2021</xref>).</p><p>To address the increasing need for an effective combination therapy for H3-K27M DMGs, we tested whether dual targeting of histone acetylation and MYC activation, using Vorinostat and Sulfopin, would yield beneficial outcome. We show that the combined treatment substantially reduces viability of patient-derived glioma cells, in concordance with the inhibition of prominent oncogenic pathways, including the mTOR pathway. Treatment of H3-K27M DMG xenograft mice models with this drug combination led to reduced tumor growth and confirmed downregulation of mTOR in vivo. Together, these results suggest the combination of PIN1 and HDAC inhibitors as a promising therapeutic strategy for H3-K27M gliomas.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Sulfopin inhibits MYC targets and reduces viability of H3-K27M glioma cells</title><p>In light of the important role of MYC in H3-K27M DMGs, we set to explore whether the PIN1 inhibitor, Sulfopin, may affect MYC signaling in these cells and thus confer therapeutic potential. Sulfopin-dependent inhibition of PIN1 was shown to downregulate the expression of MYC target genes in several cancer cell lines (<xref ref-type="bibr" rid="bib22">Dubiella et al., 2021</xref>). Indeed, RNA sequencing (RNA-seq) analysis of H3-K27M-mutant patient-derived glioma cells (SU-DIPG13) treated with Sulfopin revealed strong enrichment of MYC targets among the downregulated genes (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). The genes downregulated by Sulfopin were also enriched for MYC-bound genes identified in several non-glioma cell lines, supporting a role for PIN1 in activation of the MYC pathway also in these glioma cells (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A and B</xref>). Of note, Sulfopin was developed as a covalent inhibitor of PIN1, and did not lead to PIN1 degradation, as previously shown (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>; <xref ref-type="bibr" rid="bib22">Dubiella et al., 2021</xref>). We further validated the decreased expression of prominent MYC targets (<xref ref-type="bibr" rid="bib25">Farrell et al., 2013</xref>; <xref ref-type="bibr" rid="bib41">Hölzel et al., 2005</xref>; <xref ref-type="bibr" rid="bib110">Teng et al., 2004</xref>) upon Sulfopin treatment by RT-qPCR analysis (<xref ref-type="fig" rid="fig1">Figure 1B</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>). Interestingly, Cut&amp;Run analysis (<xref ref-type="bibr" rid="bib102">Skene and Henikoff, 2017</xref>) revealed an increase in H3K27me3 levels, indicative of repressed chromatin (<xref ref-type="bibr" rid="bib28">Ferrari et al., 2014</xref>), around the transcriptional start sites (TSS) of MYC target genes, correlating with silencing of these genes upon PIN1 inhibition (<xref ref-type="fig" rid="fig1">Figure 1C</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref>). Of note, global H3K27me3 distribution on all TSS and gene body regions was not affected by Sulfopin treatment, supporting a specific increase in H3K27me3 on the TSS of MYC target genes (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1F and G</xref>). Furthermore, Sulfopin-unique H3K27me3 peaks (i.e. peaks that were found only in the Sulfopin-treated cells, and not in DMSO-treated cells) were enriched for MYC target genes (<xref ref-type="fig" rid="fig1">Figure 1D</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Sulfopin inhibits MYC signaling and reduces viability of diffuse midline glioma (DMG) cells in an H3-K27M-dependent manner.</title><p>(<bold>A</bold>) Functional enrichment analysis on significantly downregulated genes in SU-DIPG13 cells treated with 10 µM Sulfopin for 12 hr, compared to DMSO. Enrichr algorithm (<xref ref-type="bibr" rid="bib57">Kuleshov et al., 2016</xref>) was used to compare downregulated genes against the Molecular Signatures Database (MSigDB) hallmark gene set (<xref ref-type="bibr" rid="bib64">Liberzon et al., 2015</xref>). Dashed line denotes adjusted p-value=0.05. MYC targets are significantly enriched among the Sulfopin downregulated genes. (<bold>B</bold>) RT-qPCR analysis of selected MYC target genes in SU-DIPG13 cells treated with 10 µM Sulfopin for 12 hr, compared to DMSO. Fold change between Sulfopin and DMSO-treated cells was calculated and the mean ± SD of two technical repeats is shown. (<bold>C</bold>) H3K27me3 Cut&amp;Run read coverage over MYC target genes (‘MYC Targets V1’ hallmark gene set; <xref ref-type="bibr" rid="bib64">Liberzon et al., 2015</xref>, n=200), in SU-DIPG13 cells treated with 10 µM Sulfopin for 8 days compared to DMSO. Sulfopin treatment increases H3K27me3 levels on the transcriptional start sites (TSS) of MYC target genes. (<bold>D</bold>) Functional enrichment analysis of the genes associated with Sulfopin-unique H3K27me3 peaks, in SU-DIPG13 cells treated as in C. Dashed line denotes adjusted p-value=0.05. MYC target gene set (‘MYC Targets V1’ hallmark gene set; <xref ref-type="bibr" rid="bib64">Liberzon et al., 2015</xref>) is mildly enriched among these genes, with adjusted p-value of 0.077. (<bold>E</bold>) Cell viability, as measured by CellTiterGlo, of eight DMG cultures (H3.3K27M: SU-DIPG13, SU-DIPG6, SU-DIPG17, SU-DIPG25, and SU-DIPG50. H3.1K27M: SU-DIPG36, SU-DIPG38, and SU-DIPG21), treated with Sulfopin for 8 days with pulse at day 4, compared to DMSO. Mean ± SD of two technical replicates is shown. Logarithmic scale is used for the x-axis. Sulfopin treatment led to a mild reduction in cell viability in all H3-K27M glioma cultures. (<bold>F</bold>) Cell viability, as measured by CellTiterGlo, of two isogenic DMG cell lines (SU-DIPG13 and BT245) in which the mutant histone was knocked out (KO), treated with the indicated concentration of Sulfopin for 8 days, compared to DMSO. For each cell line and concentration, the fold change in viability between Sulfopin and DMSO-treated cells is shown. For SU-DIPG13 mean±SE of at least two independent experiments is shown. For BT245 mean ± SD of three technical replicates is shown. H3-K27M glioma cells show higher sensitivity to Sulfopin treatment compared to the KO cells. *p&lt;0.05; **p&lt;0.01 (two-sample t-test over all technical replicates). Significance adjusted after Bonferroni correction.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96257-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>The sensitivity of diffuse midline glioma (DMG) cells to Sulfopin correlates with MYC expression levels.</title><p>(<bold>A–B</bold>) Functional enrichment analysis on significantly downregulated genes in SU-DIPG13 cells treated with 10 µM Sulfopin for 12 hr, compared to DMSO. Enrichr (<xref ref-type="bibr" rid="bib57">Kuleshov et al., 2016</xref>) algorithm was used to compare the dataset against the ChEA (<xref ref-type="bibr" rid="bib52">Keenan et al., 2019</xref>) (<bold>A</bold>) and ENCODE TF ChIP (<xref ref-type="bibr" rid="bib24">Dunham et al., 2012</xref>) sets (<bold>B</bold>) databases. Dashed line denotes adjusted p-value=0.05. Sulfopin downregulated genes are strongly enriched for MYC target genes as identified in different non-glioma cell lines (black bars). (<bold>C</bold>) Western blot of SU-DIPG13 treated either with Sulfopin (10 µM, 8 days) or DMSO, using the indicated antibodies. (<bold>D</bold>) RT-qPCR analysis of E2F2 and mTOR genes in SU-DIPG6 cells treated with 10 µM Sulfopin for 12 hr, compared to DMSO. Fold change between Sulfopin and DMSO-treated cells was calculated and the mean ± SD of two technical repeats is shown. (<bold>E</bold>) IGV track of the transcriptional start sites (TSS) region of three MYC targets, PSMC4, NCL, and PES1, showing H3K27me3 coverage in SU-DIPG13 cells treated with 10 µM Sulfopin for 8 days, compared to DMSO. (<bold>F–G</bold>) H3K27me3 coverage over all TSS (<bold>F</bold>) and gene body (<bold>G</bold>), in SU-DIPG13 cells treated as in C. Sulfopin does not affect H3K27me3 global deposition over these regions. (<bold>H</bold>) Percentage of cell viability as measured by CellTiterGlo of SU-DIPG6-GFP and astrocytic-like cells (CRL-1718) treated with Sulfopin (0.5, 1, 3.5, 10, 30 µM) for 4 days, compared to DMSO. Mean ± SD of two technical repeats is shown. SU-DIPG6-GFP cells show higher sensitivity to Sulfopin compared to the astrocytes at all concentrations. (<bold>I–K</bold>) Expression levels of MYC (<bold>I</bold>), ‘MYC Targets V1’ hallmark gene set (<xref ref-type="bibr" rid="bib64">Liberzon et al., 2015</xref>) (<bold>J</bold>), and PIN1 (<bold>K</bold>) in 18 DMG tumor samples and their matched normal samples (<xref ref-type="bibr" rid="bib8">Berlow et al., 2018</xref>). Box plots show center line as median, box limits as upper and lower quartiles, whiskers as minimum and maximum values. Individual data points are shown in gray circles. ***p&lt;0.001 (two-sample t-test). MYC and its target genes show higher expression in the DMG tumor samples, compared to their matched normal samples. (<bold>L–M</bold>) Expression levels of MYC (<bold>K</bold>) and PIN1 (<bold>L</bold>) in WT and H3-K27M DMG tumor samples (n=201) (<xref ref-type="bibr" rid="bib68">Mackay et al., 2017</xref>). Boxplot as in J. ***p&lt;0.001 (two-sample t-test). (<bold>N</bold>) Doubling time (days) and Sulfopin IC50 levels measured in eight DMG cultures. Pearson correlation coefficient (r) is indicated. Gray area depicts 95% confidence interval for regression line. Positive correlation was detected between the two measures. (<bold>O</bold>) Doubling time (days) and MYC expression levels measured in eight DMG cultures. Pearson correlation coefficient (r) is indicated. Gray area depicts 95% confidence interval for regression line. Negative correlation was detected between the two measures. (<bold>P</bold>) MYC expression and Sulfopin IC50 levels measured in eight DMG cultures. Pearson correlation coefficient (r) is indicated. Gray area depicts 95% confidence interval for regression line. Negative correlation was detected between the two measures. (<bold>Q</bold>) H3K27me3 coverage over CpG islands (CGIs), in SU-DIPG13 cells treated as in C. H3K27me3 signal is decreased in the Sulfopin-treated cells compared to the DMSO-treated cells.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Original scan for the western blot analysis shown in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96257-fig1-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata2"><label>Figure 1—figure supplement 1—source data 2.</label><caption><title>Annotation of the original scan for the western blot analysis shown in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96257-fig1-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96257-fig1-figsupp1-v1.tif"/></fig></fig-group><p>We next explored the effect of Sulfopin on the viability of eight patient-derived DMG cultures, harboring either the H3.3-K27M or H3.1-K27M mutation. Inhibition of PIN1 by Sulfopin was previously shown to delay cell cycle progression and thus reduce cell viability after extended treatments of 6–8 days (<xref ref-type="bibr" rid="bib22">Dubiella et al., 2021</xref>). In line with downregulation of MYC signaling, Sulfopin treatment led to a mild reduction in cell viability, conserved across the different cultures (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). To examine whether H3-K27M mutation renders DMG cells more sensitive to Sulfopin treatment, we took advantage of two sets of isogenic H3-K27M-mutant patient-derived DMG cell lines (SU-DIPG13, BT245) in which the <italic>H3F3A</italic>-K27M-mutant allele has been knocked out (KO). In both lines, the reduction in cell viability was partially rescued in the KO cells (<xref ref-type="fig" rid="fig1">Figure 1F</xref>), suggesting higher sensitivity of H3-K27M-mutant cells to MYC inhibition by Sulfopin. These results are in line with previous reports showing H3-K27M-dependent activation of the MYC/RAS axis in mouse and human cells (<xref ref-type="bibr" rid="bib56">Krug et al., 2019</xref>; <xref ref-type="bibr" rid="bib82">Pajovic et al., 2020</xref>; <xref ref-type="bibr" rid="bib23">Dubois et al., 2022</xref>). Of note, DMG cells showed greater sensitivity to the inhibitor compared to human astrocytic-like cells (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1H</xref>).</p><p>To further explore the status of MYC and PIN1 as indicators of response to Sulfopin inhibition, we analyzed published transcriptomic dataset of DMG tumors (<xref ref-type="bibr" rid="bib8">Berlow et al., 2018</xref>). Interestingly, while DMG samples showed significantly higher expression of MYC and its target genes compared to normal samples, PIN1 expression was lower in the cancer compared to matched normal tissue (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1I–K</xref>). Furthermore, H3-K27M-mutant tumors showed higher expression of MYC, compared to H3 WT tumors, while PIN1 levels were reduced across samples (<xref ref-type="bibr" rid="bib68">Mackay et al., 2017</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1L and M</xref>). These results suggest that MYC expression levels, and not PIN1, may determine the sensitivity of H3-K27M cells to Sulfopin treatment. To examine this notion, we measured the expression levels of MYC, as well as the doubling time of the different DMG cultures. The response to Sulfopin treatment (as reflected by IC50 measurements) correlated with the cells’ doubling time (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1N</xref>). Cells that divide faster were more sensitive to Sulfopin treatment, in line with PIN1 role in regulating cell cycle progression, and specifically G2/M transition (<xref ref-type="bibr" rid="bib123">Yeh and Means, 2007</xref>; <xref ref-type="bibr" rid="bib86">Pinch et al., 2020</xref>). As expected, the doubling time negatively correlated with MYC expression, suggesting that MYC levels may predict the response to Sulfopin (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1O</xref>). Indeed, MYC levels negatively correlated with the IC50 of Sulfopin; thus, cells relaying on high MYC activity showed higher sensitivity to Sulfopin (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1P</xref>).</p><p>H3K27me3 levels were shown to be drastically deregulated in DMG cells expressing H3-K27M, with global loss of this modification across the genome, and retention of residual H3K27me3 at CpG islands (CGIs). These residual H3K27me3 levels were shown to be necessary to silence tumor suppressor genes and maintain cell proliferation in DMG cells (<xref ref-type="bibr" rid="bib75">Mohammad et al., 2017</xref>; <xref ref-type="bibr" rid="bib44">Jain et al., 2020</xref>). Interestingly, Sulfopin treatment resulted in reduction of H3K27me3 signal over CGIs, perhaps contributing to Sulfopin-dependent growth inhibition in these cells (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1Q</xref>). Taken together, our results indicate that PIN1 inhibition by Sulfopin downregulated MYC target genes, reduced H3K27me3 levels at CGIs, and led to reduce viability of DMG cells in an H3-K27M-dependent manner.</p></sec><sec id="s2-2"><title>Combination of Sulfopin and Vorinostat elicits robust inhibition of oncogenic pathways and an additive effect on cell viability</title><p>Inspired by the positive outcome of combinatorial drug therapy in H3-K27M DMG models (<xref ref-type="bibr" rid="bib34">Grasso et al., 2015</xref>; <xref ref-type="bibr" rid="bib65">Lin et al., 2019</xref>), we aimed to explore whether combining Sulfopin treatment with an epigenetic drug will further reduce cell viability. H3-K27M gliomas are characterized by deregulation of epigenetic pathways affecting post-translational modifications of lysine 27 (methylation and acetylation) and lysine 4 (methylation) on histone H3 (<xref ref-type="bibr" rid="bib7">Bender et al., 2013</xref>; <xref ref-type="bibr" rid="bib15">Chan et al., 2013</xref>; <xref ref-type="bibr" rid="bib63">Lewis et al., 2013</xref>; <xref ref-type="bibr" rid="bib56">Krug et al., 2019</xref>; <xref ref-type="bibr" rid="bib33">Furth et al., 2022</xref>; <xref ref-type="bibr" rid="bib37">Harutyunyan et al., 2019</xref>). Thus, we explored the effects of combining sub-IC50 concentration of Sulfopin with four epigenetic inhibitors targeting critical components associated with these modifications: (1) EPZ-6438, an inhibitor of EZH2, the catalytic subunit of the PRC2 complex that deposits H3K27me3 (<xref ref-type="bibr" rid="bib96">Schuettengruber et al., 2017</xref>). H3-K27M cells were reported to be sensitive to EZH2 inhibition as they rely on the residual H3K27me3 levels to suppress key tumor suppressor genes (<xref ref-type="bibr" rid="bib87">Piunti et al., 2017</xref>; <xref ref-type="bibr" rid="bib75">Mohammad et al., 2017</xref>; <xref ref-type="bibr" rid="bib105">Stafford et al., 2018</xref>; <xref ref-type="bibr" rid="bib43">Jain et al., 2019</xref>); (2) GSK-J4, an inhibitor of the H3K27me3 demethylase JMJD3 (<xref ref-type="bibr" rid="bib2">Agger et al., 2007</xref>), shown to rescue H3K27me3 levels in H3-K27M gliomas (<xref ref-type="bibr" rid="bib34">Grasso et al., 2015</xref>; <xref ref-type="bibr" rid="bib38">Hashizume et al., 2014</xref>); (3) MM-102, an inhibitor of the H3K4me3 methyltransferase MLL1 (<xref ref-type="bibr" rid="bib96">Schuettengruber et al., 2017</xref>), shown to reduce viability of H3-K27M-mutant cells (<xref ref-type="bibr" rid="bib33">Furth et al., 2022</xref>); and (4) Vorinostat, an HDACi that was shown to have clinical benefit in H3-K27M gliomas (<xref ref-type="bibr" rid="bib34">Grasso et al., 2015</xref>; <xref ref-type="bibr" rid="bib124">Yin et al., 2007</xref>; <xref ref-type="bibr" rid="bib106">Su et al., 2022</xref>). Treatment dosages of these drugs were set according to previous studies (<xref ref-type="bibr" rid="bib75">Mohammad et al., 2017</xref>; <xref ref-type="bibr" rid="bib34">Grasso et al., 2015</xref>; <xref ref-type="bibr" rid="bib33">Furth et al., 2022</xref>). We found that the combination of Sulfopin and Vorinostat (HDACi) had the strongest effect, reducing viability by 80% (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>).</p><p>Next, we adjusted treatment protocols to account for the optimal treatment period for each drug, and examined the effect of this drug combination on the viability of eight H3-K27M-mutant patient-derived DMG cultures, across different dosages (<xref ref-type="fig" rid="fig2">Figure 2A and B</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B–D</xref>). For each pair of concentrations, we calculated a BLISS index; an additive effect of the two drugs was determined as BLISS index ~1 (<xref ref-type="bibr" rid="bib122">Yadav et al., 2015</xref>; <xref ref-type="bibr" rid="bib10">Bliss, 1939</xref>; <xref ref-type="fig" rid="fig2">Figure 2C</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>). While the combined treatment was effective in all the cultures, cells harboring H3.3-K27M showed higher sensitivity (<xref ref-type="fig" rid="fig2">Figure 2D</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F</xref>). Moreover, while an additive effect of Sulfopin and Vorinostat was detected in all the H3.3-K27M DMG cultures in most of the drug doses, for the H3.1-K27M cultures we measured an additive effect only in higher dosages of Vorinostat (<xref ref-type="fig" rid="fig2">Figure 2C–E</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E and F</xref>). In line with the difference in sensitivity, H3.1- and H3.3-K27M cells differed substantially in MYC expression levels, with H3.1-K27M cells expressing significantly lower levels of MYC (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1G</xref>). Indeed, BLISS indexes negatively correlated with MYC expression levels (<xref ref-type="fig" rid="fig2">Figure 2F</xref>), indicating that H3.3-K27M cells, which express higher levels of MYC, are more sensitive to the combination of Sulfopin and Vorinostat. Importantly, this highlights MYC, and MYC target genes, as potential biomarkers of response for the combined treatment. For example, the expression levels of the two MYC targets, NOC4L and PSMD3, negatively correlated with the BLISS indexes and significantly differed between H3.1- and H3.3-K27M cells (<xref ref-type="fig" rid="fig2">Figure 2F</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1H</xref>). Furthermore, these and additional MYC targets were downregulated following the combined treatment in the H3.3-K27M culture, SU-DIPG13 (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1I</xref>). Overall, our data demonstrates that combining Sulfopin treatment with Vorinostat results in an additive effect on the viability of DMG cultures, with H3.3-K27M cells showing higher sensitivity. This is in line with previous studies highlighting clinical and molecular distinction between H3.1- and H3.3-K27M-mutant tumors, which is thought to dictate their targetable vulnerabilities (<xref ref-type="bibr" rid="bib14">Castel et al., 2015</xref>; <xref ref-type="bibr" rid="bib79">Nagaraja et al., 2019</xref>; <xref ref-type="bibr" rid="bib46">Jessa et al., 2022</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Combination of Sulfopin and Vorinostat elicits robust downregulation of oncogenic pathways.</title><p>(<bold>A</bold>) Timeline demonstrating the treatment protocol for the combination of Sulfopin and Vorinostat. (<bold>B</bold>) Percentage of cell viability, as measured by CellTiterGlo of SU-DIPG13 cells treated with Sulfopin and Vorinostat at the indicated concentrations, compared to DMSO. (<bold>C</bold>) BLISS index measured as the ratio between the observed and the expected effect of the combination of Sulfopin and Vorinostat, for each pair of concentrations, in SU-DIPG13. Synergy: Bliss &lt; 1,Additive: Bliss = 1, Antagonist: Bliss &gt; 1. (<bold>D</bold>) Cell viability as measured by CellTiterGlo, of eight diffuse midline glioma (DMG) cultures treated with Sulfopin (0 µM, 2.5 µM, 5 µM, 10 µM, 20 µM, and 40 µM) and Vorinostat (1 µM), compared to DMSO. H3.3-K27M and H3.1-K27M cultures are indicated in blue and orange, respectively. Mean ± SD of two technical replicates is shown. H3.3-K27M cells showed higher sensitivity to the combined treatment compared to H3.1-K27M cells. (<bold>E</bold>) The BLISS index of the combination of Sulfopin (10 µM) and Vorinostat (1 µM), in the indicated cultures. An additive effect was detected in all the H3.3-K27M cultures at this set of concentrations. (<bold>F</bold>) Pearson correlation coefficient matrix of BLISS index of the combined treatment (Sulfopin [10 µM] and Vorinostat [1 µM]) and mRNA levels of MYC and its target genes, in the eight DMG cultures tested. mRNA levels were measured by RT-qPCR (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1G and H</xref>). Blue and yellow colors indicate negative or positive correlation, respectively. Negative correlation was detected between the BLISS indexes and the expression levels of MYC and its target genes. (<bold>G</bold>) Unsupervised hierarchical clustering of expression levels of 620 significantly differentially expressed (DE) genes detected in SU-DIPG13 cells treated with either Sulfopin (10 µM, 8 days), Vorinostat (1 µM, 72 hr), the combination of Sulfopin and Vorinostat or DMSO (see also <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Gene expression rld values (log2 transformed and normalized) were standardized for each gene (row) across all samples. Color intensity corresponds to the standardized expression, low (blue) to high (red). Clusters 1 and 4 demonstrate additive transcriptional patterns associated with the combined treatment. (<bold>H</bold>) Top: Gene set enrichment analysis (GSEA) on SU-DIPG13 treated with combination of 10 µM Sulfopin and 1 µM Vorinostat compared to DMSO, showing significant downregulation of mTORC1 signaling (‘HALLMARK_MTORC1_SIGNALING’ gene set; <xref ref-type="bibr" rid="bib64">Liberzon et al., 2015</xref>) in the combined treatment. NES: normalized enrichment score. FDR: false discovery rate. Bottom: Expression levels of significantly DE genes detected in the combined treatment compared to DMSO that are part of the mTORC1 signaling gene set. <italic>MTOR</italic> gene was added manually to the heatmap. Heatmaps were generated as described in B. (<bold>I</bold>) Top: GSEA on SU-DIPG13 treated as in C, showing significant downregulation of the epigenetic BMI-1 pathway and the oncogenic cAMP pathway in the combined treatment (BMI1_DN.V1_UP; CAMP_UP.V1_UP; Molecular Signatures Database [MSigDB] C6 oncogenic signature; <xref ref-type="bibr" rid="bib119">Wiederschain et al., 2007</xref>; <xref ref-type="bibr" rid="bib113">van Staveren et al., 2006</xref>). Bottom: Expression levels of significantly DE genes detected in the combined treatment compared to DMSO that are part of the BMI-1 and cAMP gene sets. Heatmaps were generated as described B. (<bold>J</bold>) Western blot of SU-DIPG13 treated either with Sulfopin (10 µM, 8 days), Vorinostat (1 µM, 72 hr), the combination of Sulfopin and Vorinostat or DMSO, using the indicated antibodies. β-Tubulin is used as loading control.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Original scan for the western blot analysis shown in <xref ref-type="fig" rid="fig2">Figure 2J</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96257-fig2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Annotation of the original scan for the western blot analysis shown in <xref ref-type="fig" rid="fig2">Figure 2J</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96257-fig2-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96257-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>The additive effect of the combination of Sulfopin and Vorinostat results in downregulation of oncogenic pathways.</title><p>(<bold>A</bold>) Percentage of cell viability, as measured by CellTiterGlo, of SU-DIPG13 treated with 10 µM Sulfopin or with combined treatment of 10 µM Sulfopin and the indicated agent (putative targets left to right: JMJD3, MLL1, EZH2, histone deacetylases [HDAC]), compared to DMSO. For Sulfopin and Vorinostat mean±SE of at least two independent experiments is shown. For all the other drugs mean ± SD of three technical replicates is shown. In the combination of Sulfopin and Vorinostat, only ~20% of cells survive the treatment. ***p&lt;0.001 (two-sample t-test). (<bold>B</bold>) Cell viability, as measured by CellTiterGlo, of eight diffuse midline glioma (DMG) cultures (SU-DIPG13, SU-DIPG6, SU-DIPG17, SU-DIPG25, SU-DIPG50, SU-DIPG36, SU-DIPG38, and SU-DIPG21), treated with the indicated concentrations of Vorinostat for 3 days, compared to DMSO. Mean ± SD of two technical replicates is shown. Logarithmic scale is used for the x-axis. (<bold>C</bold>) Percentage of cell viability, as measured by CellTiterGlo, of seven DMG cultures (SU-DIPG6, SU-DIPG17, SU-DIPG25, SU-DIPG50, SU-DIPG36, SU-DIPG38, and SU-DIPG21), treated with Sulfopin and Vorinostat at the indicated concentrations, compared to DMSO. (<bold>D</bold>) Cell viability as measured by CellTiterGlo, of SU-DIPG13 and SU-DIPG6-GFP cells treated as indicated, relative to DMSO. Mean ± SE of two independent experiments is shown. (<bold>E</bold>) BLISS index for each concentration of Sulfopin and Vorinostat, in the eight DMG cultures indicated in C. Synergy: Bliss &lt; 1,Additive: Bliss = 1, Antagonist: Bliss &gt; 1. Additive effect was detected in the majority of the drug doses of the H3.3-K27M DMG cells, and in the higher dosages of Vorinostat in the H3.1-K27M cells. (<bold>F</bold>) Cell viability as measured by CellTiterGlo, of eight DMG cultures treated with Sulfopin (0 µM, 2.5 µM, 5 µM, 10 µM, 20 µM, and 40 µM) and Vorinostat (0.33 µM), compared to DMSO. H3.3-K27M and H3.1-K27M cultures are indicated in blue and orange, respectively. Mean ± SD of two technical replicates is shown. H3.3-K27M cells showed higher sensitivity to the combined treatment compared to H3.1-K27M cells. (<bold>G–H</bold>) RT-qPCR analysis of MYC, and its target genes NOC4L and PSMD3, in eight DMG cultures. Mean ± SD of two technical repeats is shown. H3.3-K27M cells show higher expression compared to the H3.1-K27M cells. ***p&lt;0.001 (two-sample t-test). (<bold>I</bold>) Normalized expression levels of the indicated MYC target genes in SU-DIPG13 cells treated as described in <xref ref-type="fig" rid="fig2">Figure 2G</xref>. Mean ± SD of three technical repeats is shown. The expression of these genes is reduced following the combined treatment. **p&lt;0.01, ***p&lt;0.001 (two-sample t-test). (<bold>J</bold>) RNA sequencing was performed on SU-DIPG13 treated with either Sulfopin (10 µM, 8 days), Vorinostat (1 µM, 72 hr) or Sulfopin+Vorinosat (10 µM, 8 days and 1 µM, 72 hr), compared to DMSO. Principal component analysis (PCA) of all genes detected by RNA-seq is shown. Three technical repeats are shown. (<bold>K</bold>) Table presenting the total numbers of significantly differentially expressed genes in each treatment compared to DMSO (adjusted p-value≤0.05, |log2FoldChange|≥1, and baseMean≥5). (<bold>L</bold>) Volcano plots presenting all genes detected in each treatment compared to DMSO. Significantly differentially expressed genes are colored. (<bold>M</bold>) Heatmap presenting selected genes from cluster 1 (as shown in <xref ref-type="fig" rid="fig2">Figure 2B</xref>) that were downregulated in the combined treatment compared to DMSO. Color intensity corresponds to the standardized expression, low (blue) to high (red). Only oncogenes and genes that are involved in glioma progression are shown. (<bold>N</bold>) Functional enrichment analysis on genes comprising cluster 1 using Enrichr (<xref ref-type="bibr" rid="bib57">Kuleshov et al., 2016</xref>) algorithm comparing to the Molecular Signatures Database (MSigDB) hallmark gene set collection (<xref ref-type="bibr" rid="bib64">Liberzon et al., 2015</xref>). Dashed line denotes adjusted p-value=0.05. mTORC1 signaling is highly enriched among cluster 1 genes. (<bold>O</bold>) Gene set enrichment analysis (GSEA) on SU-DIPG13 treated with combination of 10 µM Sulfopin and 1 µM Vorinostat compared to DMSO, showing significant downregulation of the mTOR oncogenic signature (MTOR_UP.N4.V1_UP; MSigDB C6 Oncogenic Signature; <xref ref-type="bibr" rid="bib117">Wei et al., 2006</xref>), and the IL-6/JAK/STAT3 signaling pathway (HALLMARK_IL6_JAK_STAT3_SIGNALING; MSigDB hallmark gene set collection; <xref ref-type="bibr" rid="bib64">Liberzon et al., 2015</xref>), in the combined treatment. NES: normalized enrichment score. FDR: false discovery rate. (<bold>P</bold>) RT-qPCR analysis of mTOR gene in SU-DIPG6 cells (left) and SU-DIPG13 (right), treated as indicated in <xref ref-type="fig" rid="fig2">Figure 2G</xref>. Mean ± SD of two technical repeats is shown. The expression of mTOR is reduced following the combined treatment. (<bold>Q</bold>) mTOR expression and BLISS index measured in eight DMG cultures. Pearson correlation coefficient (r) is indicated. Gray area depicts 95% confidence interval for regression line. Negative correlation was detected between the two measures.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96257-fig2-figsupp1-v1.tif"/></fig></fig-group><p>To gain more insights on the molecular mechanisms underlying this effect on viability, we profiled the transcriptome of SU-DIPG13 cells (H3.3-K27M) treated with each of the drugs alone and the combined treatment (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1J</xref>). A total of 494 genes were significantly differentially expressed (DE) in cells treated with the drug combination, compared to only 145 and 167 in cells treated solely with Sulfopin or Vorinostat, respectively (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1K and L</xref>). Hierarchical clustering of all 620 DE genes confirmed strong additive effect of the combined treatment on gene expression, primarily demonstrated by clusters 1 and 4 (<xref ref-type="fig" rid="fig2">Figure 2G</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Cluster 1, consisting of approximately half of the DE genes, was strongly downregulated by the combined treatment, compared to single-agent treated cells. This cluster included genes that play crucial roles in glioma progression such as <italic>MTOR</italic>, <italic>ATF3</italic>, <italic>CREB3</italic>, and <italic>TGFA</italic> (<xref ref-type="bibr" rid="bib5">Annovazzi et al., 2009</xref>; <xref ref-type="bibr" rid="bib67">Ma et al., 2015</xref>; <xref ref-type="bibr" rid="bib121">Xue et al., 2016</xref>; <xref ref-type="bibr" rid="bib109">Tang et al., 1997</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1M</xref>). Moreover, the mTORC1 signaling pathway was highly enriched within the genes comprising cluster 1 (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1N</xref>). Importantly, gene set enrichment analysis (GSEA) revealed that this pathway was significantly enriched in downregulated genes following the combined treatment (<xref ref-type="fig" rid="fig2">Figure 2H</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1O</xref>). Of note, additional epigenetic and oncogenic pathways such as BMI1, cAMP, and IL-6/JAK/STAT3 were significantly downregulated in cells treated with the drug combination (<xref ref-type="bibr" rid="bib1">Abdouh et al., 2009</xref>; <xref ref-type="bibr" rid="bib127">Zhang et al., 2020</xref>; <xref ref-type="bibr" rid="bib118">West et al., 2018</xref>; <xref ref-type="fig" rid="fig2">Figure 2I</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1O</xref>). Reduction in mTOR signaling (mTOR, phospho-mTOR, and phospho-S6; <xref ref-type="bibr" rid="bib53">Kennedy and Lamming, 2016</xref>) and ATF3 was further validated by western blot and RT-qPCR analysis (<xref ref-type="fig" rid="fig2">Figure 2J</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1P</xref>). Importantly, we also confirmed that the combined treatment with Sulfopin and Vorinostat led to induction of p21 (CDKN1A), a prominent tumor suppressor promoting cell cycle arrest and regulated by mTOR signaling (<xref ref-type="bibr" rid="bib99">Shamloo and Usluer, 2019</xref>; <xref ref-type="bibr" rid="bib108">Tahmasebi et al., 2014</xref>; <xref ref-type="bibr" rid="bib18">Cui et al., 2021</xref>; <xref ref-type="fig" rid="fig2">Figure 2H and J</xref>). Finally, exploring mTOR expression in all the tested DMG cultures revealed a strong negative correlation with the BLISS indexes of the combined treatment (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1Q</xref>), suggesting mTOR as a potential biomarker of response for the combined treatment of Sulfopin and Vorinostat. Overall, our data revealed that the combined inhibition of HDACs and MYC results in robust downregulation of prominent oncogenic pathways.</p></sec><sec id="s2-3"><title>Sulfopin attenuates HDACi-mediated accumulation of H3K27ac on genomic regions associated with oncogenic pathways</title><p>We next examined epigenetic features that may underlie the inhibition of oncogenic pathways by the combined treatment (keeping the same experimental setup as shown in <xref ref-type="fig" rid="fig2">Figure 2A</xref>). Inhibition of HDACs is expected to increase and alter genome-wide histone acetylation patterns, including the H3K27ac mark associated with active promoters and enhancers (<xref ref-type="bibr" rid="bib73">Minucci and Pelicci, 2006</xref>). Indeed, global quantification by single-molecule measurements of H3K27-acetylated nucleosomes, as well as western blot analysis, confirmed HDACi-mediated increase in H3K27ac global levels (<xref ref-type="fig" rid="fig3">Figure 3A–C</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). Interestingly, treatment with Sulfopin alone had the opposite effect, reducing the percentage of acetylated nucleosomes (<xref ref-type="fig" rid="fig3">Figure 3B and C</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). As acetylation is coupled with transcription activation, this is in line with the function of Sulfopin as an inhibitor of MYC transcriptional activity (<xref ref-type="bibr" rid="bib22">Dubiella et al., 2021</xref>; <xref ref-type="bibr" rid="bib88">Poole and van Riggelen, 2017</xref>). As a result, the global HDACi-mediated increase in histone acetylation was also attenuated in the combined treatment with Sulfopin (<xref ref-type="fig" rid="fig3">Figure 3B and C</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>The combined treatment attenuates H3K27ac levels on oncogenic targets.</title><p>(<bold>A</bold>) Scheme of the single-molecule imaging experimental setup (<xref ref-type="bibr" rid="bib100">Shema et al., 2016</xref>): cell-derived mono-nucleosomes are anchored in a spatially distributed manner on polyethylene glycol (PEG)-coated surface. Captured nucleosomes are incubated with fluorescently labeled antibodies directed against the H3K27ac modification. Total internal reflection fluorescence (TIRF) microscopy is utilized to record the position and modification state of each nucleosome. Time series images are taken to allow detection of maximal binding events. (<bold>B</bold>) Single-molecule imaging quantification of the percentage of H3K27ac nucleosomes, in SU-DIPG13 cells treated with either Sulfopin (10 µM, 8 days), Vorinostat (1 µM, 72 hr), or the combination of Sulfopin and Vorinostat, normalized to DMSO. Mean fold±SE of at least two independent experiments is shown. H3K27ac global levels are lower in the combined treatment compared to cells treated solely with Vorinostat. *p&lt;0.05 (two-sample t-test). (<bold>C</bold>) SU-DIPG13 cells were treated as in B, and analyzed by western blot using the indicated antibodies. (<bold>D</bold>) Left panel: Heatmap shows H3K27ac read coverage around the transcriptional start sites (TSS) (±5 kb) of the significantly differentially expressed (DE) genes shown in <xref ref-type="fig" rid="fig2">Figure 2G</xref>, in SU-DIPG13 cells treated with the combination of 10 µM Sulfopin and 1 µM Vorinostat versus DMSO. Average coverage is shown on top. Color intensity corresponds to the standardized expression. Clusters 1–4 are indicated. Right panel: The log2 ratio of H3K27ac read coverage in SU-DIPG13 cells treated with the combination of 10 µM Sulfopin and 1 µM Vorinostat vs. DMSO was calculated. Heatmap shows the ratio around the TSS (±5 Kb) of the significantly DE genes shown in <xref ref-type="fig" rid="fig2">Figure 2G</xref>, and average coverage is shown on top. Color intensity corresponds to the ratio between samples, low (red) to high (blue). Clusters 1–4 are indicated, with cluster 1 presenting the strongest local decrease in H3K27ac following the combined treatment compared to DMSO. (<bold>E</bold>) IGV tracks of <italic>MTOR</italic> and <italic>SLC7A5</italic> gene promoters, showing H3K27ac coverage in SU-DIPG13 cells treated as indicated. (<bold>F</bold>) Functional enrichment analysis of the genes linked to enhancers (top targets of high confident enhancers) marked with H3K27ac exclusively in SU-DIPG13 cells treated with Vorinostat, and not in the combined treatment. gProfiler algorithm (<xref ref-type="bibr" rid="bib92">Raudvere et al., 2019</xref>) was used to calculate enrichment against the KEGG pathways DB (<xref ref-type="bibr" rid="bib50">Kanehisa and Goto, 2000</xref>). Dashed line denotes adjusted p-value=0.05. Genes associated with Vorinostat-unique enhancers are enriched for oncogenic signaling pathways. (<bold>G</bold>) IGV track of <italic>AKT3</italic> and <italic>SEC13</italic> linked enhancers, showing H3K27ac coverage in SU-DIPG13 cells treated with 1 µM Vorinostat or the combination of 10 µM Sulfopin and 1 µM Vorinostat. (<bold>H</bold>) Normalized expression levels of <italic>AKT3</italic> and <italic>SEC13</italic> genes in SU-DIPG13 cells treated as in G. Mean ± SD of three technical repeats is shown. *p&lt;0.05 (two-sample t-test).</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Original scan for the western blot analysis shown in <xref ref-type="fig" rid="fig3">Figure 3C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96257-fig3-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>Annotation of the original scan for the western blot analysis shown in <xref ref-type="fig" rid="fig3">Figure 3C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96257-fig3-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96257-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>H3K27ac levels decrease following the combined treatment specifically on oncogenes.</title><p>(<bold>A</bold>) Representative single-molecule images of individual H3K27ac nucleosomes imaged by total internal reflection fluorescence (TIRF) microscopy (as described in <xref ref-type="fig" rid="fig3">Figure 3A</xref>), in SU-DIPG13 treated as described in <xref ref-type="fig" rid="fig3">Figure 3B</xref>. White circles indicate antibody spots, and blue circles indicate TetraSpeck beads that are used for the alignment with the nucleosomes. Number of H3K27ac antibody spots is indicated in each field of view (FOV). (<bold>B</bold>) Averaged expression levels of genes comprising cluster 1 and cluster 4, in control DMSO-treated SU-DIPG13 cells. Three technical replicates are shown. Cluster 1 genes show higher expression levels under basal conditions compared to cluster 4 genes. (<bold>C</bold>) H3K27ac Cut&amp;Run averaged signal over the transcriptional start sites (TSS) of genes comprising cluster 1 and cluster 4, in SU-DIPG13 cells treated as described in <xref ref-type="fig" rid="fig3">Figure 3D</xref>. (<bold>D</bold>) IGV tracks of the cluster 1’ genes <italic>RELB</italic> and <italic>COPB2</italic>, showing H3K27ac coverage upon their promoters in SU-DIPG13 treated as described in <xref ref-type="fig" rid="fig3">Figure 3D</xref>. (<bold>E</bold>) H3K27me3 Cut&amp;Run averaged signal over the TSS of genes comprising cluster 1. (<bold>F</bold>) Proportion of H3K27ac peaks corresponding to the indicated genomic features. Shown are peaks that were detected in both Vorinostat and Sulfopin+Vorinostat-treated cells (shared peaks, bottom line), as well as H3K27ac peaks that were only present in Vorinostat-treated cells and were lost in the combined treatment with Sulfopin (unique peaks). H3K27ac peaks that were lost in the combined treatment with Sulfopin are associated with distal genomic regions. (<bold>G</bold>) Functional enrichment analysis of the genes linked to enhancers (top targets of high confident enhancers), marked with H3K27ac exclusively in SU-DIPG13 cells treated with Vorinostat, and are lost in the combined treatment. gProfiler algorithm (<xref ref-type="bibr" rid="bib92">Raudvere et al., 2019</xref>) was used to calculate enrichment against the WikiPathways gene sets (<xref ref-type="bibr" rid="bib69">Martens et al., 2021</xref>). Dashed line denotes adjusted p-value=0.05. Genes associated with Vorinostat-unique enhancers are enriched for oncogenic signaling pathways. (<bold>H</bold>) IGV track of <italic>JAK1, NFKB2,</italic> and <italic>CD93</italic> enhancer locus, showing H3K27ac coverage in SU-DIPG13 treated with 1 µM Vorinostat or the combination of 10 µM Sulfopin and 1 µM Vorinostat. (<bold>I</bold>) Normalized expression levels of <italic>JAK1, NFKB2,</italic> and <italic>CD93</italic> genes in SU-DIPG13 treated as in F. Mean ± SD of three technical repeats is shown. *p&lt;0.05; ***p&lt;0.001 (two-sample t-test).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96257-fig3-figsupp1-v1.tif"/></fig></fig-group><p>To profile changes in the genomic distribution of H3K27ac and H3K27me3, we applied Cut&amp;Run in SU-DIPG13 cells treated with Vorinostat alone or in combination with Sulfopin. We first examined the promoters of genes DE in the combined treatment (as clustered in <xref ref-type="fig" rid="fig2">Figure 2G</xref>). Genes comprising cluster 1 showed higher basal expression levels compared to genes from cluster 4, and these expression differences were also reflected in higher H3K27ac at these genes’ promoters (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B and C</xref>). Moreover, in accordance with the reduction in RNA expression levels of genes comprising cluster 1, the combined treatment led to the strongest local reduction of H3K27ac levels associated with their promoters (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Specifically, we found that several of the oncogenes that comprise cluster 1, such as mTOR, and mTOR regulator SLC7A5, RELB, and COPB2, showed decreased levels of H3K27ac at their promoters following the combined treatment (<xref ref-type="bibr" rid="bib49">Kanai, 2022</xref>; <xref ref-type="bibr" rid="bib61">Lee et al., 2013</xref>; <xref ref-type="bibr" rid="bib26">Feng et al., 2021</xref>; <xref ref-type="fig" rid="fig3">Figure 3E</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>). Cluster 1 genes also gained H3K27me3 on their promoters upon the combined treatment, supporting their epigenetic repression following Sulfopin and Vorinostat treatment (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>).</p><p>We further identified genomic regions in which histone acetylation is lost in a Sulfopin-dependent manner (i.e. H3K27ac peaks that are present in Vorinostat-treated cells, but are lost in the combined treatment with Sulfopin). Genome distribution analysis of these unique peaks revealed that the majority of them localize to distal regions (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1F</xref>) and more than 60% of them localize to annotated enhancers. Importantly, genes associated with these enhancers were strongly enriched for oncogenic pathways such as RAS, MAPK, and PI3K-AKT signaling pathways (<xref ref-type="bibr" rid="bib27">Fernández-Medarde and Santos, 2011</xref>; <xref ref-type="bibr" rid="bib11">Braicu et al., 2019</xref>; <xref ref-type="bibr" rid="bib91">Rascio et al., 2021</xref>; <xref ref-type="fig" rid="fig3">Figure 3F</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1G</xref>). Specifically, the combined treatment reduced H3K27ac levels on several enhancers linked to genes involved in mTOR pathway and gliomagenesis, such as <italic>AKT3</italic>, <italic>JAK1,</italic> and <italic>NFKB2</italic> genes, that were shown to have critical role in malignant gliomas (<xref ref-type="bibr" rid="bib85">Peng et al., 2022</xref>; <xref ref-type="bibr" rid="bib77">Mure et al., 2010</xref>; <xref ref-type="bibr" rid="bib20">Ding et al., 2020</xref>; <xref ref-type="bibr" rid="bib112">Tu et al., 2011</xref>; <xref ref-type="bibr" rid="bib93">Raychaudhuri et al., 2007</xref>), <italic>SEC13</italic> gene that indirectly activates mTOR (<xref ref-type="bibr" rid="bib6">Bar-Peled et al., 2013</xref>; <xref ref-type="bibr" rid="bib13">Cai et al., 2016</xref>), and <italic>CD93</italic>, a key regulator in glioma (<xref ref-type="bibr" rid="bib59">Langenkamp et al., 2015</xref>; <xref ref-type="fig" rid="fig3">Figure 3G</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1H</xref>). Concomitant with the lower H3K27ac levels associated with these enhancers, we also observed lower expression of the associated genes (<xref ref-type="fig" rid="fig3">Figure 3H</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1I</xref>). Taken together, the results show attenuation of HDACi-mediated accumulation of H3K27ac levels upon combined treatment with Sulfopin, associated with promoters and enhancers of prominent oncogenes. This is in line with reduced expression of these oncogenic pathways, strengthening the therapeutic potential of the combined treatment.</p></sec><sec id="s2-4"><title>The combined treatment reduces tumor growth in a DMG xenograft mouse model</title><p>Finally, we examined whether the combined inhibition of HDACs and PIN1 elicits an additive effect also in vivo. Thus, we established an H3-K27M DMG orthotopic xenograft model by injections of SU-DIPG13P* cells, engineered to express firefly luciferase, to the pons of immunodeficient mice (<xref ref-type="bibr" rid="bib34">Grasso et al., 2015</xref>). Mice were given 10 days to develop tumors, and then randomly assigned to four groups: control mice treated with DMSO, mice treated with Sulfopin or Vorinostat as single agents, and mice treated with the combination of Sulfopin and Vorinostat. Both drugs were given daily and tumor growth was monitored by in vivo bioluminescence imaging. In line with our in vitro results, we found significant reduction in tumor growth following the combined treatment compared to control DMSO-treated mice (<xref ref-type="fig" rid="fig4">Figure 4A and B</xref>). Importantly, the reduction was also seen when comparing to mice treated solely with Vorinostat, supporting the additive value of Sulfopin to the well-known anti-tumorigenic effect of HDACi in H3-K27M gliomas (<xref ref-type="bibr" rid="bib34">Grasso et al., 2015</xref>; <xref ref-type="fig" rid="fig4">Figure 4A and B</xref>). Of note, mice from all groups showed signs of severe dehydration and general deterioration after 18 days of treatment, and thus we could not measure a survival benefit for the combined treatment. This rapid deterioration is likely a result of the aggressiveness of the transplanted tumors and does not represent side effects of the treatment, as mice from all groups, including the non-treated mice, showed similar signs of deterioration.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>The combined treatment with Sulfopin and Vorinostat reduces tumor growth in vivo.</title><p>(<bold>A–B</bold>) SU-DIPG13P* cells were injected to the pons of immunodeficient mice to form tumors. Ten days post injection, mice were treated for 18 days with either DMSO, Sulfopin, Vorinostat, or the combination of Sulfopin and Vorinostat. (<bold>A</bold>) In vivo bioluminescent imaging of diffuse midline glioma (DMG) xenografts following 18 days of treatment. The heatmap superimposed over the mouse head represents the degree of photon emission by DMG cells expressing firefly luciferase. (<bold>B</bold>) DMG xenograft tumor growth as measured by change in bioluminescent photon emission following 15 days of treatment with either DMSO (n=8), Sulfopin (n=4), Vorinostat (n=5), or the combination of Sulfopin and Vorinostat (n=6). Data points represent the fold change in maximum photon flux between day 3 and day 18 under treatment for each mouse. Mean ± SE is shown. *p&lt;0.05 (two-tailed Mann-Whitney U-test). (<bold>C–D</bold>) Immunofluorescent staining of brain sections from mice injected with SU-DIPG13 cells and treated with DMSO (n=4) or the combination of Sulfopin and Vorinostat (n=4). (<bold>C</bold>) Representative fluorescence images of H3-K27M (red) and mTOR (green). Scale-bar = 100mm. (<bold>D</bold>) Percentage of mTOR-positive cells out of the total H3-K27M-positive cells (n=13–198 cells per field of view [FOV]). H3-K27M-positive cells show lower levels of mTOR following the combined treatment compared to DMSO. Mean ± SE is shown. *p&lt;0.05 (two-tailed t-test).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96257-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>The combined treatment with Sulfopin and Vorinostat results in tumor growth reduction in vivo.</title><p>(<bold>A–B</bold>) mTOR immunofluorescent signal (% of positive area) detected in region of interest (ROI) of H3-K27M-negative cells (mouse cells), from brain sections of mice treated with either DMSO or the combination of Sulfopin and Vorinostat. N.S. indicates p&gt;0.05 (two-sample t-test). Representative images are shown in B.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96257-fig4-figsupp1-v1.tif"/></fig></fig-group><p>To link our in vitro transcriptomic analysis to the in vivo effect on tumor growth, we assessed the percentage of H3-K27M cells that are positive to mTOR signal (double-positive), out of the total number of H3-K27M cells, by immunofluorescence staining. The combined treatment significantly reduced the fraction of the double-positive cells, compared to DMSO (<xref ref-type="fig" rid="fig4">Figure 4C and D</xref>). Of note, mTOR signal in the mouse cells surrounding the tumor showed no significant differences between the DMSO and the combination-treated mice (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A and B</xref>). Overall, these results verify the potency of this treatment in restricting oncogenic pathways also in vivo, and the potential clinical benefit of PIN1 and HDAC combined inhibition in H3-K27M-mutant DMGs.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Despite decades of efforts to improve treatment for children diagnosed with H3-K27M-mutant DMGs, the standard of care remains solely radiation, with no significant improvement in overall survival (<xref ref-type="bibr" rid="bib47">Johung and Monje, 2017</xref>; <xref ref-type="bibr" rid="bib39">Hayden et al., 2021</xref>; <xref ref-type="bibr" rid="bib78">Nagaraja et al., 2017</xref>). High-throughput drug screens in patient-derived cells identified HDAC inhibition as a promising therapeutic strategy, and ongoing clinical trials revealed preliminary evidence of clinical benefit (<xref ref-type="bibr" rid="bib65">Lin et al., 2019</xref>; <xref ref-type="bibr" rid="bib17">Cooney et al., 2018</xref>) (NCT02717455, NCT03566199). However, emerging resistance to HDACi in glioma cells (<xref ref-type="bibr" rid="bib34">Grasso et al., 2015</xref>), as well as limited therapeutic benefits of HDACi treatment as a sole agent (<xref ref-type="bibr" rid="bib40">Hennika et al., 2017</xref>; <xref ref-type="bibr" rid="bib62">Leszczynska et al., 2021</xref>), highlight the necessity to discover additional therapy modalities that could prolong survival and relieve symptoms.</p><p>In H3-K27M-mutant DMGs, as well as in many other malignancies, high MYC activity is correlated with poor prognosis and therefore considered as an attractive therapeutic target (<xref ref-type="bibr" rid="bib12">Buczkowicz et al., 2014</xref>; <xref ref-type="bibr" rid="bib80">Oster et al., 2002</xref>). Nevertheless, direct targeting of MYC is highly challenging, functional, and structural wise. MYC signaling, while amplified in cancer cells, is also essential to normal cell function (<xref ref-type="bibr" rid="bib84">Pelengaris et al., 2002</xref>). Moreover, as a transcription factor, MYC lacks traditionally druggable binding pockets, hindering the development of direct small molecule binders (<xref ref-type="bibr" rid="bib115">Wang et al., 2021</xref>). To overcome this, in this study we exploited Sulfopin, a novel, potent, and selective PIN1 inhibitor (<xref ref-type="bibr" rid="bib22">Dubiella et al., 2021</xref>). Preclinical studies have shown in vivo activity and negligible toxicity of Sulfopin in murine models of PDAC and neuroblastoma (<xref ref-type="bibr" rid="bib22">Dubiella et al., 2021</xref>). While PIN1 is not overexpressed in DMG tumors, we show that Sulfopin, although not inhibiting MYC directly, downregulates MYC target genes in patient-derived DMG cells and affects cell survival in an H3-K27M-dependent manner. These results are in line with the contribution of MYC signaling to H3-K27M-driven tumorigenesis (<xref ref-type="bibr" rid="bib82">Pajovic et al., 2020</xref>; <xref ref-type="bibr" rid="bib23">Dubois et al., 2022</xref>), underscoring the therapeutic potential of Sulfopin for these aggressive brain tumors. Notably, despite a significant reduction in tumor size in vivo, the combined treatment did not increase mice survival. This is perhaps due to the relatively large tumors already formed at the onset of treatment, leading to rapid deterioration of mice in all experimental groups. Thus, further optimization of the modeling system and therapeutic regime is needed.</p><p>We showed that combining Sulfopin treatment with the HDAC inhibitor Vorinostat reduced cell viability by 80% in several tumor-derived DMG lines originating from different patients. Importantly, the combination resulted in an additive effect not only on cell viability, but also on transcriptional programs. A key oncogenic pathway that was robustly downregulated in the combined treatment, in vitro and in vivo, is the mTOR signaling pathway. Preclinical and clinical data support a role for mTOR in gliomagenesis (<xref ref-type="bibr" rid="bib3">Akhavan et al., 2010</xref>). Specifically, AKT gain or PTEN loss is detected in approximately 70% of DMG tumors, and a recent study showed high expression of mTOR in DMGs. Thus, the PTEN/AKT/mTOR pathway is suggested to play a key role in this disease (<xref ref-type="bibr" rid="bib116">Warren et al., 2012</xref>; <xref ref-type="bibr" rid="bib83">Panditharatna et al., 2015</xref>; <xref ref-type="bibr" rid="bib126">Zarghooni et al., 2010</xref>; <xref ref-type="bibr" rid="bib111">Tsoli et al., 2018</xref>). Attempts to restrict mTOR signaling using first-generation mTOR inhibitors primarily inhibited mTORC1, which often caused upregulation of mTORC2 (<xref ref-type="bibr" rid="bib35">Guertin and Sabatini, 2009</xref>). The combined treatment with Sulfopin and Vorinostat led to robust inhibition of several target proteins in the mTOR signaling pathway, likely via alternative pathways. One potential candidate is the mTOR-dependent cell growth through MYC regulation, which may be impaired by Sulfopin treatment, inhibiting MYC transcriptional activity (<xref ref-type="bibr" rid="bib128">Zoncu et al., 2011</xref>; <xref ref-type="bibr" rid="bib95">Schmidt et al., 2009</xref>; <xref ref-type="bibr" rid="bib103">Sodi et al., 2015</xref>; <xref ref-type="bibr" rid="bib58">Kuo et al., 2015</xref>). Of note, drug agents targeting both mTORC1 and mTORC2 were shown to be highly effective in DMG cells as well as in murine models (<xref ref-type="bibr" rid="bib74">Miyahara et al., 2017</xref>; <xref ref-type="bibr" rid="bib31">Flannery et al., 2018</xref>).</p><p>Expression of the H3-K27M oncohistone is associated with a prominent increase in H3K27ac levels (<xref ref-type="bibr" rid="bib63">Lewis et al., 2013</xref>; <xref ref-type="bibr" rid="bib56">Krug et al., 2019</xref>; <xref ref-type="bibr" rid="bib87">Piunti et al., 2017</xref>; <xref ref-type="bibr" rid="bib33">Furth et al., 2022</xref>). Among the loci that accumulate this modification are repetitive elements and endogenous retroviruses, resulting in their aberrant expression, potentially inducing innate immune responses (<xref ref-type="bibr" rid="bib56">Krug et al., 2019</xref>). However, H3-K27M cells do not show an increase in interferon stimulated genes (ISGs), preassembly due to high levels of MYC, which is potent antagonist of interferon responses (<xref ref-type="bibr" rid="bib56">Krug et al., 2019</xref>; <xref ref-type="bibr" rid="bib94">Schlee et al., 2007</xref>). Thus, dual targeting of both HDAC and MYC pathways has the potential of inducing robust expression of ISGs, thus promoting tumor cell death mediated by viral mimicry (<xref ref-type="bibr" rid="bib48">Jones et al., 2019</xref>).</p><p>The high levels of H3K27ac in H3-K27M cells was also linked to activation of super-enhancers, which regulate the expression of oncogenes and genes that are associated with an undifferentiated state (<xref ref-type="bibr" rid="bib78">Nagaraja et al., 2017</xref>). Here, we show that H3-K27M cells are vulnerable to transcriptional disruption mediated by the combined treatment with Sulfopin and Vorinostat. While treating cells with Vorinostat alone increased H3K27ac levels, as expected, the combined treatment attenuated the accumulation of this mark on promoters and enhancers of prominent oncogenes, resulting in their decreased expression. This Sulfopin-mediated attenuation could potentially result from downregulation of MYC targets, as it was recently shown that MYC overexpression results in H3K27ac gain on super-enhancers (<xref ref-type="bibr" rid="bib98">See et al., 2022</xref>).</p><p>In summary, we propose a novel therapeutic strategy targeting epigenetic and transcriptional pathways in H3-K27M-mutant DMG tumors. HDAC inhibition, in combination with the novel MYC inhibitor, inhibited oncogenic transcriptional signatures and reduced tumor growth in vivo. Our findings emphasize epigenetic dependencies of H3-K27M-driven gliomas and highlight the therapeutic potential of combined treatments for this aggressive malignancy.</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><sec id="s4-1"><title>Cell cultures</title><p>All cell lines were maintained at 37°C with 5% CO<sub>2</sub>. Exclusion of <italic>Mycoplasma</italic> contamination was monitored and conducted by test with EZ-PCR kit (Biological Industries #20-700-20).</p></sec><sec id="s4-2"><title>Glioma cultures</title><p>DIPG-derived cells, SU-DIPG13 (H3.3-K27M, female), SU-DIPG6 (H3.3-K27M, female), SU-DIPG17 (H3.3-K27M, male), SU-DIPG25 (H3.3-K27M, female), SU-DIPG50 (H3.3-K27M, sex unknown), SU-DIPG36 (H3.1-K27M, female), SU-DIPG38 (H3.1-K27M, female), SU-DIPG21 (H3.1-K27M, male), and SU-DIPG13P* were generated in the lab of Dr. Michelle Monje, Stanford University (<xref ref-type="bibr" rid="bib34">Grasso et al., 2015</xref>). SU-DIPG13P* are a subclone of the patient-derived SU-DIPG13 pons culture that demonstrates more aggressive growth in vivo (<xref ref-type="bibr" rid="bib65">Lin et al., 2019</xref>; <xref ref-type="bibr" rid="bib78">Nagaraja et al., 2017</xref>).</p><p>K27M-KO SU-DIPG13, BT245-KO (sex information is unavailable), and corresponding control clones were generated in the lab of Prof. Nada Jabado, McGill University, as previously described by <xref ref-type="bibr" rid="bib56">Krug et al., 2019</xref>.</p><p>Cells were cultured in Tumor Stem Media consisting of a 1:1 mixture of DMEM/F12 (Invitrogen, 31330038) and Neurobasal-A (Invitrogen, 10888022) media, with 1:100 addition of HEPES Buffer Solution (Invitrogen, 15630-080), MEM Sodium Pyruvate Solution (Invitrogen, 11360-070), MEM Non-Essential Amino Acids Solution (Invitrogen, 11140-050), GlutaMAX-I (Invitrogen, 35050-061), and Antibiotic-Antimycotic (Invitrogen, 15240-096). The following additives were added freshly: B27-A (1:50, Invitrogen, 12587010), human FGF (20 ng/ml, Shenandoah Biotechnology, 100-146), human EGF (20 ng/ml, Shenandoah Biotechnology, 100-26), human PDGF-AA (20 ng/ml, Shenandoah Biotechnology, 100-16), human PDGF-BB (20 ng/ml, 100-18, Shenandoah Biotechnology), and heparin (10 ng/ml, STEMCELL Technologies, 07980). Doubling times were computed using: <ext-link ext-link-type="uri" xlink:href="http://www.doubling-time.com/compute.php">http://www.doubling-time.com/compute.php</ext-link>.</p></sec><sec id="s4-3"><title>Astrocytic-like cells culture</title><p>CRL-1718 cells, an astrocytic-like cells isolated from the brain of patient with astrocytoma, were kindly provided by Dr. D Michaelson, Tel-Aviv University, Israel. Cells were cultured in RPMI media (Biological Industries, #01-101-1A) supplemented with 10% heat-inactivated fetal bovine serum, 1 mM L-glutamine and 1% penicillin/streptomycin solution (all from Biological Industries).</p></sec><sec id="s4-4"><title>Isolation of total RNA, reverse transcription, and RT-qPCR</title><p>RNA was isolated from 2 million cells using the NucleoSpin kit (Macherey Nagel, #740955.50). 1 µg of each RNA sample was reverse-transcribed using Moloney Murine Leukemia Virus reverse transcriptase (M-MLV-RT, Promega, #M1701) and random hexamer primers (Thermo Scientific, #SO142). Real-time qPCR was performed using KAPA SYBR FAST mix (Kapa Biosystems, #KK4660) with a StepOne real-time PCR instrument (Applied Biosystems). For each gene, standard curve was determined and the relative quantity was normalized to GAPDH or HPRT mRNA (see Resources table in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>).</p></sec><sec id="s4-5"><title>Isolation of total RNA, bulk MARS-seq library preparation, and sequencing</title><p>RNA was isolated from SU-DIPG cells treated as indicated in <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3a</xref>, using the NucleoSpin kit (Macherey Nagel, 740955). A bulk adaptation of the MARS-seq protocol (<xref ref-type="bibr" rid="bib45">Jaitin et al., 2014</xref>; <xref ref-type="bibr" rid="bib54">Keren-Shaul et al., 2019</xref>) was used to generate RNA-seq libraries for expression profiling. Briefly, 30 ng of input RNA from each sample was barcoded during reverse transcription and pooled. Following Agencourct Ampure XP beads cleanup (Beckman Coulter, A63880), the pooled samples underwent second strand synthesis and were linearly amplified by T7 in vitro transcription. The resulting RNA was fragmented and converted into a sequencing-ready library by tagging the samples with Illumina sequences during ligation, RT, and PCR. Libraries were quantified by Qubit (Thermo Fisher Scientific) and TapeStation (Agilent) as well as by qPCR for GAPDH housekeeping gene as described below. Sequencing was done on a NextSeq 75 cycles high-output kit (Illumina, 20024906).</p></sec><sec id="s4-6"><title>Bulk MARS-seq analysis</title><p>A median of 10.5–20 million reads were obtained for each dataset (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3a</xref>). MARS-seq analysis was preformed using the UTAP transcriptome analysis pipeline (<xref ref-type="bibr" rid="bib55">Kohen et al., 2019</xref>). Reads were trimmed to remove adapters and low-quality bases using cutadapt (<xref ref-type="bibr" rid="bib70">Martin, 2011</xref>) and mapped to the human genome (hg38, UCSC) using STAR v2.4.2a18 (<xref ref-type="bibr" rid="bib21">Dobin et al., 2013</xref>) (parameters: –alignEndsType EndToEnd, –outFilterMismatchNoverLmax 0.05, –twopassMode Basic, –alignSoftClipAtReferenceEnds No). In short, the pipeline quantifies the 3’ of annotated genes (the 3’ region contains 1000 bases upstream of the 3’ end and 100 bases downstream). Counting was done using HTSeq-count in union mode (<xref ref-type="bibr" rid="bib4">Anders et al., 2015</xref>). Genes having a minimum 5 UMI-corrected reads in at least one sample were considered. Normalization of the counts and differential expression analysis was done using DESeq2 (<xref ref-type="bibr" rid="bib66">Love et al., 2014</xref>) (parameters: betaPrior = True, cooksCutoff = FALSE, independentFiltering = FALSE). Significantly DE genes were defined having adjusted p-value (with Benjamini and Hochberg procedure)≤0.05, |log2FoldChange|≥1, and baseMean ≥ 5. Heatmaps of gene expression were calculated using the log-normalized expression values (rld), with row standardization (scaling the mean of a row to 0, with standard deviation of 1). Clustering of gene expression (rld values) was done using Euclidean average linkage method, and visualized using Partek Genomics Suite 7.0 software (Partek, an Illumina company (2020). Partek Genomics Suite (Version 7.0)). Boxplot was used to visualize gene expression values (rld) of each DE gene from clusters 1 and 4 (in each of the three replicates).</p></sec><sec id="s4-7"><title>Expression analysis from published datasets</title><p>Gene expression data and histone mutation status of pediatric high-grade gliomas (<xref ref-type="bibr" rid="bib68">Mackay et al., 2017</xref>) was downloaded from PedcBioPortal (<ext-link ext-link-type="uri" xlink:href="https://pedcbioportal.kidsfirstdrc.org/">https://pedcbioportal.kidsfirstdrc.org/</ext-link>). For matched tumor-normal samples, RPKM values were obtained from <xref ref-type="bibr" rid="bib8">Berlow et al., 2018</xref> (S2_Table). For boxplots the log2 (RPKM+1) or z-score values were used (ggpubr R package). Differences between groups were assessed using two-sided ‘t_test’ (rstatix R package). For heatmaps, gene expression values were obtained for genes from Molecular Signatures Database (MsigDB) signatures ‘HALLMARK_MYC_TARGETS_V1’, with MYC and PIN1 genes added manually. Heatmaps of gene expression were calculated using RPKM values, with row standardization (scaling the mean of a row to 0, with standard deviation of 1).</p></sec><sec id="s4-8"><title>Functional enrichment analysis</title><p>GSEA was performed as described in <ext-link ext-link-type="uri" xlink:href="https://www.broadinstitute.org/software/gsea">https://www.broadinstitute.org/software/gsea</ext-link>; <xref ref-type="bibr" rid="bib107">Subramanian et al., 2005</xref>; <xref ref-type="bibr" rid="bib76">Mootha et al., 2003</xref>. Genes detected by MARS-seq were pre-ranked according to their fold change (log2) in Sulfopin+Vorinostat vs. DMSO-treated cells. Pre-ranked GSEA was applied using the Human MSigDB Collections H: hallmark gene sets (<xref ref-type="bibr" rid="bib64">Liberzon et al., 2015</xref>) and the C6: oncogenic signature gene sets (<xref ref-type="bibr" rid="bib119">Wiederschain et al., 2007</xref>; <xref ref-type="bibr" rid="bib113">van Staveren et al., 2006</xref>; <xref ref-type="bibr" rid="bib117">Wei et al., 2006</xref>). Significantly downregulated gene sets were selected using cutoff of FDR q-value≤0.1.</p><p>Enrichr algorithm (<xref ref-type="bibr" rid="bib57">Kuleshov et al., 2016</xref>) was used to compare significantly downregulated genes detected in the different treatments, against one or more of the following databases: the MSigDB hallmark (<xref ref-type="bibr" rid="bib64">Liberzon et al., 2015</xref>), ChEA (<xref ref-type="bibr" rid="bib52">Keenan et al., 2019</xref>), or ENCODE TF ChIP (<xref ref-type="bibr" rid="bib24">Dunham et al., 2012</xref>).</p><p>gProfiler algorithm (<xref ref-type="bibr" rid="bib92">Raudvere et al., 2019</xref>) was used to analyze genes that are putative targets of elite enhancers which overlap with Vorinostat-unique H3K27ac peaks (see Cut&amp;Run analysis), against the KEGG (<xref ref-type="bibr" rid="bib51">Kanehisa, 2019</xref>; <xref ref-type="bibr" rid="bib50">Kanehisa and Goto, 2000</xref>) or Wiki (<xref ref-type="bibr" rid="bib69">Martens et al., 2021</xref>) pathway databases.</p></sec><sec id="s4-9"><title>Cut&amp;Run pulldown assay followed by high-throughput sequencing</title><p>Cut&amp;Run assay was done as described in <xref ref-type="bibr" rid="bib102">Skene and Henikoff, 2017</xref>; <xref ref-type="bibr" rid="bib72">Meers et al., 2019</xref>, with slight modifications as follows: Cells were harvested and counted, with 200,000 cells taken per reaction. Permeabilized cells, bound to Concanavalin A-coated beads (Bangs Laboratories, BP531), were mixed with individual primary antibody (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>) and incubated overnight at 4°C while rotating. Secondary antibody, anti-rabbit HRP, was used as a negative control. pAG-MNase enzyme (generated in the Department of Life Sciences Core Facilities, WIS, using Addgene plasmid 123461) was added to each sample followed by incubation step of 1 hr at 4°C. Targeted digestion was done by 15 min incubation on ice block (0°C) under low salt conditions. DNA purification was done using Nucleospin gel and PCR clean-up kit (Machery-Nagel, 740609).</p><p>Libraries were prepared from 1 to 20 ng of DNA as previously described in <xref ref-type="bibr" rid="bib9">Blecher-Gonen et al., 2013</xref>. Briefly, DNA fragments were repaired by T4 DNA polymerase (NEB, M0203), and T4 polynucleotide kinase (T4 PNK, NEB, M0201) was used to add a phosphate group at the 5’ ends. An adenosine base was then added by Klenow fragments (NEB, M0212) to allow efficient ligation, using T4 quick ligase (NEB, M2200), of sequencing adapters, which contain a T-overhang. DNA fragments were amplified by PCR (Pfu Ultra II fusion, Agilent Technologies, 600670), which also introduced the Illumina-P5 adapter at one end of the molecule. SPRI beads were used to purify proper sized DNA fragments after each enzymatic step. Libraries were quantified by Qubit (Thermo Fisher Scientific) and proper fragment range (200–400 bp) was verified by TapeStation (Agilent). Sequencing was done on a NextSeq 500 instrument (Illumina, #20024904) using a V2 150 cycles mid output kit (paired-end sequencing).</p><p>Paired-end reads of each sample (~7.5 million median reads per sample, <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3b</xref>) were preprocessed with cutadapt (<xref ref-type="bibr" rid="bib70">Martin, 2011</xref>), to remove adapters and low-quality bases (parameters: --times 2 -q 30 -m 20), following evaluation of quality with FastQC. Reads were mapped to human genome (hg38, UCSC) using Bowtie version 2.3.5.1 (<xref ref-type="bibr" rid="bib60">Langmead and Salzberg, 2012</xref>) (--local --very-sensitive-local --no-unal --no-mixed --no-discordant --dovetail -I 10 -X 700). Nucleosome fragments at the length &gt;120 bp were selected from the remaining unique reads using picard-tools, and broad peaks were called using MACS2 against the HRP samples as background control (parameters: -f BAMPE --SPMR --nomodel --extsize 100 --keep-dup auto -q 0.05). Analysis of genomic features was done using ChIPseeker (<xref ref-type="bibr" rid="bib125">Yu et al., 2015</xref>). Reads coverage on TSS, gene body regions, specific gene-signatures, and CGI were visualized using ngs.plot (<xref ref-type="bibr" rid="bib101">Shen et al., 2014</xref>). Annotation of CGI were downloaded for UCSC table browser. Association of peaks with specific genes was done using GREAT (<xref ref-type="bibr" rid="bib71">McLean et al., 2010</xref>). Bigwig files were constructed from BAM alignments using deepTools2 suite (<xref ref-type="bibr" rid="bib90">Ramírez et al., 2016</xref>), by ‘bamCoverage’ command, using RPKM normalization in 10 bp bins. Heatmaps and profiles were constructed in ‘scale-regions’ mode around peak summits, with missingDataAsZero parameter using ‘plotHeatmap’ and ‘plotProfile’ commands. In the heatmap of H3K27ac ratio (<xref ref-type="fig" rid="fig3">Figure 3D</xref>) coverage was calculated as the log2 between treatment and DMSO, on TSS of genes which were depicted as DE by MARS-seq. RPKM-normalized coverage files were visualized on the genome using IGV (2.8.6). H3K27ac peaks were further distinguished into Vorinostat-unique peaks (i.e. H3K27ac peaks that are present in Vorinostat-treated cells, but are lost in the combined treatment with Sulfopin), and to shared peaks (i.e. H3K27ac peaks that are present both in Vorinostat and in Sulfopin+Vorinostat-treated cells, with a minimum of 1 bp overlap) using bedtools (<xref ref-type="bibr" rid="bib89">Quinlan and Hall, 2010</xref>). H3K27me3 peaks unique to Sulfopin treatment were defined similarly. To detect the overlap between the Vorinostat-unique peaks with enhancer regions, we used the GeneHancer database v5.9 (<xref ref-type="bibr" rid="bib30">Fishilevich et al., 2017</xref>). We required a 30% overlap of the peak length with a known enhancer categorized as ‘Elite’ group, and excluded enhancers annotated to promoters regions.</p></sec><sec id="s4-10"><title>Cell viability assay by CellTiterGlo</title><p>For Sulfopin and Vorinostat combination experiments, 384-well plates were pre-plated with twofold dilution matrix of Vorinostat (MCE Cat#HY-10221) and Sulfopin (generous gift from Dr. Nir London’s Lab, Weizmann Institute of Science), in five concentrations ranging from 120 to 10,000 nM (Vorinostat) and 2500 to 40,000 nM (Sulfopin). 1400 DIPG cells/well were plated into each well containing 75 µl of growth media, and subjected to drug treatment for 3 days (Vorinostat) or 8 days with pulse at day 4 (Sulfopin). Single-agent titrations were run in parallel. Following the treatment, cells were subjected to cell viability assay using CellTiterGlo assay (#G7572, Promega, USA) in accordance with the manufacturer’s protocol. Luminescence signal was detected by luminescence module of PheraStar FS plate reader (BMG Labtech, Ortenberg, Germany). Viability data was analyzed using GeneData 15 (Switzerland).</p><p>For generating Sulfopin dosage curves in DIPG versus astrocyte cells, the appropriated amounts of Sulfopin or DMSO (control) were transferred using Echo Liquid Handler 550 (Beckman, USA) into white/white 384-well TC plate (Greiner, #781080). 1400 cells/well were dispensed by MultiDrop 384 dispenser (Thermo Scientific, USA) into 384-well plates. After 4 days, cells were subjected to cell viability assay using CellTiterGlo assay (#G7572, Promega, USA) in accordance with the manufacturer’s protocol. Luminescence signal was detected by luminescence module of PheraStar FS plate reader (BMG Labtech, Ortenberg, Germany). Viability data was analyzed using GeneData 15 (Switzerland).</p><p>For all the other viability assays, cells were plated at a density of 2500 cells/well in 96-well plates and subjected to drug treatment for 3 days (Vorinostat-MCE Cat#HY-10221, GSK-J4-Selleck Cat#S7070, EPZ-6438-Selleck Cat#S7128) or 8 days (Sulfopin, generous gift from Dr. Nir London’s Lab, and MM-102-Selleck Cat#S7265) (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). At least two replicates were measured for each treatment. When treated for 8 days drug was also added at day 4. Cell viability was measured by CellTiterGlo assay (G7571, Promega) according to the manufacturer’s instructions. Luminescence was measured by Cytation 5 plate reader and viability was compared to DMSO-treated control cells.</p><p>At least two technical replicates were averaged in each experiment, and mean±SE of all biological repeats was calculated. Two-sample t-test on all technical replicates was used to determine significant difference between the treatments. Bonferroni correction was applied whenever more than two comparisons were made.</p></sec><sec id="s4-11"><title>IC50 quantification</title><p>Sulfopin IC50 values were determined by 4-parameter log-logistic dose-response model using SynergyFinder 2.0 (<xref ref-type="bibr" rid="bib42">Ianevski et al., 2020</xref>).</p></sec><sec id="s4-12"><title>BLISS index calculation</title><p>The BLISS index was calculated as the ratio between observed effect of combined drug treatment and expected effect (based on the calculated effect of combining single-drug treatment) (<xref ref-type="bibr" rid="bib122">Yadav et al., 2015</xref>; <xref ref-type="bibr" rid="bib10">Bliss, 1939</xref>):<disp-formula id="equ1"><mml:math id="m1"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">x</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mi mathvariant="normal">O</mml:mi><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">x</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:msub><mml:mi>J</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>J</mml:mi><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>×</mml:mo><mml:msub><mml:mi>J</mml:mi><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula></p><list list-type="simple"><list-item><p><inline-formula><mml:math id="inf1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi mathvariant="normal">J</mml:mi><mml:mrow><mml:mi mathvariant="normal">A</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> is the effect on growth of drug A only compared to DMSO</p></list-item><list-item><p><inline-formula><mml:math id="inf2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi mathvariant="normal">J</mml:mi><mml:mrow><mml:mi mathvariant="normal">B</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> is the effect on growth of drug B only compared to DMSO</p><p><inline-formula><mml:math id="inf3"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi mathvariant="normal">J</mml:mi><mml:mrow><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">B</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> is the effect on growth of drug A and B together compared to DMSO</p></list-item><list-item><p>Synergy: Bliss &lt; 1</p></list-item><list-item><p>Additive: Bliss = 1</p></list-item><list-item><p>Antagonist: Bliss &gt; 1</p></list-item></list></sec><sec id="s4-13"><title>Western blot analysis</title><p>An equal number of cells from different treatments were suspended in Laemmli sample buffer (Bio-Rad, #1610747) containing 50 mM DTT (Promega, #V3151), vortexed and heated up to 98°C. Samples were loaded onto Novex WedgeWell 4–20%, Tris-Glycine 4–20% gel (Thermo Fisher Scientific, XP04205BOX) and electrophoresis was carried out in TG-SDS buffer (Bio-Rad #1610732) for 1–1.5 hr at 120 V. After electrophoresis, proteins were transferred to nitrocellulose membranes using transfer kit (Bio-Rad, #1704156), followed by brief rinse in TBS (Bio-Rad, #1706435) and blocking with 5% (wt/vol) milk powder in TBST (Tween20-Sigma, #P1379) for 60 min. The membranes were then rinsed in TBST and incubated with primary antibodies overnight at 4°C with gentle rocking. Primary antibodies (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>) were diluted according to the manufacturer’s instructions in TBST containing 5% (wt/vol) milk powder. The following day the membranes were rinsed in TBST, then incubated with HRP-conjugated secondary antibody (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>) diluted according to the manufacturer’s instructions in a solution containing 5% (wt/vol) milk powder in TBST. The membranes were then rinsed in TBST and dipped in an ECL WB Detection Reagent (Bio-Rad #1705061) prior to exposure. Membranes were imaged using a Bio-Rad ChemiDoc MP imaging system.</p></sec><sec id="s4-14"><title>Nucleosome preparation for single-molecule imaging</title><p>Nucleosomes for single-molecule imaging were extracted and labeled as described in <xref ref-type="bibr" rid="bib33">Furth et al., 2022</xref>. Briefly, 2–2.5 million cells were collected, washed once with PBS supplemented with protease inhibitors cocktail, 1:100, Sigma P8340), and HDAC inhibitors (20 mM sodium butyrate, Sigma 303410, and 0.1 mM Vorinostat V-8477), and then resuspended in 0.05% IGEPAL (Sigma I8896) diluted in PBS (supplemented with inhibitors). Cell pellets were then lysed in parallel to chromatin digestion (100 mM Tris-HCl pH 7.5, 300 mM NaCl, 2% Triton X-100, 0.2% sodium deoxycholate, 10 mM CaCl<sub>2</sub>) supplemented with inhibitors and Micrococcal Nuclease (Thermo Fisher Scientific, 88216). The suspension was incubated at 37°C for 10 min and the MNase reaction was inactivated by addition of EGTA at a final concentration of 20 mM. Lysate was cleared by centrifugation and nucleosomes were concentrated using an Amicon ultra-4 (Millipore, UFC810024). Inhibitors were supplemented following concentration. Nucleosomes labeling the following reaction was used: NEBuffer 2 (NEB B7202), inhibitors (as detailed above, 0.25 mM MnCl<sub>2</sub>, 33 µM fluorescently labeled dATP (Jena Bioscience, NU-1611-Cy3), 33 µM biotinylated dUTP (Jena Bioscience, NU-803-BIOX), 1.5 µl of Klenow Fragment (3'→5′ exo-, NEB, M0212S), and 1.5 µl of T4 Polynucleotide Kinase (NEB, M0201L). Samples were incubated at 37°C for 1 hr and then inactivated by the addition of EDTA at a final concentration of 20 mM. Nucleosomes were then purified on Performa Spin Columns (EdgeBio, 13266) followed by the addition of inhibitors.</p></sec><sec id="s4-15"><title>Surface preparation for single-molecule imaging</title><p>PEG-biotin microscope slides were prepared as described in <xref ref-type="bibr" rid="bib33">Furth et al., 2022</xref>. Ibidi glass coverslips (25×75 mm<sup>2</sup>, IBIDI, IBD-10812) were cleaned with (1) ddH<sub>2</sub>O (3× washes, 5 min sonication, 3× washes), (2) 2% Alconox (Sigma 242985, 20 min sonication followed by 5× washes with ddH<sub>2</sub>O), (3) 100% acetone (20 min sonication followed by 3× washes with ddH<sub>2</sub>O). Slides were then incubated in 1 M KOH solution for 30 min while sonicated (Sigma 484016), followed by 3× washes with ddH<sub>2</sub>O. Slides were sonicated for 10 min in 100% HPLC EtOH (J.T baker 8462-25) and then incubated for 24 min in a mixture of 3% 3-aminopropyltriethoxysilane (ACROS Organics, 430941000) and 5% acetic acid in HPLC EtOH, with 1 min sonication in the middle. Following washes with HPLC EtOH (3×) and ddH<sub>2</sub>O (3×) slides were dried and mPEG:biotin-PEG solution was applied (20 mg Biotin-PEG [Laysan, Biotin-PEG-SVA-5000] and 180 mg mPEG [Laysan, MPEG-SVA-5000] dissolved in 1560 µl 0.1 M sodium bicarbonate [Sigma, S6297] on one surface followed by the assembly of another surface on top). Surfaces were incubated overnight in a dark humid environment and at the following day, were washed with ddH<sub>2</sub>O and dried. MS (PEG) 4 (Thermo Fisher Scientific, TS-22341) was diluted in 0.1 M of sodium bicarbonate to a final concentration of 11.7 mg/ml and applied on the surfaces for overnight incubation in dark humid environment. Surfaces were washed with ddH<sub>2</sub>O and dried.</p></sec><sec id="s4-16"><title>Single-molecule imaging of histone modifications</title><p>PEG-biotin-coated coverslips were assembled into Ibidi flowcell (Sticky Slide VI hydrophobic, IBIDI, IBD-80608). Streptavidin (Sigma, S4762) was added to a final concentration of 0.2 mg/ml followed by an incubation of 10 min. TetraSpeck beads (used for image alignment, Thermo Fisher Scientific, T7279) diluted in PBS were added and incubated on surface for at least 30 min. Labeled nucleosomes were incubated for 10 min in imaging buffer (10 mM MES pH 6.5 [Boston Bioproducts Inc, NC9904354], 60 mM KCl, 0.32 mM EDTA, 3 mM MgCl<sub>2</sub>, 10% glycerol, 0.1 mg/ml BSA [Sigma, A7906], 0.02% Igepal [Sigma, I8896]) to allow immobilization via biotin-streptavidin interactions and washed with imaging buffer. H3K27ac antibody was diluted in imaging buffer (1:2000) and incubated for 30 min. All positions (80–100 fields of view [FOVs] per experiment) were then imaged by a total internal reflection fluorescence (TIRF) microscope by Nikon (Ti2 LU-N4 TIRF) every 10 min (10–15 cycles).</p><p>Image analysis was performed with Cell Profiler image analysis tools (<ext-link ext-link-type="uri" xlink:href="http://www.cellprofiler.org/">http://www.cellprofiler.org/</ext-link>) as described in <xref ref-type="bibr" rid="bib33">Furth et al., 2022</xref>. Image analysis is done in two steps: (1) Time-lapse images of antibody binding events and TetraSpeck beads are aligned, stacked, and summed to one image. Antibody spots and TetraSpeck beads spots were distinguished based on the size of the spot. (2) Stacked images are aligned to the initial images of the nucleosomes based on TetraSpeck beads location spots, and only binding events that align with nucleosomes are filtered and saved for further analysis. To evaluate random co-localization (negative control), each stacked image is aligned to a 90° flipped image of the initial nucleosomes. The use of TetraSpeck beads and a highly accurate microscope stage allowed alignment of images with shifts of up to 30 pixels. Nucleosomes are initially distributed on the surface in low density to minimize overlap between spots. Average percentage of modified nucleosomes over all FOV images was calculated in each experiment. Mean±SE of three to five biological repeats was calculated. Two-sample t-test on all biological repeats was used to determine significant difference between the treatments.</p></sec><sec id="s4-17"><title>Mouse injection and treatment</title><p>All animal studies were approved by the Weizmann Institutional Board and were performed in accordance with the Israeli law and the guidelines of the Institutional Animal Care and Use Committee (IACUC) approval number 07821021-1 and IRB approval number 1528-1. Mice were housed and handled in a pathogen-free, temperature-controlled (22C±1°C) facility on a 12 hr light/dark cycle. Animals were fed a regular chow diet and given ad libitum access to food and water. All surgeries were performed under isoflurane anesthesia, and every effort was made to minimize suffering.</p><p>Single-cell suspension of SU-DIPG13P* or SU-DIPG13 cells were stereotactically injected into the pons of 12-week-old male NGS mice (NOD-SCID-IL2R gamma chain-deficient, The Jackson Laboratory) as previously described in <xref ref-type="bibr" rid="bib114">Venkatesh et al., 2019</xref>. Injection coordinates were: 0.8 mm posterior to lambda, 1 mm lateral to the sagittal suture, and 5 mm deep. Briefly, the skull of the mouse was exposed, and a small bore hole (0.5 mm) was made using a high-speed drill at the appropriate stereotactic coordinates. Approximately 300,000–400,000 cells in 3 µl volume were injected at a speed of 0.3 µl per minute into the pons with a 26-gauge Hamilton syringe; following 10 min pause, the needle was removed at a speed of 0.2 mm/min. After closing the scalp, mice were placed on a heating pad and returned to their cages after full recovery. All injected mice that recovered were randomized to treatment groups, and treatment started 10 days (SU-DIPG13P*) or 5 weeks (SU-DIPG13) post injection. Treatment was given daily for 18 days, by intraperitoneal injection according to the following groups: Vorinostat 200 mg/kg daily (LC, V-8477-SU-DIPG13P*; MCE, HY-10221- SU-DIPG13), Sulfopin 40 mg/kg (gift from Dr. Nir London’s Lab), combination 200 mg/kg Vorinostst and 40 mg/kg Sulfopin, control mice received solvent 15% DMSO in 50% PEG400 (Sigma) in 0.15 M NaCl.</p></sec><sec id="s4-18"><title>Tumor size imaging using IVIS</title><p>For bioluminescence imaging, mice received 100 μl D-luciferin (33 mg/ml; Perkin-elmer, Cat#122799) intraperitoneally 10 min before isoflurane anesthesia and were placed in LagoX Imaging System (Spectral Instruments Imaging).</p><p>The bioluminescence signal was measured using the region of interest (ROI) tool in LagoX software (Spectral Instruments Imaging). The fold change in total photon flux (p/s) over time was used to compare tumor growth between the groups. Mann-Whitney U-test (two-tailed) was used to determine significant difference between the DMSO and Sulfopin+Vorinostat-treated mice.</p></sec><sec id="s4-19"><title>Mouse brain slides staining</title><p>Brains were collected, fixed in 4% paraformaldehyde, and embedded in paraffin blocks. For H3-K27M and mTOR staining, slides were de-paraffinized (1 - Xylene-Bio-lab #242500; 2 - Xylene; 3 - Eth 100%-Bio-lab #05250501; 4 - Eth 96%; 5 - Eth 70%;) and incubated in acetone (Bio-lab, #010352) at –20°C. Slides were incubated in hydrogen peroxide blocking solution (200 ml Methanol-Bio-lab #136805, 1% HCl-Bio-lab #084102, 3% H<sub>2</sub>O<sub>2</sub>- JT Baker #2186-01) for blocking endogenous peroxidase activity. Antigen retrieval was performed using citric acid buffer at pH 6, followed by blocking with 20% NHS and 0.5% Triton in PBS. Rabbit anti-mTOR (1:100, <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>) was diluted in 2% NHS and 0.5% Triton and was incubated overnight at room temperature. Slides were then incubated with HRP-conjugated goat anti-rabbit (1:100, <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>) diluted 2% NHS for 1.5 hr followed by OPAL 650 (1:500, Akoya FP1496001KT) reagent incubation for 15 min. Antibodies were stripped using microwave treatment with citric acid at pH 6, blocked and again incubated with rabbit anti H3-K27M (1:100 <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>) overnight at room temperature. Slides were then incubated with HRP-conjugated goat anti-rabbit (1:100, <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>) diluted 2% NHS for 1.5 hr followed by OPAL 570 (1:500, Akoya FP1488001KT) reagent incubation for 15 min. Slides were then washed with PBS and incubated with Hoechst (1:1000) for 1 min, followed by mounting with 25×75×1 mm<sup>3</sup> glass slides using Aqua-Poly/Mount Mounting Medium. All slides were scanned using the Panoramic MIDI slide scanner (3D Histech, Hungary) at ×20 magnification, to receive a full scan of the tumor section.</p><p>For H3-K27M and mTOR co-localization analysis, double stained cells were counted using ImageJ. First, threshold-based segmentation was used to detect positive cells in each of the channels and the image calculator feature was used to find the double positive cells. The total number of double-positive cells was then divided by the total number of H3-K27M-positive cells to calculate the percentage co-localization/H3-K27M cells. Similar-sized FOVs were used for all the images analyzed, and 13-198 H3-K27M-positive cells were detected per FOV (an average of 90 cells per FOV). For mTOR signal quantification in non-tumor cells (mice cells), an ROI was selected in a location on the section with no positive H3-K27M cells. Threshold-based segmentation was used to detect the percentage mTOR stained area.</p></sec><sec id="s4-20"><title>Statistical analysis</title><p>Unless noted otherwise, p-values were determined using two-sample t-test and are indicated in the figure legends.</p><p>Pearson correlation coefficient was used to assess the relationship between all variables. Scatter plot was generated using ggscatter (R ggpubr package).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>N.L. is an inventor on a patent describing Sulfopin (US 2021/0332024 A1)</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>designed the study, conducted the experiments, performed bioinformatics analysis, conducted the in-vivo image analysis and wrote the manuscript</p></fn><fn fn-type="con" id="con2"><p>established the xenograft mice model and performed in-vivo experiments and conducted the in-vivo image analysis</p></fn><fn fn-type="con" id="con3"><p>performed bioinformatics analysis</p></fn><fn fn-type="con" id="con4"><p>conducted the in-vivo image analysis</p></fn><fn fn-type="con" id="con5"><p>conducted part of the viability assays</p></fn><fn fn-type="con" id="con6"><p>conducted part of the viability assays</p></fn><fn fn-type="con" id="con7"><p>established the xenograft mice model</p></fn><fn fn-type="con" id="con8"><p>suggested and provided Sulfopin and valuable usage information</p></fn><fn fn-type="con" id="con9"><p>conducted the in-vivo image analysis</p></fn><fn fn-type="con" id="con10"><p>designed the study, performed bioinformatics analysis and wrote the manuscript</p></fn><fn fn-type="con" id="con11"><p>designed the study, performed bioinformatics analysis and wrote the manuscript</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All animal studies were approved by the Weizmann institutional board and were performed in accordance with the Israeli law and the guidelines of the Institutional Animal Care and Use Committee (IACUC) approval number 07821021-1 and IRB approval number 1528-1. Mice were housed and handled in a pathogen-free, temperature-controlled (22C ± 1C) facility on a 12 h light/dark cycle. Animals were fed a regular chow diet and given ad libitum access to food and water. All surgeries were performed under isoflurane anesthesia, and every effort was made to minimize suffering.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>List of differentially expressed genes and their corresponding cluster.</title><p>Related to <xref ref-type="fig" rid="fig2">Figure 2G</xref>.</p></caption><media xlink:href="elife-96257-supp1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Reagents and resources.</title></caption><media xlink:href="elife-96257-supp2-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Summary information of NGS libraries.</title><p>(a) Summary information of MARS-seq libraries. (b) Summary information of Cut&amp;Run libraries.</p></caption><media xlink:href="elife-96257-supp3-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-96257-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All sequencing data is deposited in NCBI's Gene Expression Omnibus (GEO) and available through GEO series accession number GSE221614.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Algranati</surname><given-names>D</given-names></name><name><surname>Oren</surname><given-names>R</given-names></name><name><surname>Dassa</surname><given-names>B</given-names></name><name><surname>Fellus-Alyagor</surname><given-names>L</given-names></name><name><surname>Plotnikov</surname><given-names>A</given-names></name><name><surname>Barr</surname><given-names>H</given-names></name><name><surname>Harmelin</surname><given-names>A</given-names></name><name><surname>London</surname><given-names>N</given-names></name><name><surname>Ron</surname><given-names>G</given-names></name><name><surname>Furth</surname><given-names>N</given-names></name><name><surname>Shema</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Dual Targeting of Histone Deacetylases and MYC as Potential Treatment Strategy for H3-K27M Pediatric Gliomas</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE221614">GSE221614</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank H Keren-Shaul, D Robbins, Y Elazari, and N Adler (G-INCPM, WIS) for their help with NGS; N Morris for her help with conducting part of the cell viability assays; C Raanan and M Zerbib for their contribution in establishing the DIPG mouse model; I Savchenko for his help with immunohistochemistry; R Gabizon for generously providing Sulfopin for in vitro and in vivo experiments and helping with Sulfopin handling; S Fishilevich for providing the GeneHancers data; L Segev for computational framework for single-molecule image analysis; N Harpaz and O Beresh for helping with cultures maintenance; O Griess for helping with transcriptomic protocols; S Gillespie for providing valid information on DMG cells growth and maintenance; and I Ulitsky for providing the pAG-MNase enzyme. We are thankful to O Golani for helping with the immunohistochemistry image analysis. We are grateful to M Monje for generously sharing with us the SU-DIPG13, SU-DIPG13P*, SU-DIPG6, SU-DIPG17, SU-DIPG25, SU-DIPG36, SU-DIPG38, SU-DIPG21, and SU-DIPG50 cells. We are grateful to N Jabado for her kind gift of the isogenic BT245 and SU-DIPG13 cultures. We would like to express our sincere gratitude to D Deitch for producing part of the graphs, designing the figures and illustrations, and helping with statistical analysis. ES is an incumbent of the Lisa and Jeffrey Aronin Family Career Development chair and is also supported by Henry Chanoch Krenter Institute for Biomedical Imaging and Genomics. This research was supported by grants from the European Research Council (ERC801655), The Israel Science Foundation (1881/19), Emerson Collective, and The Israel Cancer Research Fund: Research Career Development Award.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdouh</surname><given-names>M</given-names></name><name><surname>Facchino</surname><given-names>S</given-names></name><name><surname>Chatoo</surname><given-names>W</given-names></name><name><surname>Balasingam</surname><given-names>V</given-names></name><name><surname>Ferreira</surname><given-names>J</given-names></name><name><surname>Bernier</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>BMI1 sustains human glioblastoma multiforme stem cell renewal</article-title><source>The Journal of Neuroscience</source><volume>29</volume><fpage>8884</fpage><lpage>8896</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0968-09.2009</pub-id><pub-id pub-id-type="pmid">19605626</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agger</surname><given-names>K</given-names></name><name><surname>Cloos</surname><given-names>PAC</given-names></name><name><surname>Christensen</surname><given-names>J</given-names></name><name><surname>Pasini</surname><given-names>D</given-names></name><name><surname>Rose</surname><given-names>S</given-names></name><name><surname>Rappsilber</surname><given-names>J</given-names></name><name><surname>Issaeva</surname><given-names>I</given-names></name><name><surname>Canaani</surname><given-names>E</given-names></name><name><surname>Salcini</surname><given-names>AE</given-names></name><name><surname>Helin</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development</article-title><source>Nature</source><volume>449</volume><fpage>731</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1038/nature06145</pub-id><pub-id pub-id-type="pmid">17713478</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akhavan</surname><given-names>D</given-names></name><name><surname>Cloughesy</surname><given-names>TF</given-names></name><name><surname>Mischel</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>mTOR signaling in glioblastoma: lessons learned from bench to bedside</article-title><source>Neuro-Oncology</source><volume>12</volume><fpage>882</fpage><lpage>889</lpage><pub-id pub-id-type="doi">10.1093/neuonc/noq052</pub-id><pub-id pub-id-type="pmid">20472883</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anders</surname><given-names>S</given-names></name><name><surname>Pyl</surname><given-names>PT</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>HTSeq—a python framework to work with high-throughput sequencing data</article-title><source>Bioinformatics</source><volume>31</volume><fpage>166</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu638</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Annovazzi</surname><given-names>L</given-names></name><name><surname>Mellai</surname><given-names>M</given-names></name><name><surname>Caldera</surname><given-names>V</given-names></name><name><surname>Valente</surname><given-names>G</given-names></name><name><surname>Tessitore</surname><given-names>L</given-names></name><name><surname>Schiffer</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>mTOR, S6 and AKT expression in relation to proliferation and apoptosis/autophagy in glioma</article-title><source>Anticancer Research</source><volume>29</volume><fpage>3087</fpage><lpage>3094</lpage><pub-id pub-id-type="pmid">19661320</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bar-Peled</surname><given-names>L</given-names></name><name><surname>Chantranupong</surname><given-names>L</given-names></name><name><surname>Cherniack</surname><given-names>AD</given-names></name><name><surname>Chen</surname><given-names>WW</given-names></name><name><surname>Ottina</surname><given-names>KA</given-names></name><name><surname>Grabiner</surname><given-names>BC</given-names></name><name><surname>Spear</surname><given-names>ED</given-names></name><name><surname>Carter</surname><given-names>SL</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name><name><surname>Sabatini</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1</article-title><source>Science</source><volume>340</volume><fpage>1100</fpage><lpage>1106</lpage><pub-id pub-id-type="doi">10.1126/science.1232044</pub-id><pub-id pub-id-type="pmid">23723238</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bender</surname><given-names>S</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Lindroth</surname><given-names>AM</given-names></name><name><surname>Hovestadt</surname><given-names>V</given-names></name><name><surname>Jones</surname><given-names>DTW</given-names></name><name><surname>Kool</surname><given-names>M</given-names></name><name><surname>Zapatka</surname><given-names>M</given-names></name><name><surname>Northcott</surname><given-names>PA</given-names></name><name><surname>Sturm</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Radlwimmer</surname><given-names>B</given-names></name><name><surname>Højfeldt</surname><given-names>JW</given-names></name><name><surname>Truffaux</surname><given-names>N</given-names></name><name><surname>Castel</surname><given-names>D</given-names></name><name><surname>Schubert</surname><given-names>S</given-names></name><name><surname>Ryzhova</surname><given-names>M</given-names></name><name><surname>Şeker-Cin</surname><given-names>H</given-names></name><name><surname>Gronych</surname><given-names>J</given-names></name><name><surname>Johann</surname><given-names>PD</given-names></name><name><surname>Stark</surname><given-names>S</given-names></name><name><surname>Meyer</surname><given-names>J</given-names></name><name><surname>Milde</surname><given-names>T</given-names></name><name><surname>Schuhmann</surname><given-names>M</given-names></name><name><surname>Ebinger</surname><given-names>M</given-names></name><name><surname>Monoranu</surname><given-names>C-M</given-names></name><name><surname>Ponnuswami</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>C</given-names></name><name><surname>Witt</surname><given-names>O</given-names></name><name><surname>Collins</surname><given-names>VP</given-names></name><name><surname>vonDeimling</surname><given-names>A</given-names></name><name><surname>Jabado</surname><given-names>N</given-names></name><name><surname>Puget</surname><given-names>S</given-names></name><name><surname>Grill</surname><given-names>J</given-names></name><name><surname>Helin</surname><given-names>K</given-names></name><name><surname>Korshunov</surname><given-names>A</given-names></name><name><surname>Lichter</surname><given-names>P</given-names></name><name><surname>Monje</surname><given-names>M</given-names></name><name><surname>Plass</surname><given-names>C</given-names></name><name><surname>Cho</surname><given-names>Y-J</given-names></name><name><surname>Pfister</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas</article-title><source>Cancer Cell</source><volume>24</volume><fpage>660</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2013.10.006</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berlow</surname><given-names>NE</given-names></name><name><surname>Svalina</surname><given-names>MN</given-names></name><name><surname>Quist</surname><given-names>MJ</given-names></name><name><surname>Settelmeyer</surname><given-names>TP</given-names></name><name><surname>Zherebitskiy</surname><given-names>V</given-names></name><name><surname>Kogiso</surname><given-names>M</given-names></name><name><surname>Qi</surname><given-names>L</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Hawkins</surname><given-names>CE</given-names></name><name><surname>Hulleman</surname><given-names>E</given-names></name><name><surname>Li</surname><given-names>X-N</given-names></name><name><surname>Gultekin</surname><given-names>SH</given-names></name><name><surname>Keller</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>IL-13 receptors as possible therapeutic targets in diffuse intrinsic pontine glioma</article-title><source>PLOS ONE</source><volume>13</volume><elocation-id>e0193565</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0193565</pub-id><pub-id pub-id-type="pmid">29621254</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blecher-Gonen</surname><given-names>R</given-names></name><name><surname>Barnett-Itzhaki</surname><given-names>Z</given-names></name><name><surname>Jaitin</surname><given-names>D</given-names></name><name><surname>Amann-Zalcenstein</surname><given-names>D</given-names></name><name><surname>Lara-Astiaso</surname><given-names>D</given-names></name><name><surname>Amit</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>High-throughput chromatin immunoprecipitation for genome-wide mapping of in vivo protein-DNA interactions and epigenomic states</article-title><source>Nature Protocols</source><volume>8</volume><fpage>539</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1038/nprot.2013.023</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bliss</surname><given-names>CI</given-names></name></person-group><year iso-8601-date="1939">1939</year><article-title>The toxicity of poisons applied jointly1</article-title><source>Annals of Applied Biology</source><volume>26</volume><fpage>585</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1111/j.1744-7348.1939.tb06990.x</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braicu</surname><given-names>C</given-names></name><name><surname>Buse</surname><given-names>M</given-names></name><name><surname>Busuioc</surname><given-names>C</given-names></name><name><surname>Drula</surname><given-names>R</given-names></name><name><surname>Gulei</surname><given-names>D</given-names></name><name><surname>Raduly</surname><given-names>L</given-names></name><name><surname>Rusu</surname><given-names>A</given-names></name><name><surname>Irimie</surname><given-names>A</given-names></name><name><surname>Atanasov</surname><given-names>AG</given-names></name><name><surname>Slaby</surname><given-names>O</given-names></name><name><surname>Ionescu</surname><given-names>C</given-names></name><name><surname>Berindan-Neagoe</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A Comprehensive review on MAPK: a promising therapeutic target in cancer</article-title><source>Cancers</source><volume>11</volume><elocation-id>1618</elocation-id><pub-id pub-id-type="doi">10.3390/cancers11101618</pub-id><pub-id pub-id-type="pmid">31652660</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buczkowicz</surname><given-names>P</given-names></name><name><surname>Hoeman</surname><given-names>C</given-names></name><name><surname>Rakopoulos</surname><given-names>P</given-names></name><name><surname>Pajovic</surname><given-names>S</given-names></name><name><surname>Letourneau</surname><given-names>L</given-names></name><name><surname>Dzamba</surname><given-names>M</given-names></name><name><surname>Morrison</surname><given-names>A</given-names></name><name><surname>Lewis</surname><given-names>P</given-names></name><name><surname>Bouffet</surname><given-names>E</given-names></name><name><surname>Bartels</surname><given-names>U</given-names></name><name><surname>Zuccaro</surname><given-names>J</given-names></name><name><surname>Agnihotri</surname><given-names>S</given-names></name><name><surname>Ryall</surname><given-names>S</given-names></name><name><surname>Barszczyk</surname><given-names>M</given-names></name><name><surname>Chornenkyy</surname><given-names>Y</given-names></name><name><surname>Bourgey</surname><given-names>M</given-names></name><name><surname>Bourque</surname><given-names>G</given-names></name><name><surname>Montpetit</surname><given-names>A</given-names></name><name><surname>Cordero</surname><given-names>F</given-names></name><name><surname>Castelo-Branco</surname><given-names>P</given-names></name><name><surname>Mangerel</surname><given-names>J</given-names></name><name><surname>Tabori</surname><given-names>U</given-names></name><name><surname>Ho</surname><given-names>KC</given-names></name><name><surname>Huang</surname><given-names>A</given-names></name><name><surname>Taylor</surname><given-names>KR</given-names></name><name><surname>Mackay</surname><given-names>A</given-names></name><name><surname>Bendel</surname><given-names>AE</given-names></name><name><surname>Nazarian</surname><given-names>J</given-names></name><name><surname>Fangusaro</surname><given-names>JR</given-names></name><name><surname>Karajannis</surname><given-names>MA</given-names></name><name><surname>Zagzag</surname><given-names>D</given-names></name><name><surname>Foreman</surname><given-names>NK</given-names></name><name><surname>Donson</surname><given-names>A</given-names></name><name><surname>Hegert</surname><given-names>JV</given-names></name><name><surname>Smith</surname><given-names>A</given-names></name><name><surname>Chan</surname><given-names>J</given-names></name><name><surname>Lafay-Cousin</surname><given-names>L</given-names></name><name><surname>Dunn</surname><given-names>S</given-names></name><name><surname>Hukin</surname><given-names>J</given-names></name><name><surname>Dunham</surname><given-names>C</given-names></name><name><surname>Scheinemann</surname><given-names>K</given-names></name><name><surname>Michaud</surname><given-names>J</given-names></name><name><surname>Zelcer</surname><given-names>S</given-names></name><name><surname>Ramsay</surname><given-names>D</given-names></name><name><surname>Cain</surname><given-names>J</given-names></name><name><surname>Brennan</surname><given-names>C</given-names></name><name><surname>Souweidane</surname><given-names>MM</given-names></name><name><surname>Jones</surname><given-names>C</given-names></name><name><surname>Allis</surname><given-names>CD</given-names></name><name><surname>Brudno</surname><given-names>M</given-names></name><name><surname>Becher</surname><given-names>O</given-names></name><name><surname>Hawkins</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations</article-title><source>Nature Genetics</source><volume>46</volume><fpage>451</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1038/ng.2936</pub-id><pub-id pub-id-type="pmid">24705254</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>W</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Jarnik</surname><given-names>M</given-names></name><name><surname>Reich</surname><given-names>J</given-names></name><name><surname>Lilly</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The GATOR2 component Wdr24 regulates TORC1 activity and lysosome function</article-title><source>PLOS Genetics</source><volume>12</volume><elocation-id>e1006036</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1006036</pub-id><pub-id pub-id-type="pmid">27166823</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castel</surname><given-names>D</given-names></name><name><surname>Philippe</surname><given-names>C</given-names></name><name><surname>Calmon</surname><given-names>R</given-names></name><name><surname>Le Dret</surname><given-names>L</given-names></name><name><surname>Truffaux</surname><given-names>N</given-names></name><name><surname>Boddaert</surname><given-names>N</given-names></name><name><surname>Pagès</surname><given-names>M</given-names></name><name><surname>Taylor</surname><given-names>KR</given-names></name><name><surname>Saulnier</surname><given-names>P</given-names></name><name><surname>Lacroix</surname><given-names>L</given-names></name><name><surname>Mackay</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>C</given-names></name><name><surname>Sainte-Rose</surname><given-names>C</given-names></name><name><surname>Blauwblomme</surname><given-names>T</given-names></name><name><surname>Andreiuolo</surname><given-names>F</given-names></name><name><surname>Puget</surname><given-names>S</given-names></name><name><surname>Grill</surname><given-names>J</given-names></name><name><surname>Varlet</surname><given-names>P</given-names></name><name><surname>Debily</surname><given-names>M-A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes</article-title><source>Acta Neuropathologica</source><volume>130</volume><fpage>815</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.1007/s00401-015-1478-0</pub-id><pub-id pub-id-type="pmid">26399631</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>K-M</given-names></name><name><surname>Fang</surname><given-names>D</given-names></name><name><surname>Gan</surname><given-names>H</given-names></name><name><surname>Hashizume</surname><given-names>R</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Schroeder</surname><given-names>M</given-names></name><name><surname>Gupta</surname><given-names>N</given-names></name><name><surname>Mueller</surname><given-names>S</given-names></name><name><surname>James</surname><given-names>CD</given-names></name><name><surname>Jenkins</surname><given-names>R</given-names></name><name><surname>Sarkaria</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression</article-title><source>Genes &amp; Development</source><volume>27</volume><fpage>985</fpage><lpage>990</lpage><pub-id pub-id-type="doi">10.1101/gad.217778.113</pub-id><pub-id pub-id-type="pmid">23603901</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Qing</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Targeting oncogenic Myc as a strategy for cancer treatment</article-title><source>Signal Transduction and Targeted Therapy</source><volume>3</volume><elocation-id>0008-7</elocation-id><pub-id pub-id-type="doi">10.1038/s41392-018-0008-7</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooney</surname><given-names>T</given-names></name><name><surname>Onar-Thomas</surname><given-names>A</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Lulla</surname><given-names>R</given-names></name><name><surname>Fangusaro</surname><given-names>J</given-names></name><name><surname>Kramer</surname><given-names>K</given-names></name><name><surname>Baxter</surname><given-names>P</given-names></name><name><surname>Fouladi</surname><given-names>M</given-names></name><name><surname>Dunkel</surname><given-names>IJ</given-names></name><name><surname>Warren</surname><given-names>KE</given-names></name><name><surname>Monje</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>DIPG-22. a phase 1 trial of the histone deacetylase inhibitor panobinostat in pediatric patients with recurrent or refractory diffuse intrinsic pontine glioma: a pediatric brain tumor coNSORTIUM (PBTC) study</article-title><source>Neuro-Oncology</source><volume>20</volume><elocation-id>i53</elocation-id><pub-id pub-id-type="doi">10.1093/neuonc/noy059.115</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>D</given-names></name><name><surname>Qu</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Xiong</surname><given-names>X</given-names></name><name><surname>Liang</surname><given-names>T</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The cross talk between p53 and mtor pathways in response to physiological and genotoxic stresses</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>9</volume><elocation-id>775507</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2021.775507</pub-id><pub-id pub-id-type="pmid">34869377</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D’Artista</surname><given-names>L</given-names></name><name><surname>Bisso</surname><given-names>A</given-names></name><name><surname>Piontini</surname><given-names>A</given-names></name><name><surname>Doni</surname><given-names>M</given-names></name><name><surname>Verrecchia</surname><given-names>A</given-names></name><name><surname>Kress</surname><given-names>TR</given-names></name><name><surname>Morelli</surname><given-names>MJ</given-names></name><name><surname>Del Sal</surname><given-names>G</given-names></name><name><surname>Amati</surname><given-names>B</given-names></name><name><surname>Campaner</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Pin1 is required for sustained B cell proliferation upon oncogenic activation of Myc</article-title><source>Oncotarget</source><volume>7</volume><fpage>21786</fpage><lpage>21798</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.7846</pub-id><pub-id pub-id-type="pmid">26943576</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>Z</given-names></name><name><surname>Kloss</surname><given-names>JM</given-names></name><name><surname>Tuncali</surname><given-names>S</given-names></name><name><surname>Tran</surname><given-names>NL</given-names></name><name><surname>Loftus</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>TROY signals through JAK1-STAT3 to promote glioblastoma cell migration and resistance</article-title><source>Neoplasia</source><volume>22</volume><fpage>352</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1016/j.neo.2020.06.005</pub-id><pub-id pub-id-type="pmid">32629176</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>CA</given-names></name><name><surname>Schlesinger</surname><given-names>F</given-names></name><name><surname>Drenkow</surname><given-names>J</given-names></name><name><surname>Zaleski</surname><given-names>C</given-names></name><name><surname>Jha</surname><given-names>S</given-names></name><name><surname>Batut</surname><given-names>P</given-names></name><name><surname>Chaisson</surname><given-names>M</given-names></name><name><surname>Gingeras</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>STAR: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubiella</surname><given-names>C</given-names></name><name><surname>Pinch</surname><given-names>BJ</given-names></name><name><surname>Koikawa</surname><given-names>K</given-names></name><name><surname>Zaidman</surname><given-names>D</given-names></name><name><surname>Poon</surname><given-names>E</given-names></name><name><surname>Manz</surname><given-names>TD</given-names></name><name><surname>Nabet</surname><given-names>B</given-names></name><name><surname>He</surname><given-names>S</given-names></name><name><surname>Resnick</surname><given-names>E</given-names></name><name><surname>Rogel</surname><given-names>A</given-names></name><name><surname>Langer</surname><given-names>EM</given-names></name><name><surname>Daniel</surname><given-names>CJ</given-names></name><name><surname>Seo</surname><given-names>H-S</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Adelmant</surname><given-names>G</given-names></name><name><surname>Sharifzadeh</surname><given-names>S</given-names></name><name><surname>Ficarro</surname><given-names>SB</given-names></name><name><surname>Jamin</surname><given-names>Y</given-names></name><name><surname>Martins da Costa</surname><given-names>B</given-names></name><name><surname>Zimmerman</surname><given-names>MW</given-names></name><name><surname>Lian</surname><given-names>X</given-names></name><name><surname>Kibe</surname><given-names>S</given-names></name><name><surname>Kozono</surname><given-names>S</given-names></name><name><surname>Doctor</surname><given-names>ZM</given-names></name><name><surname>Browne</surname><given-names>CM</given-names></name><name><surname>Yang</surname><given-names>A</given-names></name><name><surname>Stoler-Barak</surname><given-names>L</given-names></name><name><surname>Shah</surname><given-names>RB</given-names></name><name><surname>Vangos</surname><given-names>NE</given-names></name><name><surname>Geffken</surname><given-names>EA</given-names></name><name><surname>Oren</surname><given-names>R</given-names></name><name><surname>Koide</surname><given-names>E</given-names></name><name><surname>Sidi</surname><given-names>S</given-names></name><name><surname>Shulman</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Marto</surname><given-names>JA</given-names></name><name><surname>Dhe-Paganon</surname><given-names>S</given-names></name><name><surname>Look</surname><given-names>T</given-names></name><name><surname>Zhou</surname><given-names>XZ</given-names></name><name><surname>Lu</surname><given-names>KP</given-names></name><name><surname>Sears</surname><given-names>RC</given-names></name><name><surname>Chesler</surname><given-names>L</given-names></name><name><surname>Gray</surname><given-names>NS</given-names></name><name><surname>London</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo</article-title><source>Nature Chemical Biology</source><volume>17</volume><fpage>954</fpage><lpage>963</lpage><pub-id pub-id-type="doi">10.1038/s41589-021-00786-7</pub-id><pub-id pub-id-type="pmid">33972797</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubois</surname><given-names>FPB</given-names></name><name><surname>Shapira</surname><given-names>O</given-names></name><name><surname>Greenwald</surname><given-names>NF</given-names></name><name><surname>Zack</surname><given-names>T</given-names></name><name><surname>Wala</surname><given-names>J</given-names></name><name><surname>Tsai</surname><given-names>JW</given-names></name><name><surname>Crane</surname><given-names>A</given-names></name><name><surname>Baguette</surname><given-names>A</given-names></name><name><surname>Hadjadj</surname><given-names>D</given-names></name><name><surname>Harutyunyan</surname><given-names>AS</given-names></name><name><surname>Kumar</surname><given-names>KH</given-names></name><name><surname>Blattner-Johnson</surname><given-names>M</given-names></name><name><surname>Vogelzang</surname><given-names>J</given-names></name><name><surname>Sousa</surname><given-names>C</given-names></name><name><surname>Kang</surname><given-names>KS</given-names></name><name><surname>Sinai</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>DK</given-names></name><name><surname>Khadka</surname><given-names>P</given-names></name><name><surname>Lewis</surname><given-names>K</given-names></name><name><surname>Nguyen</surname><given-names>L</given-names></name><name><surname>Malkin</surname><given-names>H</given-names></name><name><surname>Ho</surname><given-names>P</given-names></name><name><surname>O’Rourke</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Gold</surname><given-names>R</given-names></name><name><surname>Deng</surname><given-names>D</given-names></name><name><surname>Serrano</surname><given-names>J</given-names></name><name><surname>Snuderl</surname><given-names>M</given-names></name><name><surname>Jones</surname><given-names>C</given-names></name><name><surname>Wright</surname><given-names>KD</given-names></name><name><surname>Chi</surname><given-names>SN</given-names></name><name><surname>Grill</surname><given-names>J</given-names></name><name><surname>Kleinman</surname><given-names>CL</given-names></name><name><surname>Goumnerova</surname><given-names>LC</given-names></name><name><surname>Jabado</surname><given-names>N</given-names></name><name><surname>Jones</surname><given-names>DTW</given-names></name><name><surname>Kieran</surname><given-names>MW</given-names></name><name><surname>Ligon</surname><given-names>KL</given-names></name><name><surname>Beroukhim</surname><given-names>R</given-names></name><name><surname>Bandopadhayay</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Structural variants shape driver combinations and outcomes in pediatric high-grade glioma</article-title><source>Nature Cancer</source><volume>3</volume><fpage>994</fpage><lpage>1011</lpage><pub-id pub-id-type="doi">10.1038/s43018-022-00403-z</pub-id><pub-id pub-id-type="pmid">35788723</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunham</surname><given-names>I</given-names></name><name><surname>Kundaje</surname><given-names>A</given-names></name><name><surname>Aldred</surname><given-names>SF</given-names></name><name><surname>Collins</surname><given-names>PJ</given-names></name><name><surname>Davis</surname><given-names>CA</given-names></name><name><surname>Doyle</surname><given-names>F</given-names></name><name><surname>Epstein</surname><given-names>CB</given-names></name><name><surname>Frietze</surname><given-names>S</given-names></name><name><surname>Harrow</surname><given-names>J</given-names></name><name><surname>Kaul</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>An integrated encyclopedia of DNA elements in the human genome</article-title><source>Nature</source><volume>489</volume><fpage>57</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1038/nature11247</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farrell</surname><given-names>AS</given-names></name><name><surname>Pelz</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Daniel</surname><given-names>CJ</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Janghorban</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Morgan</surname><given-names>C</given-names></name><name><surname>Impey</surname><given-names>S</given-names></name><name><surname>Sears</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Pin1 regulates the dynamics of c-Myc DNA binding to facilitate target gene regulation and oncogenesis</article-title><source>Molecular and Cellular Biology</source><volume>33</volume><fpage>2930</fpage><lpage>2949</lpage><pub-id pub-id-type="doi">10.1128/MCB.01455-12</pub-id><pub-id pub-id-type="pmid">23716601</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Lei</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Wan</surname><given-names>H</given-names></name><name><surname>Pan</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Zou</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Mi</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>COPB2: a transport proteinwith multifaceted roles in cancer development and progression</article-title><source>Clinical and Translational Oncology</source><volume>23</volume><fpage>2195</fpage><lpage>2205</lpage><pub-id pub-id-type="doi">10.1007/s12094-021-02630-9</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernández-Medarde</surname><given-names>A</given-names></name><name><surname>Santos</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Ras in cancer and developmental diseases</article-title><source>Genes &amp; Cancer</source><volume>2</volume><fpage>344</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1177/1947601911411084</pub-id><pub-id pub-id-type="pmid">21779504</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>KJ</given-names></name><name><surname>Scelfo</surname><given-names>A</given-names></name><name><surname>Jammula</surname><given-names>SG</given-names></name><name><surname>Cuomo</surname><given-names>A</given-names></name><name><surname>Barozzi</surname><given-names>I</given-names></name><name><surname>Stützer</surname><given-names>A</given-names></name><name><surname>Fischle</surname><given-names>W</given-names></name><name><surname>Bonaldi</surname><given-names>T</given-names></name><name><surname>Pasini</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Polycomb-dependent H3K27me1 and H3K27me2 regulate active transcription and enhancer fidelity</article-title><source>Molecular Cell</source><volume>53</volume><fpage>49</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2013.10.030</pub-id><pub-id pub-id-type="pmid">24289921</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filbin</surname><given-names>M</given-names></name><name><surname>Monje</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Developmental origins and emerging therapeutic opportunities for childhood cancer</article-title><source>Nature Medicine</source><volume>25</volume><fpage>367</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1038/s41591-019-0383-9</pub-id><pub-id pub-id-type="pmid">30842674</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fishilevich</surname><given-names>S</given-names></name><name><surname>Nudel</surname><given-names>R</given-names></name><name><surname>Rappaport</surname><given-names>N</given-names></name><name><surname>Hadar</surname><given-names>R</given-names></name><name><surname>Plaschkes</surname><given-names>I</given-names></name><name><surname>Iny Stein</surname><given-names>T</given-names></name><name><surname>Rosen</surname><given-names>N</given-names></name><name><surname>Kohn</surname><given-names>A</given-names></name><name><surname>Twik</surname><given-names>M</given-names></name><name><surname>Safran</surname><given-names>M</given-names></name><name><surname>Lancet</surname><given-names>D</given-names></name><name><surname>Cohen</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>GeneHancer: genome-wide integration of enhancers and target genes in GeneCards</article-title><source>Database</source><volume>2017</volume><elocation-id>bax028</elocation-id><pub-id pub-id-type="doi">10.1093/database/bax028</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flannery</surname><given-names>PC</given-names></name><name><surname>DeSisto</surname><given-names>JA</given-names></name><name><surname>Amani</surname><given-names>V</given-names></name><name><surname>Venkataraman</surname><given-names>S</given-names></name><name><surname>Lemma</surname><given-names>RT</given-names></name><name><surname>Prince</surname><given-names>EW</given-names></name><name><surname>Donson</surname><given-names>A</given-names></name><name><surname>Moroze</surname><given-names>EE</given-names></name><name><surname>Hoffman</surname><given-names>L</given-names></name><name><surname>Levy</surname><given-names>JMM</given-names></name><name><surname>Foreman</surname><given-names>N</given-names></name><name><surname>Vibhakar</surname><given-names>R</given-names></name><name><surname>Green</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma</article-title><source>Oncology Reports</source><volume>39</volume><fpage>455</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.3892/or.2017.6122</pub-id><pub-id pub-id-type="pmid">29207163</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fontebasso</surname><given-names>AM</given-names></name><name><surname>Papillon-Cavanagh</surname><given-names>S</given-names></name><name><surname>Schwartzentruber</surname><given-names>J</given-names></name><name><surname>Nikbakht</surname><given-names>H</given-names></name><name><surname>Gerges</surname><given-names>N</given-names></name><name><surname>Fiset</surname><given-names>P-O</given-names></name><name><surname>Bechet</surname><given-names>D</given-names></name><name><surname>Faury</surname><given-names>D</given-names></name><name><surname>De Jay</surname><given-names>N</given-names></name><name><surname>Ramkissoon</surname><given-names>LA</given-names></name><name><surname>Corcoran</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>DTW</given-names></name><name><surname>Sturm</surname><given-names>D</given-names></name><name><surname>Johann</surname><given-names>P</given-names></name><name><surname>Tomita</surname><given-names>T</given-names></name><name><surname>Goldman</surname><given-names>S</given-names></name><name><surname>Nagib</surname><given-names>M</given-names></name><name><surname>Bendel</surname><given-names>A</given-names></name><name><surname>Goumnerova</surname><given-names>L</given-names></name><name><surname>Bowers</surname><given-names>DC</given-names></name><name><surname>Leonard</surname><given-names>JR</given-names></name><name><surname>Rubin</surname><given-names>JB</given-names></name><name><surname>Alden</surname><given-names>T</given-names></name><name><surname>Browd</surname><given-names>S</given-names></name><name><surname>Geyer</surname><given-names>JR</given-names></name><name><surname>Leary</surname><given-names>S</given-names></name><name><surname>Jallo</surname><given-names>G</given-names></name><name><surname>Cohen</surname><given-names>K</given-names></name><name><surname>Gupta</surname><given-names>N</given-names></name><name><surname>Prados</surname><given-names>MD</given-names></name><name><surname>Carret</surname><given-names>A-S</given-names></name><name><surname>Ellezam</surname><given-names>B</given-names></name><name><surname>Crevier</surname><given-names>L</given-names></name><name><surname>Klekner</surname><given-names>A</given-names></name><name><surname>Bognar</surname><given-names>L</given-names></name><name><surname>Hauser</surname><given-names>P</given-names></name><name><surname>Garami</surname><given-names>M</given-names></name><name><surname>Myseros</surname><given-names>J</given-names></name><name><surname>Dong</surname><given-names>Z</given-names></name><name><surname>Siegel</surname><given-names>PM</given-names></name><name><surname>Malkin</surname><given-names>H</given-names></name><name><surname>Ligon</surname><given-names>AH</given-names></name><name><surname>Albrecht</surname><given-names>S</given-names></name><name><surname>Pfister</surname><given-names>SM</given-names></name><name><surname>Ligon</surname><given-names>KL</given-names></name><name><surname>Majewski</surname><given-names>J</given-names></name><name><surname>Jabado</surname><given-names>N</given-names></name><name><surname>Kieran</surname><given-names>MW</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma</article-title><source>Nature Genetics</source><volume>46</volume><fpage>462</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1038/ng.2950</pub-id><pub-id pub-id-type="pmid">24705250</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furth</surname><given-names>N</given-names></name><name><surname>Algranati</surname><given-names>D</given-names></name><name><surname>Dassa</surname><given-names>B</given-names></name><name><surname>Beresh</surname><given-names>O</given-names></name><name><surname>Fedyuk</surname><given-names>V</given-names></name><name><surname>Morris</surname><given-names>N</given-names></name><name><surname>Kasper</surname><given-names>LH</given-names></name><name><surname>Jones</surname><given-names>D</given-names></name><name><surname>Monje</surname><given-names>M</given-names></name><name><surname>Baker</surname><given-names>SJ</given-names></name><name><surname>Shema</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>H3-K27M-mutant nucleosomes interact with MLL1 to shape the glioma epigenetic landscape</article-title><source>Cell Reports</source><volume>39</volume><elocation-id>110836</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2022.110836</pub-id><pub-id pub-id-type="pmid">35584667</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grasso</surname><given-names>CS</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Truffaux</surname><given-names>N</given-names></name><name><surname>Berlow</surname><given-names>NE</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Debily</surname><given-names>M-A</given-names></name><name><surname>Quist</surname><given-names>MJ</given-names></name><name><surname>Davis</surname><given-names>LE</given-names></name><name><surname>Huang</surname><given-names>EC</given-names></name><name><surname>Woo</surname><given-names>PJ</given-names></name><name><surname>Ponnuswami</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Johung</surname><given-names>TB</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Kogiso</surname><given-names>M</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Qi</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Hütt-Cabezas</surname><given-names>M</given-names></name><name><surname>Warren</surname><given-names>KE</given-names></name><name><surname>Le Dret</surname><given-names>L</given-names></name><name><surname>Meltzer</surname><given-names>PS</given-names></name><name><surname>Mao</surname><given-names>H</given-names></name><name><surname>Quezado</surname><given-names>M</given-names></name><name><surname>van Vuurden</surname><given-names>DG</given-names></name><name><surname>Abraham</surname><given-names>J</given-names></name><name><surname>Fouladi</surname><given-names>M</given-names></name><name><surname>Svalina</surname><given-names>MN</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Hawkins</surname><given-names>C</given-names></name><name><surname>Nazarian</surname><given-names>J</given-names></name><name><surname>Alonso</surname><given-names>MM</given-names></name><name><surname>Raabe</surname><given-names>EH</given-names></name><name><surname>Hulleman</surname><given-names>E</given-names></name><name><surname>Spellman</surname><given-names>PT</given-names></name><name><surname>Li</surname><given-names>X-N</given-names></name><name><surname>Keller</surname><given-names>C</given-names></name><name><surname>Pal</surname><given-names>R</given-names></name><name><surname>Grill</surname><given-names>J</given-names></name><name><surname>Monje</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Functionally defined therapeutic targets in diffuse intrinsic pontine glioma</article-title><source>Nature Medicine</source><volume>21</volume><fpage>555</fpage><lpage>559</lpage><pub-id pub-id-type="doi">10.1038/nm.3855</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guertin</surname><given-names>DA</given-names></name><name><surname>Sabatini</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The pharmacology of mTOR inhibition</article-title><source>Science Signaling</source><volume>2</volume><elocation-id>pe24</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.267pe24</pub-id><pub-id pub-id-type="pmid">19383975</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harpaz</surname><given-names>N</given-names></name><name><surname>Mittelman</surname><given-names>T</given-names></name><name><surname>Beresh</surname><given-names>O</given-names></name><name><surname>Griess</surname><given-names>O</given-names></name><name><surname>Furth</surname><given-names>N</given-names></name><name><surname>Salame</surname><given-names>TM</given-names></name><name><surname>Oren</surname><given-names>R</given-names></name><name><surname>Fellus Alyagor</surname><given-names>L</given-names></name><name><surname>Harmelin</surname><given-names>A</given-names></name><name><surname>Alexandrescu</surname><given-names>S</given-names></name><name><surname>Marques</surname><given-names>JG</given-names></name><name><surname>Filbin</surname><given-names>MG</given-names></name><name><surname>Ron</surname><given-names>G</given-names></name><name><surname>Shema</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Single-cell epigenetic analysis reveals principles of chromatin states in H3.3-K27M gliomas</article-title><source>Molecular Cell</source><volume>82</volume><fpage>2696</fpage><lpage>2713</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2022.05.023</pub-id><pub-id pub-id-type="pmid">35716669</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harutyunyan</surname><given-names>AS</given-names></name><name><surname>Krug</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Papillon-Cavanagh</surname><given-names>S</given-names></name><name><surname>Zeinieh</surname><given-names>M</given-names></name><name><surname>De Jay</surname><given-names>N</given-names></name><name><surname>Deshmukh</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>CCL</given-names></name><name><surname>Belle</surname><given-names>J</given-names></name><name><surname>Mikael</surname><given-names>LG</given-names></name><name><surname>Marchione</surname><given-names>DM</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Nikbakht</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Cagnone</surname><given-names>G</given-names></name><name><surname>Cheung</surname><given-names>WA</given-names></name><name><surname>Mohammadnia</surname><given-names>A</given-names></name><name><surname>Bechet</surname><given-names>D</given-names></name><name><surname>Faury</surname><given-names>D</given-names></name><name><surname>McConechy</surname><given-names>MK</given-names></name><name><surname>Pathania</surname><given-names>M</given-names></name><name><surname>Jain</surname><given-names>SU</given-names></name><name><surname>Ellezam</surname><given-names>B</given-names></name><name><surname>Weil</surname><given-names>AG</given-names></name><name><surname>Montpetit</surname><given-names>A</given-names></name><name><surname>Salomoni</surname><given-names>P</given-names></name><name><surname>Pastinen</surname><given-names>T</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Lewis</surname><given-names>PW</given-names></name><name><surname>Garcia</surname><given-names>BA</given-names></name><name><surname>Kleinman</surname><given-names>CL</given-names></name><name><surname>Jabado</surname><given-names>N</given-names></name><name><surname>Majewski</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>H3K27M induces defective chromatin spread of PRC2-mediated repressive H3K27me2/me3 and is essential for glioma tumorigenesis</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>1262</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-09140-x</pub-id><pub-id pub-id-type="pmid">30890717</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashizume</surname><given-names>R</given-names></name><name><surname>Andor</surname><given-names>N</given-names></name><name><surname>Ihara</surname><given-names>Y</given-names></name><name><surname>Lerner</surname><given-names>R</given-names></name><name><surname>Gan</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Fang</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Tom</surname><given-names>MW</given-names></name><name><surname>Ngo</surname><given-names>V</given-names></name><name><surname>Solomon</surname><given-names>D</given-names></name><name><surname>Mueller</surname><given-names>S</given-names></name><name><surname>Paris</surname><given-names>PL</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Petritsch</surname><given-names>C</given-names></name><name><surname>Gupta</surname><given-names>N</given-names></name><name><surname>Waldman</surname><given-names>TA</given-names></name><name><surname>James</surname><given-names>CD</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma</article-title><source>Nature Medicine</source><volume>20</volume><fpage>1394</fpage><lpage>1396</lpage><pub-id pub-id-type="doi">10.1038/nm.3716</pub-id><pub-id pub-id-type="pmid">25401693</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayden</surname><given-names>E</given-names></name><name><surname>Holliday</surname><given-names>H</given-names></name><name><surname>Lehmann</surname><given-names>R</given-names></name><name><surname>Khan</surname><given-names>A</given-names></name><name><surname>Tsoli</surname><given-names>M</given-names></name><name><surname>Rayner</surname><given-names>BS</given-names></name><name><surname>Ziegler</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Therapeutic targets in diffuse midline gliomas-an emerging landscape</article-title><source>Cancers</source><volume>13</volume><elocation-id>6251</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13246251</pub-id><pub-id pub-id-type="pmid">34944870</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hennika</surname><given-names>T</given-names></name><name><surname>Hu</surname><given-names>G</given-names></name><name><surname>Olaciregui</surname><given-names>NG</given-names></name><name><surname>Barton</surname><given-names>KL</given-names></name><name><surname>Ehteda</surname><given-names>A</given-names></name><name><surname>Chitranjan</surname><given-names>A</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name><name><surname>Gifford</surname><given-names>AJ</given-names></name><name><surname>Tsoli</surname><given-names>M</given-names></name><name><surname>Ziegler</surname><given-names>DS</given-names></name><name><surname>Carcaboso</surname><given-names>AM</given-names></name><name><surname>Becher</surname><given-names>OJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Pre-clinical study of panobinostat in xenograft and genetically engineered murine diffuse intrinsic pontine glioma models</article-title><source>PLOS ONE</source><volume>12</volume><elocation-id>e0169485</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0169485</pub-id><pub-id pub-id-type="pmid">28052119</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hölzel</surname><given-names>M</given-names></name><name><surname>Rohrmoser</surname><given-names>M</given-names></name><name><surname>Schlee</surname><given-names>M</given-names></name><name><surname>Grimm</surname><given-names>T</given-names></name><name><surname>Harasim</surname><given-names>T</given-names></name><name><surname>Malamoussi</surname><given-names>A</given-names></name><name><surname>Gruber-Eber</surname><given-names>A</given-names></name><name><surname>Kremmer</surname><given-names>E</given-names></name><name><surname>Hiddemann</surname><given-names>W</given-names></name><name><surname>Bornkamm</surname><given-names>GW</given-names></name><name><surname>Eick</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Mammalian WDR12 is a novel member of the Pes1-Bop1 complex and is required for ribosome biogenesis and cell proliferation</article-title><source>The Journal of Cell Biology</source><volume>170</volume><fpage>367</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1083/jcb.200501141</pub-id><pub-id pub-id-type="pmid">16043514</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ianevski</surname><given-names>A</given-names></name><name><surname>Giri</surname><given-names>AK</given-names></name><name><surname>Aittokallio</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SynergyFinder 2.0: visual analytics of multi-drug combination synergies</article-title><source>Nucleic Acids Research</source><volume>48</volume><fpage>W488</fpage><lpage>W493</lpage><pub-id pub-id-type="doi">10.1093/nar/gkaa216</pub-id><pub-id pub-id-type="pmid">32246720</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>SU</given-names></name><name><surname>Do</surname><given-names>TJ</given-names></name><name><surname>Lund</surname><given-names>PJ</given-names></name><name><surname>Rashoff</surname><given-names>AQ</given-names></name><name><surname>Diehl</surname><given-names>KL</given-names></name><name><surname>Cieslik</surname><given-names>M</given-names></name><name><surname>Bajic</surname><given-names>A</given-names></name><name><surname>Juretic</surname><given-names>N</given-names></name><name><surname>Deshmukh</surname><given-names>S</given-names></name><name><surname>Venneti</surname><given-names>S</given-names></name><name><surname>Muir</surname><given-names>TW</given-names></name><name><surname>Garcia</surname><given-names>BA</given-names></name><name><surname>Jabado</surname><given-names>N</given-names></name><name><surname>Lewis</surname><given-names>PW</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>2146</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-09981-6</pub-id><pub-id pub-id-type="pmid">31086175</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>SU</given-names></name><name><surname>Rashoff</surname><given-names>AQ</given-names></name><name><surname>Krabbenhoft</surname><given-names>SD</given-names></name><name><surname>Hoelper</surname><given-names>D</given-names></name><name><surname>Do</surname><given-names>TJ</given-names></name><name><surname>Gibson</surname><given-names>TJ</given-names></name><name><surname>Lundgren</surname><given-names>SM</given-names></name><name><surname>Bondra</surname><given-names>ER</given-names></name><name><surname>Deshmukh</surname><given-names>S</given-names></name><name><surname>Harutyunyan</surname><given-names>AS</given-names></name><name><surname>Juretic</surname><given-names>N</given-names></name><name><surname>Jabado</surname><given-names>N</given-names></name><name><surname>Harrison</surname><given-names>MM</given-names></name><name><surname>Lewis</surname><given-names>PW</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>H3 K27M and EZHIP Impede H3K27-methylation spreading by inhibiting allosterically stimulated PRC2</article-title><source>Molecular Cell</source><volume>80</volume><fpage>726</fpage><lpage>735</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2020.09.028</pub-id><pub-id pub-id-type="pmid">33049227</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaitin</surname><given-names>DA</given-names></name><name><surname>Kenigsberg</surname><given-names>E</given-names></name><name><surname>Keren-Shaul</surname><given-names>H</given-names></name><name><surname>Elefant</surname><given-names>N</given-names></name><name><surname>Paul</surname><given-names>F</given-names></name><name><surname>Zaretsky</surname><given-names>I</given-names></name><name><surname>Mildner</surname><given-names>A</given-names></name><name><surname>Cohen</surname><given-names>N</given-names></name><name><surname>Jung</surname><given-names>S</given-names></name><name><surname>Tanay</surname><given-names>A</given-names></name><name><surname>Amit</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Massively parallel single-cell RNA-seq for marker-free decomposition of tissues into cell types</article-title><source>Science</source><volume>343</volume><fpage>776</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.1126/science.1247651</pub-id><pub-id pub-id-type="pmid">24531970</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jessa</surname><given-names>S</given-names></name><name><surname>Mohammadnia</surname><given-names>A</given-names></name><name><surname>Harutyunyan</surname><given-names>AS</given-names></name><name><surname>Hulswit</surname><given-names>M</given-names></name><name><surname>Varadharajan</surname><given-names>S</given-names></name><name><surname>Lakkis</surname><given-names>H</given-names></name><name><surname>Kabir</surname><given-names>N</given-names></name><name><surname>Bashardanesh</surname><given-names>Z</given-names></name><name><surname>Hébert</surname><given-names>S</given-names></name><name><surname>Faury</surname><given-names>D</given-names></name><name><surname>Vladoiu</surname><given-names>MC</given-names></name><name><surname>Worme</surname><given-names>S</given-names></name><name><surname>Coutelier</surname><given-names>M</given-names></name><name><surname>Krug</surname><given-names>B</given-names></name><name><surname>Faria Andrade</surname><given-names>A</given-names></name><name><surname>Pathania</surname><given-names>M</given-names></name><name><surname>Bajic</surname><given-names>A</given-names></name><name><surname>Weil</surname><given-names>AG</given-names></name><name><surname>Ellezam</surname><given-names>B</given-names></name><name><surname>Atkinson</surname><given-names>J</given-names></name><name><surname>Dudley</surname><given-names>RWR</given-names></name><name><surname>Farmer</surname><given-names>J-P</given-names></name><name><surname>Perreault</surname><given-names>S</given-names></name><name><surname>Garcia</surname><given-names>BA</given-names></name><name><surname>Larouche</surname><given-names>V</given-names></name><name><surname>Blanchette</surname><given-names>M</given-names></name><name><surname>Garzia</surname><given-names>L</given-names></name><name><surname>Bhaduri</surname><given-names>A</given-names></name><name><surname>Ligon</surname><given-names>KL</given-names></name><name><surname>Bandopadhayay</surname><given-names>P</given-names></name><name><surname>Taylor</surname><given-names>MD</given-names></name><name><surname>Mack</surname><given-names>SC</given-names></name><name><surname>Jabado</surname><given-names>N</given-names></name><name><surname>Kleinman</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>K27M in canonical and noncanonical H3 variants occurs in distinct oligodendroglial cell lineages in brain midline gliomas</article-title><source>Nature Genetics</source><volume>54</volume><fpage>1865</fpage><lpage>1880</lpage><pub-id pub-id-type="doi">10.1038/s41588-022-01205-w</pub-id><pub-id pub-id-type="pmid">36471070</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johung</surname><given-names>TB</given-names></name><name><surname>Monje</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Diffuse intrinsic pontine glioma: new pathophysiological insights and emerging therapeutic targets</article-title><source>Current Neuropharmacology</source><volume>15</volume><fpage>88</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.2174/1570159X14666160509123229</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>PA</given-names></name><name><surname>Ohtani</surname><given-names>H</given-names></name><name><surname>Chakravarthy</surname><given-names>A</given-names></name><name><surname>De Carvalho</surname><given-names>DD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Epigenetic therapy in immune-oncology</article-title><source>Nature Reviews. Cancer</source><volume>19</volume><fpage>151</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1038/s41568-019-0109-9</pub-id><pub-id pub-id-type="pmid">30723290</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanai</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics</article-title><source>Pharmacology &amp; Therapeutics</source><volume>230</volume><elocation-id>107964</elocation-id><pub-id pub-id-type="doi">10.1016/j.pharmthera.2021.107964</pub-id><pub-id pub-id-type="pmid">34390745</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanehisa</surname><given-names>M</given-names></name><name><surname>Goto</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>KEGG: kyoto encyclopedia of genes and genomes</article-title><source>Nucleic Acids Research</source><volume>28</volume><fpage>27</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1093/nar/28.1.27</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanehisa</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Toward understanding the origin and evolution of cellular organisms</article-title><source>Protein Science</source><volume>28</volume><fpage>1947</fpage><lpage>1951</lpage><pub-id pub-id-type="doi">10.1002/pro.3715</pub-id><pub-id pub-id-type="pmid">31441146</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keenan</surname><given-names>AB</given-names></name><name><surname>Torre</surname><given-names>D</given-names></name><name><surname>Lachmann</surname><given-names>A</given-names></name><name><surname>Leong</surname><given-names>AK</given-names></name><name><surname>Wojciechowicz</surname><given-names>ML</given-names></name><name><surname>Utti</surname><given-names>V</given-names></name><name><surname>Jagodnik</surname><given-names>KM</given-names></name><name><surname>Kropiwnicki</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Ma’ayan</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>ChEA3: transcription factor enrichment analysis by orthogonal omics integration</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>W212</fpage><lpage>W224</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz446</pub-id><pub-id pub-id-type="pmid">31114921</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>BK</given-names></name><name><surname>Lamming</surname><given-names>DW</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The mechanistic target of rapamycin: the grand conducTOR of metabolism and aging</article-title><source>Cell Metabolism</source><volume>23</volume><fpage>990</fpage><lpage>1003</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2016.05.009</pub-id><pub-id pub-id-type="pmid">27304501</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keren-Shaul</surname><given-names>H</given-names></name><name><surname>Kenigsberg</surname><given-names>E</given-names></name><name><surname>Jaitin</surname><given-names>DA</given-names></name><name><surname>David</surname><given-names>E</given-names></name><name><surname>Paul</surname><given-names>F</given-names></name><name><surname>Tanay</surname><given-names>A</given-names></name><name><surname>Amit</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>MARS-seq2.0: an experimental and analytical pipeline for indexed sorting combined with single-cell RNA sequencing</article-title><source>Nature Protocols</source><volume>14</volume><fpage>1841</fpage><lpage>1862</lpage><pub-id pub-id-type="doi">10.1038/s41596-019-0164-4</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohen</surname><given-names>R</given-names></name><name><surname>Barlev</surname><given-names>J</given-names></name><name><surname>Hornung</surname><given-names>G</given-names></name><name><surname>Stelzer</surname><given-names>G</given-names></name><name><surname>Feldmesser</surname><given-names>E</given-names></name><name><surname>Kogan</surname><given-names>K</given-names></name><name><surname>Safran</surname><given-names>M</given-names></name><name><surname>Leshkowitz</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>UTAP: user-friendly transcriptome analysis pipeline</article-title><source>BMC Bioinformatics</source><volume>20</volume><elocation-id>154</elocation-id><pub-id pub-id-type="doi">10.1186/s12859-019-2728-2</pub-id><pub-id pub-id-type="pmid">30909881</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krug</surname><given-names>B</given-names></name><name><surname>De Jay</surname><given-names>N</given-names></name><name><surname>Harutyunyan</surname><given-names>AS</given-names></name><name><surname>Deshmukh</surname><given-names>S</given-names></name><name><surname>Marchione</surname><given-names>DM</given-names></name><name><surname>Guilhamon</surname><given-names>P</given-names></name><name><surname>Bertrand</surname><given-names>KC</given-names></name><name><surname>Mikael</surname><given-names>LG</given-names></name><name><surname>McConechy</surname><given-names>MK</given-names></name><name><surname>Chen</surname><given-names>CCL</given-names></name><name><surname>Khazaei</surname><given-names>S</given-names></name><name><surname>Koncar</surname><given-names>RF</given-names></name><name><surname>Agnihotri</surname><given-names>S</given-names></name><name><surname>Faury</surname><given-names>D</given-names></name><name><surname>Ellezam</surname><given-names>B</given-names></name><name><surname>Weil</surname><given-names>AG</given-names></name><name><surname>Ursini-Siegel</surname><given-names>J</given-names></name><name><surname>De Carvalho</surname><given-names>DD</given-names></name><name><surname>Dirks</surname><given-names>PB</given-names></name><name><surname>Lewis</surname><given-names>PW</given-names></name><name><surname>Salomoni</surname><given-names>P</given-names></name><name><surname>Lupien</surname><given-names>M</given-names></name><name><surname>Arrowsmith</surname><given-names>C</given-names></name><name><surname>Lasko</surname><given-names>PF</given-names></name><name><surname>Garcia</surname><given-names>BA</given-names></name><name><surname>Kleinman</surname><given-names>CL</given-names></name><name><surname>Jabado</surname><given-names>N</given-names></name><name><surname>Mack</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Pervasive H3K27 acetylation leads to erv expression and a therapeutic vulnerability in H3K27M gliomas</article-title><source>Cancer Cell</source><volume>35</volume><fpage>782</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2019.04.004</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuleshov</surname><given-names>MV</given-names></name><name><surname>Jones</surname><given-names>MR</given-names></name><name><surname>Rouillard</surname><given-names>AD</given-names></name><name><surname>Fernandez</surname><given-names>NF</given-names></name><name><surname>Duan</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Koplev</surname><given-names>S</given-names></name><name><surname>Jenkins</surname><given-names>SL</given-names></name><name><surname>Jagodnik</surname><given-names>KM</given-names></name><name><surname>Lachmann</surname><given-names>A</given-names></name><name><surname>McDermott</surname><given-names>MG</given-names></name><name><surname>Monteiro</surname><given-names>CD</given-names></name><name><surname>Gundersen</surname><given-names>GW</given-names></name><name><surname>Ma’ayan</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Enrichr: a comprehensive gene set enrichment analysis web server 2016 update</article-title><source>Nucleic Acids Research</source><volume>44</volume><fpage>W90</fpage><lpage>W97</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw377</pub-id><pub-id pub-id-type="pmid">27141961</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuo</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Cai</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Target of rapamycin complex 2 regulates cell growth via Myc in <italic>Drosophila</italic></article-title><source>Scientific Reports</source><volume>5</volume><elocation-id>srep10339</elocation-id><pub-id pub-id-type="doi">10.1038/srep10339</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langenkamp</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Lugano</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Elhassan</surname><given-names>TEA</given-names></name><name><surname>Georganaki</surname><given-names>M</given-names></name><name><surname>Bazzar</surname><given-names>W</given-names></name><name><surname>Lööf</surname><given-names>J</given-names></name><name><surname>Trendelenburg</surname><given-names>G</given-names></name><name><surname>Essand</surname><given-names>M</given-names></name><name><surname>Pontén</surname><given-names>F</given-names></name><name><surname>Smits</surname><given-names>A</given-names></name><name><surname>Dimberg</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Elevated expression of the C-type lectin CD93 in the glioblastoma vasculature regulates cytoskeletal rearrangements that enhance vessel function and reduce host survival</article-title><source>Cancer Research</source><volume>75</volume><fpage>4504</fpage><lpage>4516</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-3636</pub-id><pub-id pub-id-type="pmid">26363010</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langmead</surname><given-names>B</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fast gapped-read alignment with Bowtie 2</article-title><source>Nature Methods</source><volume>9</volume><fpage>357</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1923</pub-id><pub-id pub-id-type="pmid">22388286</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>DW</given-names></name><name><surname>Ramakrishnan</surname><given-names>D</given-names></name><name><surname>Valenta</surname><given-names>J</given-names></name><name><surname>Parney</surname><given-names>IF</given-names></name><name><surname>Bayless</surname><given-names>KJ</given-names></name><name><surname>Sitcheran</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The NF-κB RelB protein is an oncogenic driver of mesenchymal glioma</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e57489</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0057489</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leszczynska</surname><given-names>KB</given-names></name><name><surname>Jayaprakash</surname><given-names>C</given-names></name><name><surname>Kaminska</surname><given-names>B</given-names></name><name><surname>Mieczkowski</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>emerging advances in combinatorial treatments of epigenetically altered pediatric high-grade H3K27M gliomas</article-title><source>Frontiers in Genetics</source><volume>12</volume><elocation-id>742561</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2021.742561</pub-id><pub-id pub-id-type="pmid">34646308</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>PW</given-names></name><name><surname>Müller</surname><given-names>MM</given-names></name><name><surname>Koletsky</surname><given-names>MS</given-names></name><name><surname>Cordero</surname><given-names>F</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Banaszynski</surname><given-names>LA</given-names></name><name><surname>Garcia</surname><given-names>BA</given-names></name><name><surname>Muir</surname><given-names>TW</given-names></name><name><surname>Becher</surname><given-names>OJ</given-names></name><name><surname>Allis</surname><given-names>CD</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma</article-title><source>Science</source><volume>340</volume><fpage>857</fpage><lpage>861</lpage><pub-id pub-id-type="doi">10.1126/science.1232245</pub-id><pub-id pub-id-type="pmid">23539183</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liberzon</surname><given-names>A</given-names></name><name><surname>Birger</surname><given-names>C</given-names></name><name><surname>Thorvaldsdóttir</surname><given-names>H</given-names></name><name><surname>Ghandi</surname><given-names>M</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The molecular signatures database (MSigDB) hallmark gene set collection</article-title><source>Cell Systems</source><volume>1</volume><fpage>417</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2015.12.004</pub-id><pub-id pub-id-type="pmid">26771021</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>GL</given-names></name><name><surname>Wilson</surname><given-names>KM</given-names></name><name><surname>Ceribelli</surname><given-names>M</given-names></name><name><surname>Stanton</surname><given-names>BZ</given-names></name><name><surname>Woo</surname><given-names>PJ</given-names></name><name><surname>Kreimer</surname><given-names>S</given-names></name><name><surname>Qin</surname><given-names>EY</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Lennon</surname><given-names>J</given-names></name><name><surname>Nagaraja</surname><given-names>S</given-names></name><name><surname>Morris</surname><given-names>PJ</given-names></name><name><surname>Quezada</surname><given-names>M</given-names></name><name><surname>Gillespie</surname><given-names>SM</given-names></name><name><surname>Duveau</surname><given-names>DY</given-names></name><name><surname>Michalowski</surname><given-names>AM</given-names></name><name><surname>Shinn</surname><given-names>P</given-names></name><name><surname>Guha</surname><given-names>R</given-names></name><name><surname>Ferrer</surname><given-names>M</given-names></name><name><surname>Klumpp-Thomas</surname><given-names>C</given-names></name><name><surname>Michael</surname><given-names>S</given-names></name><name><surname>McKnight</surname><given-names>C</given-names></name><name><surname>Minhas</surname><given-names>P</given-names></name><name><surname>Itkin</surname><given-names>Z</given-names></name><name><surname>Raabe</surname><given-names>EH</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Ghanem</surname><given-names>R</given-names></name><name><surname>Geraghty</surname><given-names>AC</given-names></name><name><surname>Ni</surname><given-names>L</given-names></name><name><surname>Andreasson</surname><given-names>KI</given-names></name><name><surname>Vitanza</surname><given-names>NA</given-names></name><name><surname>Warren</surname><given-names>KE</given-names></name><name><surname>Thomas</surname><given-names>CJ</given-names></name><name><surname>Monje</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening</article-title><source>Science Translational Medicine</source><volume>11</volume><elocation-id>eaaw0064</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aaw0064</pub-id><pub-id pub-id-type="pmid">31748226</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>0550-8</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>Pang</surname><given-names>C</given-names></name><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>F</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Activating transcription factor 3 is overexpressed in human glioma and its knockdown in glioblastoma cells causes growth inhibition both in vitro and in vivo</article-title><source>International Journal of Molecular Medicine</source><volume>35</volume><fpage>1561</fpage><lpage>1573</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2015.2173</pub-id><pub-id pub-id-type="pmid">25872784</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackay</surname><given-names>A</given-names></name><name><surname>Burford</surname><given-names>A</given-names></name><name><surname>Carvalho</surname><given-names>D</given-names></name><name><surname>Izquierdo</surname><given-names>E</given-names></name><name><surname>Fazal-Salom</surname><given-names>J</given-names></name><name><surname>Taylor</surname><given-names>KR</given-names></name><name><surname>Bjerke</surname><given-names>L</given-names></name><name><surname>Clarke</surname><given-names>M</given-names></name><name><surname>Vinci</surname><given-names>M</given-names></name><name><surname>Nandhabalan</surname><given-names>M</given-names></name><name><surname>Temelso</surname><given-names>S</given-names></name><name><surname>Popov</surname><given-names>S</given-names></name><name><surname>Molinari</surname><given-names>V</given-names></name><name><surname>Raman</surname><given-names>P</given-names></name><name><surname>Waanders</surname><given-names>AJ</given-names></name><name><surname>Han</surname><given-names>HJ</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Marshall</surname><given-names>L</given-names></name><name><surname>Zacharoulis</surname><given-names>S</given-names></name><name><surname>Vaidya</surname><given-names>S</given-names></name><name><surname>Mandeville</surname><given-names>HC</given-names></name><name><surname>Bridges</surname><given-names>LR</given-names></name><name><surname>Martin</surname><given-names>AJ</given-names></name><name><surname>Al-Sarraj</surname><given-names>S</given-names></name><name><surname>Chandler</surname><given-names>C</given-names></name><name><surname>Ng</surname><given-names>H-K</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Mu</surname><given-names>K</given-names></name><name><surname>Trabelsi</surname><given-names>S</given-names></name><name><surname>Brahim</surname><given-names>DH-B</given-names></name><name><surname>Kisljakov</surname><given-names>AN</given-names></name><name><surname>Konovalov</surname><given-names>DM</given-names></name><name><surname>Moore</surname><given-names>AS</given-names></name><name><surname>Carcaboso</surname><given-names>AM</given-names></name><name><surname>Sunol</surname><given-names>M</given-names></name><name><surname>de Torres</surname><given-names>C</given-names></name><name><surname>Cruz</surname><given-names>O</given-names></name><name><surname>Mora</surname><given-names>J</given-names></name><name><surname>Shats</surname><given-names>LI</given-names></name><name><surname>Stavale</surname><given-names>JN</given-names></name><name><surname>Bidinotto</surname><given-names>LT</given-names></name><name><surname>Reis</surname><given-names>RM</given-names></name><name><surname>Entz-Werle</surname><given-names>N</given-names></name><name><surname>Farrell</surname><given-names>M</given-names></name><name><surname>Cryan</surname><given-names>J</given-names></name><name><surname>Crimmins</surname><given-names>D</given-names></name><name><surname>Caird</surname><given-names>J</given-names></name><name><surname>Pears</surname><given-names>J</given-names></name><name><surname>Monje</surname><given-names>M</given-names></name><name><surname>Debily</surname><given-names>M-A</given-names></name><name><surname>Castel</surname><given-names>D</given-names></name><name><surname>Grill</surname><given-names>J</given-names></name><name><surname>Hawkins</surname><given-names>C</given-names></name><name><surname>Nikbakht</surname><given-names>H</given-names></name><name><surname>Jabado</surname><given-names>N</given-names></name><name><surname>Baker</surname><given-names>SJ</given-names></name><name><surname>Pfister</surname><given-names>SM</given-names></name><name><surname>Jones</surname><given-names>DTW</given-names></name><name><surname>Fouladi</surname><given-names>M</given-names></name><name><surname>von Bueren</surname><given-names>AO</given-names></name><name><surname>Baudis</surname><given-names>M</given-names></name><name><surname>Resnick</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma</article-title><source>Cancer Cell</source><volume>32</volume><fpage>520</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2017.08.017</pub-id><pub-id pub-id-type="pmid">28966033</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martens</surname><given-names>M</given-names></name><name><surname>Ammar</surname><given-names>A</given-names></name><name><surname>Riutta</surname><given-names>A</given-names></name><name><surname>Waagmeester</surname><given-names>A</given-names></name><name><surname>Slenter</surname><given-names>DN</given-names></name><name><surname>Hanspers</surname><given-names>K</given-names></name><name><surname>A Miller</surname><given-names>R</given-names></name><name><surname>Digles</surname><given-names>D</given-names></name><name><surname>Lopes</surname><given-names>EN</given-names></name><name><surname>Ehrhart</surname><given-names>F</given-names></name><name><surname>Dupuis</surname><given-names>LJ</given-names></name><name><surname>Winckers</surname><given-names>LA</given-names></name><name><surname>Coort</surname><given-names>SL</given-names></name><name><surname>Willighagen</surname><given-names>EL</given-names></name><name><surname>Evelo</surname><given-names>CT</given-names></name><name><surname>Pico</surname><given-names>AR</given-names></name><name><surname>Kutmon</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>WikiPathways: connecting communities</article-title><source>Nucleic Acids Research</source><volume>49</volume><fpage>D613</fpage><lpage>D621</lpage><pub-id pub-id-type="doi">10.1093/nar/gkaa1024</pub-id><pub-id pub-id-type="pmid">33211851</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Cutadapt removes adapter sequences from high-throughput sequencing reads</article-title><source>EMBnet</source><volume>17</volume><elocation-id>10</elocation-id><pub-id pub-id-type="doi">10.14806/ej.17.1.200</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLean</surname><given-names>CY</given-names></name><name><surname>Bristor</surname><given-names>D</given-names></name><name><surname>Hiller</surname><given-names>M</given-names></name><name><surname>Clarke</surname><given-names>SL</given-names></name><name><surname>Schaar</surname><given-names>BT</given-names></name><name><surname>Lowe</surname><given-names>CB</given-names></name><name><surname>Wenger</surname><given-names>AM</given-names></name><name><surname>Bejerano</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>GREAT improves functional interpretation of cis-regulatory regions</article-title><source>Nature Biotechnology</source><volume>28</volume><fpage>495</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1038/nbt.1630</pub-id><pub-id pub-id-type="pmid">20436461</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meers</surname><given-names>MP</given-names></name><name><surname>Bryson</surname><given-names>TD</given-names></name><name><surname>Henikoff</surname><given-names>JG</given-names></name><name><surname>Henikoff</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Improved CUT&amp;RUN chromatin profiling tools</article-title><source>eLife</source><volume>8</volume><elocation-id>e46314</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.46314</pub-id><pub-id pub-id-type="pmid">31232687</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minucci</surname><given-names>S</given-names></name><name><surname>Pelicci</surname><given-names>PG</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer</article-title><source>Nature Reviews. Cancer</source><volume>6</volume><fpage>38</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1038/nrc1779</pub-id><pub-id pub-id-type="pmid">16397526</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyahara</surname><given-names>H</given-names></name><name><surname>Yadavilli</surname><given-names>S</given-names></name><name><surname>Natsumeda</surname><given-names>M</given-names></name><name><surname>Rubens</surname><given-names>JA</given-names></name><name><surname>Rodgers</surname><given-names>L</given-names></name><name><surname>Kambhampati</surname><given-names>M</given-names></name><name><surname>Taylor</surname><given-names>IC</given-names></name><name><surname>Kaur</surname><given-names>H</given-names></name><name><surname>Asnaghi</surname><given-names>L</given-names></name><name><surname>Eberhart</surname><given-names>CG</given-names></name><name><surname>Warren</surname><given-names>KE</given-names></name><name><surname>Nazarian</surname><given-names>J</given-names></name><name><surname>Raabe</surname><given-names>EH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma</article-title><source>Cancer Letters</source><volume>400</volume><fpage>110</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2017.04.019</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammad</surname><given-names>F</given-names></name><name><surname>Weissmann</surname><given-names>S</given-names></name><name><surname>Leblanc</surname><given-names>B</given-names></name><name><surname>Pandey</surname><given-names>DP</given-names></name><name><surname>Højfeldt</surname><given-names>JW</given-names></name><name><surname>Comet</surname><given-names>I</given-names></name><name><surname>Zheng</surname><given-names>C</given-names></name><name><surname>Johansen</surname><given-names>JV</given-names></name><name><surname>Rapin</surname><given-names>N</given-names></name><name><surname>Porse</surname><given-names>BT</given-names></name><name><surname>Tvardovskiy</surname><given-names>A</given-names></name><name><surname>Jensen</surname><given-names>ON</given-names></name><name><surname>Olaciregui</surname><given-names>NG</given-names></name><name><surname>Lavarino</surname><given-names>C</given-names></name><name><surname>Suñol</surname><given-names>M</given-names></name><name><surname>de Torres</surname><given-names>C</given-names></name><name><surname>Mora</surname><given-names>J</given-names></name><name><surname>Carcaboso</surname><given-names>AM</given-names></name><name><surname>Helin</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas</article-title><source>Nature Medicine</source><volume>23</volume><fpage>483</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1038/nm.4293</pub-id><pub-id pub-id-type="pmid">28263309</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Lindgren</surname><given-names>CM</given-names></name><name><surname>Eriksson</surname><given-names>K-F</given-names></name><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Sihag</surname><given-names>S</given-names></name><name><surname>Lehar</surname><given-names>J</given-names></name><name><surname>Puigserver</surname><given-names>P</given-names></name><name><surname>Carlsson</surname><given-names>E</given-names></name><name><surname>Ridderstråle</surname><given-names>M</given-names></name><name><surname>Laurila</surname><given-names>E</given-names></name><name><surname>Houstis</surname><given-names>N</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>Patterson</surname><given-names>N</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Spiegelman</surname><given-names>B</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Hirschhorn</surname><given-names>JN</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name><name><surname>Groop</surname><given-names>LC</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes</article-title><source>Nature Genetics</source><volume>34</volume><fpage>267</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1038/ng1180</pub-id><pub-id pub-id-type="pmid">12808457</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mure</surname><given-names>H</given-names></name><name><surname>Matsuzaki</surname><given-names>K</given-names></name><name><surname>Kitazato</surname><given-names>KT</given-names></name><name><surname>Mizobuchi</surname><given-names>Y</given-names></name><name><surname>Kuwayama</surname><given-names>K</given-names></name><name><surname>Kageji</surname><given-names>T</given-names></name><name><surname>Nagahiro</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Akt2 and Akt3 play a pivotal role in malignant gliomas</article-title><source>Neuro-Oncology</source><volume>12</volume><fpage>221</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1093/neuonc/nop026</pub-id><pub-id pub-id-type="pmid">20167810</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagaraja</surname><given-names>S</given-names></name><name><surname>Vitanza</surname><given-names>NA</given-names></name><name><surname>Woo</surname><given-names>PJ</given-names></name><name><surname>Taylor</surname><given-names>KR</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Meng</surname><given-names>W</given-names></name><name><surname>Ponnuswami</surname><given-names>A</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Hulleman</surname><given-names>E</given-names></name><name><surname>Swigut</surname><given-names>T</given-names></name><name><surname>Wysocka</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Monje</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Transcriptional dependencies in diffuse intrinsic pontine glioma</article-title><source>Cancer Cell</source><volume>31</volume><fpage>635</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2017.03.011</pub-id><pub-id pub-id-type="pmid">28434841</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagaraja</surname><given-names>S</given-names></name><name><surname>Quezada</surname><given-names>MA</given-names></name><name><surname>Gillespie</surname><given-names>SM</given-names></name><name><surname>Arzt</surname><given-names>M</given-names></name><name><surname>Lennon</surname><given-names>JJ</given-names></name><name><surname>Woo</surname><given-names>PJ</given-names></name><name><surname>Hovestadt</surname><given-names>V</given-names></name><name><surname>Kambhampati</surname><given-names>M</given-names></name><name><surname>Filbin</surname><given-names>MG</given-names></name><name><surname>Suva</surname><given-names>ML</given-names></name><name><surname>Nazarian</surname><given-names>J</given-names></name><name><surname>Monje</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Histone variant and cell context determine H3K27M reprogramming of the enhancer landscape and oncogenic state</article-title><source>Molecular Cell</source><volume>76</volume><fpage>965</fpage><lpage>980</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2019.08.030</pub-id><pub-id pub-id-type="pmid">31588023</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oster</surname><given-names>SK</given-names></name><name><surname>Ho</surname><given-names>CSW</given-names></name><name><surname>Soucie</surname><given-names>EL</given-names></name><name><surname>Penn</surname><given-names>LZ</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The myc oncogene: MarvelouslY complex</article-title><source>Advances in Cancer Research</source><volume>84</volume><fpage>81</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1016/s0065-230x(02)84004-0</pub-id><pub-id pub-id-type="pmid">11885563</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ostrom</surname><given-names>QT</given-names></name><name><surname>Gittleman</surname><given-names>H</given-names></name><name><surname>Fulop</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Blanda</surname><given-names>R</given-names></name><name><surname>Kromer</surname><given-names>C</given-names></name><name><surname>Wolinsky</surname><given-names>Y</given-names></name><name><surname>Kruchko</surname><given-names>C</given-names></name><name><surname>Barnholtz-Sloan</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012</article-title><source>Neuro-Oncology</source><volume>17</volume><fpage>iv1</fpage><lpage>iv62</lpage><pub-id pub-id-type="doi">10.1093/neuonc/nov189</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pajovic</surname><given-names>S</given-names></name><name><surname>Siddaway</surname><given-names>R</given-names></name><name><surname>Bridge</surname><given-names>T</given-names></name><name><surname>Sheth</surname><given-names>J</given-names></name><name><surname>Rakopoulos</surname><given-names>P</given-names></name><name><surname>Kim</surname><given-names>B</given-names></name><name><surname>Ryall</surname><given-names>S</given-names></name><name><surname>Agnihotri</surname><given-names>S</given-names></name><name><surname>Phillips</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Milos</surname><given-names>S</given-names></name><name><surname>Patel</surname><given-names>P</given-names></name><name><surname>Srikanthan</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>A</given-names></name><name><surname>Hawkins</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Epigenetic activation of a RAS/MYC axis in H3.3K27M-driven cancer</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>6216</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-19972-7</pub-id><pub-id pub-id-type="pmid">33277484</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panditharatna</surname><given-names>E</given-names></name><name><surname>Yaeger</surname><given-names>K</given-names></name><name><surname>Kilburn</surname><given-names>LB</given-names></name><name><surname>Packer</surname><given-names>RJ</given-names></name><name><surname>Nazarian</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Clinicopathology of diffuse intrinsic pontine glioma and its redefined genomic and epigenomic landscape</article-title><source>Cancer Genetics</source><volume>208</volume><fpage>367</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1016/j.cancergen.2015.04.008</pub-id><pub-id pub-id-type="pmid">26206682</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pelengaris</surname><given-names>S</given-names></name><name><surname>Khan</surname><given-names>M</given-names></name><name><surname>Evan</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>c-MYC: more than just a matter of life and death</article-title><source>Nature Reviews. Cancer</source><volume>2</volume><fpage>764</fpage><lpage>776</lpage><pub-id pub-id-type="doi">10.1038/nrc904</pub-id><pub-id pub-id-type="pmid">12360279</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Mei</surname><given-names>W</given-names></name><name><surname>Zeng</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>PI3K/Akt/mTOR pathway and its role in cancer therapeutics: are we making headway?</article-title><source>Frontiers in Oncology</source><volume>12</volume><elocation-id>819128</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2022.819128</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinch</surname><given-names>BJ</given-names></name><name><surname>Doctor</surname><given-names>ZM</given-names></name><name><surname>Nabet</surname><given-names>B</given-names></name><name><surname>Browne</surname><given-names>CM</given-names></name><name><surname>Seo</surname><given-names>H-S</given-names></name><name><surname>Mohardt</surname><given-names>ML</given-names></name><name><surname>Kozono</surname><given-names>S</given-names></name><name><surname>Lian</surname><given-names>X</given-names></name><name><surname>Manz</surname><given-names>TD</given-names></name><name><surname>Chun</surname><given-names>Y</given-names></name><name><surname>Kibe</surname><given-names>S</given-names></name><name><surname>Zaidman</surname><given-names>D</given-names></name><name><surname>Daitchman</surname><given-names>D</given-names></name><name><surname>Yeoh</surname><given-names>ZC</given-names></name><name><surname>Vangos</surname><given-names>NE</given-names></name><name><surname>Geffken</surname><given-names>EA</given-names></name><name><surname>Tan</surname><given-names>L</given-names></name><name><surname>Ficarro</surname><given-names>SB</given-names></name><name><surname>London</surname><given-names>N</given-names></name><name><surname>Marto</surname><given-names>JA</given-names></name><name><surname>Buratowski</surname><given-names>S</given-names></name><name><surname>Dhe-Paganon</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>XZ</given-names></name><name><surname>Lu</surname><given-names>KP</given-names></name><name><surname>Gray</surname><given-names>NS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Identification of a potent and selective covalent Pin1 inhibitor</article-title><source>Nature Chemical Biology</source><volume>16</volume><fpage>979</fpage><lpage>987</lpage><pub-id pub-id-type="doi">10.1038/s41589-020-0550-9</pub-id><pub-id pub-id-type="pmid">32483379</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piunti</surname><given-names>A</given-names></name><name><surname>Hashizume</surname><given-names>R</given-names></name><name><surname>Morgan</surname><given-names>MA</given-names></name><name><surname>Bartom</surname><given-names>ET</given-names></name><name><surname>Horbinski</surname><given-names>CM</given-names></name><name><surname>Marshall</surname><given-names>SA</given-names></name><name><surname>Rendleman</surname><given-names>EJ</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Takahashi</surname><given-names>Y-H</given-names></name><name><surname>Woodfin</surname><given-names>AR</given-names></name><name><surname>Misharin</surname><given-names>AV</given-names></name><name><surname>Abshiru</surname><given-names>NA</given-names></name><name><surname>Lulla</surname><given-names>RR</given-names></name><name><surname>Saratsis</surname><given-names>AM</given-names></name><name><surname>Kelleher</surname><given-names>NL</given-names></name><name><surname>James</surname><given-names>CD</given-names></name><name><surname>Shilatifard</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas</article-title><source>Nature Medicine</source><volume>23</volume><fpage>493</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1038/nm.4296</pub-id><pub-id pub-id-type="pmid">28263307</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poole</surname><given-names>CJ</given-names></name><name><surname>van Riggelen</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>MYC-master regulator of the cancer epigenome and transcriptome</article-title><source>Genes</source><volume>8</volume><elocation-id>142</elocation-id><pub-id pub-id-type="doi">10.3390/genes8050142</pub-id><pub-id pub-id-type="pmid">28505071</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinlan</surname><given-names>AR</given-names></name><name><surname>Hall</surname><given-names>IM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>BEDTools: a flexible suite of utilities for comparing genomic features</article-title><source>Bioinformatics</source><volume>26</volume><fpage>841</fpage><lpage>842</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btq033</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramírez</surname><given-names>F</given-names></name><name><surname>Ryan</surname><given-names>DP</given-names></name><name><surname>Grüning</surname><given-names>B</given-names></name><name><surname>Bhardwaj</surname><given-names>V</given-names></name><name><surname>Kilpert</surname><given-names>F</given-names></name><name><surname>Richter</surname><given-names>AS</given-names></name><name><surname>Heyne</surname><given-names>S</given-names></name><name><surname>Dündar</surname><given-names>F</given-names></name><name><surname>Manke</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>deepTools2: a next generation web server for deep-sequencing data analysis</article-title><source>Nucleic Acids Research</source><volume>44</volume><fpage>W160</fpage><lpage>W165</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw257</pub-id><pub-id pub-id-type="pmid">27079975</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rascio</surname><given-names>F</given-names></name><name><surname>Spadaccino</surname><given-names>F</given-names></name><name><surname>Rocchetti</surname><given-names>MT</given-names></name><name><surname>Castellano</surname><given-names>G</given-names></name><name><surname>Stallone</surname><given-names>G</given-names></name><name><surname>Netti</surname><given-names>GS</given-names></name><name><surname>Ranieri</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The pathogenic role of PI3K/AKT pathway in cancer onset and drug resistance: an updated review</article-title><source>Cancers</source><volume>13</volume><elocation-id>3949</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13163949</pub-id><pub-id pub-id-type="pmid">34439105</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raudvere</surname><given-names>U</given-names></name><name><surname>Kolberg</surname><given-names>L</given-names></name><name><surname>Kuzmin</surname><given-names>I</given-names></name><name><surname>Arak</surname><given-names>T</given-names></name><name><surname>Adler</surname><given-names>P</given-names></name><name><surname>Peterson</surname><given-names>H</given-names></name><name><surname>Vilo</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>G:Profiler: A web server for functional enrichment analysis and conversions of gene lists (2019 update)</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>W191</fpage><lpage>W198</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz369</pub-id><pub-id pub-id-type="pmid">31066453</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raychaudhuri</surname><given-names>B</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>T</given-names></name><name><surname>Vogelbaum</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Aberrant constitutive activation of nuclear factor κB in glioblastoma multiforme drives invasive phenotype</article-title><source>Journal of Neuro-Oncology</source><volume>85</volume><fpage>39</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1007/s11060-007-9390-7</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlee</surname><given-names>M</given-names></name><name><surname>Schuhmacher</surname><given-names>M</given-names></name><name><surname>Hölzel</surname><given-names>M</given-names></name><name><surname>Laux</surname><given-names>G</given-names></name><name><surname>Bornkamm</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>c-MYC impairs immunogenicity of human B cells</article-title><source>Advances in Cancer Research</source><volume>97</volume><fpage>167</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1016/S0065-230X(06)97007-9</pub-id><pub-id pub-id-type="pmid">17419945</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>EV</given-names></name><name><surname>Ravitz</surname><given-names>MJ</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Lynch</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Growth controls connect: interactions between c-myc and the tuberous sclerosis complex-mTOR pathway</article-title><source>Cell Cycle</source><volume>8</volume><fpage>1344</fpage><lpage>1351</lpage><pub-id pub-id-type="doi">10.4161/cc.8.9.8215</pub-id><pub-id pub-id-type="pmid">19342893</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuettengruber</surname><given-names>B</given-names></name><name><surname>Bourbon</surname><given-names>H-M</given-names></name><name><surname>Di Croce</surname><given-names>L</given-names></name><name><surname>Cavalli</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genome regulation by polycomb and trithorax: 70 years and counting</article-title><source>Cell</source><volume>171</volume><fpage>34</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.08.002</pub-id><pub-id pub-id-type="pmid">28938122</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartzentruber</surname><given-names>J</given-names></name><name><surname>Korshunov</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>X-Y</given-names></name><name><surname>Jones</surname><given-names>DTW</given-names></name><name><surname>Pfaff</surname><given-names>E</given-names></name><name><surname>Jacob</surname><given-names>K</given-names></name><name><surname>Sturm</surname><given-names>D</given-names></name><name><surname>Fontebasso</surname><given-names>AM</given-names></name><name><surname>Quang</surname><given-names>D-AK</given-names></name><name><surname>Tönjes</surname><given-names>M</given-names></name><name><surname>Hovestadt</surname><given-names>V</given-names></name><name><surname>Albrecht</surname><given-names>S</given-names></name><name><surname>Kool</surname><given-names>M</given-names></name><name><surname>Nantel</surname><given-names>A</given-names></name><name><surname>Konermann</surname><given-names>C</given-names></name><name><surname>Lindroth</surname><given-names>A</given-names></name><name><surname>Jäger</surname><given-names>N</given-names></name><name><surname>Rausch</surname><given-names>T</given-names></name><name><surname>Ryzhova</surname><given-names>M</given-names></name><name><surname>Korbel</surname><given-names>JO</given-names></name><name><surname>Hielscher</surname><given-names>T</given-names></name><name><surname>Hauser</surname><given-names>P</given-names></name><name><surname>Garami</surname><given-names>M</given-names></name><name><surname>Klekner</surname><given-names>A</given-names></name><name><surname>Bognar</surname><given-names>L</given-names></name><name><surname>Ebinger</surname><given-names>M</given-names></name><name><surname>Schuhmann</surname><given-names>MU</given-names></name><name><surname>Scheurlen</surname><given-names>W</given-names></name><name><surname>Pekrun</surname><given-names>A</given-names></name><name><surname>Frühwald</surname><given-names>MC</given-names></name><name><surname>Roggendorf</surname><given-names>W</given-names></name><name><surname>Kramm</surname><given-names>C</given-names></name><name><surname>Dürken</surname><given-names>M</given-names></name><name><surname>Atkinson</surname><given-names>J</given-names></name><name><surname>Lepage</surname><given-names>P</given-names></name><name><surname>Montpetit</surname><given-names>A</given-names></name><name><surname>Zakrzewska</surname><given-names>M</given-names></name><name><surname>Zakrzewski</surname><given-names>K</given-names></name><name><surname>Liberski</surname><given-names>PP</given-names></name><name><surname>Dong</surname><given-names>Z</given-names></name><name><surname>Siegel</surname><given-names>P</given-names></name><name><surname>Kulozik</surname><given-names>AE</given-names></name><name><surname>Zapatka</surname><given-names>M</given-names></name><name><surname>Guha</surname><given-names>A</given-names></name><name><surname>Malkin</surname><given-names>D</given-names></name><name><surname>Felsberg</surname><given-names>J</given-names></name><name><surname>Reifenberger</surname><given-names>G</given-names></name><name><surname>von Deimling</surname><given-names>A</given-names></name><name><surname>Ichimura</surname><given-names>K</given-names></name><name><surname>Collins</surname><given-names>VP</given-names></name><name><surname>Witt</surname><given-names>H</given-names></name><name><surname>Milde</surname><given-names>T</given-names></name><name><surname>Witt</surname><given-names>O</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Castelo-Branco</surname><given-names>P</given-names></name><name><surname>Lichter</surname><given-names>P</given-names></name><name><surname>Faury</surname><given-names>D</given-names></name><name><surname>Tabori</surname><given-names>U</given-names></name><name><surname>Plass</surname><given-names>C</given-names></name><name><surname>Majewski</surname><given-names>J</given-names></name><name><surname>Pfister</surname><given-names>SM</given-names></name><name><surname>Jabado</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma</article-title><source>Nature</source><volume>482</volume><fpage>226</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1038/nature10833</pub-id><pub-id pub-id-type="pmid">22286061</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>See</surname><given-names>YX</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Fullwood</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title><italic>MYC</italic> overexpression leads to increased chromatin interactions at super-enhancers and MYC binding sites</article-title><source>Genome Research</source><volume>32</volume><fpage>629</fpage><lpage>642</lpage><pub-id pub-id-type="doi">10.1101/gr.276313.121</pub-id><pub-id pub-id-type="pmid">35115371</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shamloo</surname><given-names>B</given-names></name><name><surname>Usluer</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>P21 in cancer research</article-title><source>Cancers</source><volume>11</volume><elocation-id>1178</elocation-id><pub-id pub-id-type="doi">10.3390/cancers11081178</pub-id><pub-id pub-id-type="pmid">31416295</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shema</surname><given-names>E</given-names></name><name><surname>Jones</surname><given-names>D</given-names></name><name><surname>Shoresh</surname><given-names>N</given-names></name><name><surname>Donohue</surname><given-names>L</given-names></name><name><surname>Ram</surname><given-names>O</given-names></name><name><surname>Bernstein</surname><given-names>BE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Single-molecule decoding of combinatorially modified nucleosomes</article-title><source>Science</source><volume>352</volume><fpage>717</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.1126/science.aad7701</pub-id><pub-id pub-id-type="pmid">27151869</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Shao</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Nestler</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>ngs.plot: Quick mining and visualization of next-generation sequencing data by integrating genomic databases</article-title><source>BMC Genomics</source><volume>15</volume><elocation-id>284</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2164-15-284</pub-id><pub-id pub-id-type="pmid">24735413</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skene</surname><given-names>PJ</given-names></name><name><surname>Henikoff</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>An efficient targeted nuclease strategy for high-resolution mapping of DNA binding sites</article-title><source>eLife</source><volume>6</volume><elocation-id>e21856</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.21856</pub-id><pub-id pub-id-type="pmid">28079019</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sodi</surname><given-names>VL</given-names></name><name><surname>Khaku</surname><given-names>S</given-names></name><name><surname>Krutilina</surname><given-names>R</given-names></name><name><surname>Schwab</surname><given-names>LP</given-names></name><name><surname>Vocadlo</surname><given-names>DJ</given-names></name><name><surname>Seagroves</surname><given-names>TN</given-names></name><name><surname>Reginato</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>MTOR/MYC axis regulates O-GlcNAc transferase expression and O-GlcNAcylation in breast cancer</article-title><source>Molecular Cancer Research</source><volume>13</volume><fpage>923</fpage><lpage>933</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-14-0536</pub-id><pub-id pub-id-type="pmid">25636967</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srikanthan</surname><given-names>D</given-names></name><name><surname>Taccone</surname><given-names>MS</given-names></name><name><surname>Van Ommeren</surname><given-names>R</given-names></name><name><surname>Ishida</surname><given-names>J</given-names></name><name><surname>Krumholtz</surname><given-names>SL</given-names></name><name><surname>Rutka</surname><given-names>JT</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Diffuse intrinsic pontine glioma: current insights and future directions</article-title><source>Chinese Neurosurgical Journal</source><volume>7</volume><elocation-id>00218-w</elocation-id><pub-id pub-id-type="doi">10.1186/s41016-020-00218-w</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stafford</surname><given-names>JM</given-names></name><name><surname>Lee</surname><given-names>C-H</given-names></name><name><surname>Voigt</surname><given-names>P</given-names></name><name><surname>Descostes</surname><given-names>N</given-names></name><name><surname>Saldaña-Meyer</surname><given-names>R</given-names></name><name><surname>Yu</surname><given-names>J-R</given-names></name><name><surname>Leroy</surname><given-names>G</given-names></name><name><surname>Oksuz</surname><given-names>O</given-names></name><name><surname>Chapman</surname><given-names>JR</given-names></name><name><surname>Suarez</surname><given-names>F</given-names></name><name><surname>Modrek</surname><given-names>AS</given-names></name><name><surname>Bayin</surname><given-names>NS</given-names></name><name><surname>Placantonakis</surname><given-names>DG</given-names></name><name><surname>Karajannis</surname><given-names>MA</given-names></name><name><surname>Snuderl</surname><given-names>M</given-names></name><name><surname>Ueberheide</surname><given-names>B</given-names></name><name><surname>Reinberg</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Multiple modes of PRC2 inhibition elicit global chromatin alterations in H3K27M pediatric glioma</article-title><source>Science Advances</source><volume>4</volume><elocation-id>eaau5935</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.aau5935</pub-id><pub-id pub-id-type="pmid">30402543</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>JM</given-names></name><name><surname>Kilburn</surname><given-names>LB</given-names></name><name><surname>Mansur</surname><given-names>DB</given-names></name><name><surname>Krailo</surname><given-names>M</given-names></name><name><surname>Buxton</surname><given-names>A</given-names></name><name><surname>Adekunle</surname><given-names>A</given-names></name><name><surname>Gajjar</surname><given-names>A</given-names></name><name><surname>Adamson</surname><given-names>PC</given-names></name><name><surname>Weigel</surname><given-names>B</given-names></name><name><surname>Fox</surname><given-names>E</given-names></name><name><surname>Blaney</surname><given-names>SM</given-names></name><name><surname>Fouladi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: a children’s oncology group report</article-title><source>Neuro-Oncology</source><volume>24</volume><fpage>655</fpage><lpage>664</lpage><pub-id pub-id-type="doi">10.1093/neuonc/noab188</pub-id><pub-id pub-id-type="pmid">34347089</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Gillette</surname><given-names>MA</given-names></name><name><surname>Paulovich</surname><given-names>A</given-names></name><name><surname>Pomeroy</surname><given-names>SL</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>PNAS</source><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tahmasebi</surname><given-names>S</given-names></name><name><surname>Alain</surname><given-names>T</given-names></name><name><surname>Rajasekhar</surname><given-names>VK</given-names></name><name><surname>Zhang</surname><given-names>J-P</given-names></name><name><surname>Prager-Khoutorsky</surname><given-names>M</given-names></name><name><surname>Khoutorsky</surname><given-names>A</given-names></name><name><surname>Dogan</surname><given-names>Y</given-names></name><name><surname>Gkogkas</surname><given-names>CG</given-names></name><name><surname>Petroulakis</surname><given-names>E</given-names></name><name><surname>Sylvestre</surname><given-names>A</given-names></name><name><surname>Ghorbani</surname><given-names>M</given-names></name><name><surname>Assadian</surname><given-names>S</given-names></name><name><surname>Yamanaka</surname><given-names>Y</given-names></name><name><surname>Vinagolu-Baur</surname><given-names>JR</given-names></name><name><surname>Teodoro</surname><given-names>JG</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>X-J</given-names></name><name><surname>Sonenberg</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Multifaceted regulation of somatic cell reprogramming by mRNA translational control</article-title><source>Cell Stem Cell</source><volume>14</volume><fpage>606</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2014.02.005</pub-id><pub-id pub-id-type="pmid">24630793</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>P</given-names></name><name><surname>Steck</surname><given-names>PA</given-names></name><name><surname>Yung</surname><given-names>WKA</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>The autocrine loop of TGF-alpha/EGFR and brain tumors</article-title><source>Journal of Neuro-Oncology</source><volume>35</volume><fpage>303</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1023/a:1005824802617</pub-id><pub-id pub-id-type="pmid">9440027</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teng</surname><given-names>SC</given-names></name><name><surname>Chen</surname><given-names>YY</given-names></name><name><surname>Su</surname><given-names>YN</given-names></name><name><surname>Chou</surname><given-names>PC</given-names></name><name><surname>Chiang</surname><given-names>YC</given-names></name><name><surname>Tseng</surname><given-names>SF</given-names></name><name><surname>Wu</surname><given-names>KJ</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Direct activation of HSP90A transcription by c-Myc contributes to c-Myc-induced transformation</article-title><source>The Journal of Biological Chemistry</source><volume>279</volume><fpage>14649</fpage><lpage>14655</lpage><pub-id pub-id-type="doi">10.1074/jbc.M308842200</pub-id><pub-id pub-id-type="pmid">14724288</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsoli</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Franshaw</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Cheng</surname><given-names>C</given-names></name><name><surname>Jung</surname><given-names>M</given-names></name><name><surname>Joshi</surname><given-names>S</given-names></name><name><surname>Ehteda</surname><given-names>A</given-names></name><name><surname>Khan</surname><given-names>A</given-names></name><name><surname>Montero-Carcabosso</surname><given-names>A</given-names></name><name><surname>Dilda</surname><given-names>PJ</given-names></name><name><surname>Hogg</surname><given-names>P</given-names></name><name><surname>Ziegler</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Dual targeting of mitochondrial function and mTOR pathway as a therapeutic strategy for diffuse intrinsic pontine glioma</article-title><source>Oncotarget</source><volume>9</volume><fpage>7541</fpage><lpage>7556</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.24045</pub-id><pub-id pub-id-type="pmid">29484131</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tu</surname><given-names>Y</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>G</given-names></name><name><surname>Tian</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Activation of JAK/STAT signal pathway predicts poor prognosis of patients with gliomas</article-title><source>Medical Oncology</source><volume>28</volume><fpage>15</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1007/s12032-010-9435-1</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Staveren</surname><given-names>WCG</given-names></name><name><surname>Solís</surname><given-names>DW</given-names></name><name><surname>Delys</surname><given-names>L</given-names></name><name><surname>Venet</surname><given-names>D</given-names></name><name><surname>Cappello</surname><given-names>M</given-names></name><name><surname>Andry</surname><given-names>G</given-names></name><name><surname>Dumont</surname><given-names>JE</given-names></name><name><surname>Libert</surname><given-names>F</given-names></name><name><surname>Detours</surname><given-names>V</given-names></name><name><surname>Maenhaut</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Gene expression in human thyrocytes and autonomous adenomas reveals suppression of negative feedbacks in tumorigenesis</article-title><source>PNAS</source><volume>103</volume><fpage>413</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1073/pnas.0507354102</pub-id><pub-id pub-id-type="pmid">16381821</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkatesh</surname><given-names>HS</given-names></name><name><surname>Morishita</surname><given-names>W</given-names></name><name><surname>Geraghty</surname><given-names>AC</given-names></name><name><surname>Silverbush</surname><given-names>D</given-names></name><name><surname>Gillespie</surname><given-names>SM</given-names></name><name><surname>Arzt</surname><given-names>M</given-names></name><name><surname>Tam</surname><given-names>LT</given-names></name><name><surname>Espenel</surname><given-names>C</given-names></name><name><surname>Ponnuswami</surname><given-names>A</given-names></name><name><surname>Ni</surname><given-names>L</given-names></name><name><surname>Woo</surname><given-names>PJ</given-names></name><name><surname>Taylor</surname><given-names>KR</given-names></name><name><surname>Agarwal</surname><given-names>A</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name><name><surname>Brang</surname><given-names>D</given-names></name><name><surname>Vogel</surname><given-names>H</given-names></name><name><surname>Hervey-Jumper</surname><given-names>S</given-names></name><name><surname>Bergles</surname><given-names>DE</given-names></name><name><surname>Suvà</surname><given-names>ML</given-names></name><name><surname>Malenka</surname><given-names>RC</given-names></name><name><surname>Monje</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Electrical and synaptic integration of glioma into neural circuits</article-title><source>Nature</source><volume>573</volume><fpage>539</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1563-y</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Yin</surname><given-names>J</given-names></name><name><surname>Gan</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Gu</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Alternative approaches to target Myc for cancer treatment</article-title><source>Signal Transduction and Targeted Therapy</source><volume>6</volume><elocation-id>117</elocation-id><pub-id pub-id-type="doi">10.1038/s41392-021-00500-y</pub-id><pub-id pub-id-type="pmid">33692331</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warren</surname><given-names>KE</given-names></name><name><surname>Killian</surname><given-names>K</given-names></name><name><surname>Suuriniemi</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Quezado</surname><given-names>M</given-names></name><name><surname>Meltzer</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Genomic aberrations in pediatric diffuse intrinsic pontine gliomas</article-title><source>Neuro-Oncology</source><volume>14</volume><fpage>326</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1093/neuonc/nor190</pub-id><pub-id pub-id-type="pmid">22064882</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>G</given-names></name><name><surname>Twomey</surname><given-names>D</given-names></name><name><surname>Lamb</surname><given-names>J</given-names></name><name><surname>Schlis</surname><given-names>K</given-names></name><name><surname>Agarwal</surname><given-names>J</given-names></name><name><surname>Stam</surname><given-names>RW</given-names></name><name><surname>Opferman</surname><given-names>JT</given-names></name><name><surname>Sallan</surname><given-names>SE</given-names></name><name><surname>den Boer</surname><given-names>ML</given-names></name><name><surname>Pieters</surname><given-names>R</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Armstrong</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance</article-title><source>Cancer Cell</source><volume>10</volume><fpage>331</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2006.09.006</pub-id><pub-id pub-id-type="pmid">17010674</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>West</surname><given-names>AJ</given-names></name><name><surname>Tsui</surname><given-names>V</given-names></name><name><surname>Stylli</surname><given-names>SS</given-names></name><name><surname>Nguyen</surname><given-names>HPT</given-names></name><name><surname>Morokoff</surname><given-names>AP</given-names></name><name><surname>Kaye</surname><given-names>AH</given-names></name><name><surname>Luwor</surname><given-names>RB</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The role of interleukin-6-STAT3 signalling in glioblastoma</article-title><source>Oncology Letters</source><volume>16</volume><fpage>4095</fpage><lpage>4104</lpage><pub-id pub-id-type="doi">10.3892/ol.2018.9227</pub-id><pub-id pub-id-type="pmid">30250528</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiederschain</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Johnson</surname><given-names>B</given-names></name><name><surname>Bettano</surname><given-names>K</given-names></name><name><surname>Jackson</surname><given-names>D</given-names></name><name><surname>Taraszka</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>YK</given-names></name><name><surname>Jones</surname><given-names>MD</given-names></name><name><surname>Morrissey</surname><given-names>M</given-names></name><name><surname>Deeds</surname><given-names>J</given-names></name><name><surname>Mosher</surname><given-names>R</given-names></name><name><surname>Fordjour</surname><given-names>P</given-names></name><name><surname>Lengauer</surname><given-names>C</given-names></name><name><surname>Benson</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Contribution of polycomb homologues Bmi-1 and Mel-18 to medulloblastoma pathogenesis</article-title><source>Molecular and Cellular Biology</source><volume>27</volume><fpage>4968</fpage><lpage>4979</lpage><pub-id pub-id-type="doi">10.1128/MCB.02244-06</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Broniscer</surname><given-names>A</given-names></name><name><surname>McEachron</surname><given-names>TA</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Paugh</surname><given-names>BS</given-names></name><name><surname>Becksfort</surname><given-names>J</given-names></name><name><surname>Qu</surname><given-names>C</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Huether</surname><given-names>R</given-names></name><name><surname>Parker</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Gajjar</surname><given-names>A</given-names></name><name><surname>Dyer</surname><given-names>MA</given-names></name><name><surname>Mullighan</surname><given-names>CG</given-names></name><name><surname>Gilbertson</surname><given-names>RJ</given-names></name><name><surname>Mardis</surname><given-names>ER</given-names></name><name><surname>Wilson</surname><given-names>RK</given-names></name><name><surname>Downing</surname><given-names>JR</given-names></name><name><surname>Ellison</surname><given-names>DW</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Baker</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas</article-title><source>Nature Genetics</source><volume>44</volume><fpage>251</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1038/ng.1102</pub-id><pub-id pub-id-type="pmid">22286216</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>CREBRF is a potent tumor suppressor of glioblastoma by blocking hypoxia-induced autophagy via the CREB3/ATG5 pathway</article-title><source>International Journal of Oncology</source><volume>49</volume><fpage>519</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.3892/ijo.2016.3576</pub-id><pub-id pub-id-type="pmid">27278737</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yadav</surname><given-names>B</given-names></name><name><surname>Wennerberg</surname><given-names>K</given-names></name><name><surname>Aittokallio</surname><given-names>T</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Searching for drug synergy in complex dose-response landscapes using an interaction potency model</article-title><source>Computational and Structural Biotechnology Journal</source><volume>13</volume><fpage>504</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1016/j.csbj.2015.09.001</pub-id><pub-id pub-id-type="pmid">26949479</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>ES</given-names></name><name><surname>Means</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>PIN1, the cell cycle and cancer</article-title><source>Nature Reviews. Cancer</source><volume>7</volume><fpage>381</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1038/nrc2107</pub-id><pub-id pub-id-type="pmid">17410202</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>D</given-names></name><name><surname>Ong</surname><given-names>JM</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Desmond</surname><given-names>JC</given-names></name><name><surname>Kawamata</surname><given-names>N</given-names></name><name><surname>Konda</surname><given-names>BM</given-names></name><name><surname>Black</surname><given-names>KL</given-names></name><name><surname>Koeffler</surname><given-names>HP</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo</article-title><source>Clinical Cancer Research</source><volume>13</volume><fpage>1045</fpage><lpage>1052</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-1261</pub-id><pub-id pub-id-type="pmid">17289901</pub-id></element-citation></ref><ref id="bib125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>LG</given-names></name><name><surname>He</surname><given-names>QY</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>ChIPseeker: an R/Bioconductor package for ChIP peak annotation, comparison and visualization</article-title><source>Bioinformatics</source><volume>31</volume><fpage>2382</fpage><lpage>2383</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btv145</pub-id><pub-id pub-id-type="pmid">25765347</pub-id></element-citation></ref><ref id="bib126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zarghooni</surname><given-names>M</given-names></name><name><surname>Bartels</surname><given-names>U</given-names></name><name><surname>Lee</surname><given-names>E</given-names></name><name><surname>Buczkowicz</surname><given-names>P</given-names></name><name><surname>Morrison</surname><given-names>A</given-names></name><name><surname>Huang</surname><given-names>A</given-names></name><name><surname>Bouffet</surname><given-names>E</given-names></name><name><surname>Hawkins</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets</article-title><source>Journal of Clinical Oncology</source><volume>28</volume><fpage>1337</fpage><lpage>1344</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.25.5463</pub-id><pub-id pub-id-type="pmid">20142589</pub-id></element-citation></ref><ref id="bib127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Kong</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Hua</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Complex roles of cAMP-PKA-CREB signaling in cancer</article-title><source>Experimental Hematology &amp; Oncology</source><volume>9</volume><elocation-id>32</elocation-id><pub-id pub-id-type="doi">10.1186/s40164-020-00191-1</pub-id><pub-id pub-id-type="pmid">33292604</pub-id></element-citation></ref><ref id="bib128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zoncu</surname><given-names>R</given-names></name><name><surname>Efeyan</surname><given-names>A</given-names></name><name><surname>Sabatini</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>MTOR: from growth signal integration to cancer, diabetes and ageing</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>12</volume><fpage>21</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1038/nrm3025</pub-id><pub-id pub-id-type="pmid">21157483</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.96257.3.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dalal</surname><given-names>Yamini</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>National Cancer Institute</institution><country>United States</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>This work contributes to the study of H3-K27M mutated pediatric gliomas. It <bold>convincingly</bold> demonstrates that the concomitant targeting of histone deacetylases (HDACs) and the transcription factor MYC results in a notable reduction in cell viability and tumor growth. This reduction is linked to the suppression of critical oncogenic pathways, particularly mTOR signaling, emphasizing the role of these pathways in the disease's pathogenesis. The current version of the manuscript is <bold>important</bold> because it unveils a vulnerability from dual targeting HDACs and MYC in the context of pediatric gliomas. This work will be of interest to cancer epigenetics and therapeutics research, with a focus on the neuro-oncology field.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.96257.3.sa1</article-id><title-group><article-title>Reviewer #2 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>This study by Algranati et al. is a important contribution to our understanding of H3-K27M pediatric gliomas. It convincingly demonstrates that the concomitant targeting of histone deacetylases (HDACs) and MYC, through a combination therapy of Sulfopin and Vorinostat, results in a notable reduction in cell viability and tumor growth. This reduction is linked to the suppression of critical oncogenic pathways, particularly mTOR signaling, emphasizing the role of these pathways in the disease's pathogenesis. The manuscript is a step forward in the field, as it unveils a vulnerability from dual targeting HDACs and MYC in the context of pediatric gliomas.</p><p>Comments on revised version</p><p>The authors have nicely explained their rationale for dose selection, treatment timing, and the relationship between MYC expression and sensitivity to the combined treatment. They have also clarified the experimental conditions for the in vitro and in vivo studies, ensuring consistency across the various analyses.</p><p>Overall, the authors have been responsive to the reviewers' comments and have made appropriate revisions to improve the clarity and robustness of their study.</p></body></sub-article><sub-article article-type="author-comment" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.96257.3.sa2</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Algranati</surname><given-names>Danielle</given-names></name><role specific-use="author">Author</role><aff><institution>Weizmann Institute of Science</institution><addr-line><named-content content-type="city">Rehovot</named-content></addr-line><country>Israel</country></aff></contrib><contrib contrib-type="author"><name><surname>Oren</surname><given-names>Roni</given-names></name><role specific-use="author">Author</role><aff><institution>Weizmann Institute of Science</institution><addr-line><named-content content-type="city">Rehovot</named-content></addr-line><country>Israel</country></aff></contrib><contrib contrib-type="author"><name><surname>Dassa</surname><given-names>Bareket</given-names></name><role specific-use="author">Author</role><aff><institution>Weizmann Institute of Science</institution><addr-line><named-content content-type="city">Rehovot</named-content></addr-line><country>Israel</country></aff></contrib><contrib contrib-type="author"><name><surname>Fellus Alyagor</surname><given-names>Liat</given-names></name><role specific-use="author">Author</role><aff><institution>Weizmann Institute of Science</institution><addr-line><named-content content-type="city">Rehovot</named-content></addr-line><country>Israel</country></aff></contrib><contrib contrib-type="author"><name><surname>Plotnikov</surname><given-names>Alexander</given-names></name><role specific-use="author">Author</role><aff><institution>Weizmann Institute of Science</institution><addr-line><named-content content-type="city">Rehovot</named-content></addr-line><country>Israel</country></aff></contrib><contrib contrib-type="author"><name><surname>Barr</surname><given-names>Haim</given-names></name><role specific-use="author">Author</role><aff><institution>Weizmann Institute of Science</institution><addr-line><named-content content-type="city">Rehovot</named-content></addr-line><country>Israel</country></aff></contrib><contrib contrib-type="author"><name><surname>Harmelin</surname><given-names>Alon</given-names></name><role specific-use="author">Author</role><aff><institution>Weizmann Institute of Science</institution><addr-line><named-content content-type="city">Rehovot</named-content></addr-line><country>Israel</country></aff></contrib><contrib contrib-type="author"><name><surname>London</surname><given-names>Nir</given-names></name><role specific-use="author">Author</role><aff><institution>Weizmann Institute of Science</institution><addr-line><named-content content-type="city">Rehovot</named-content></addr-line><country>Israel</country></aff></contrib><contrib contrib-type="author"><name><surname>Ron</surname><given-names>Guy</given-names></name><role specific-use="author">Author</role><aff><institution>Hebrew University of Jerusalem</institution><addr-line><named-content content-type="city">Jerusalem</named-content></addr-line><country>Israel</country></aff></contrib><contrib contrib-type="author"><name><surname>Furth</surname><given-names>Noa</given-names></name><role specific-use="author">Author</role><aff><institution>Weizmann Institute of Science</institution><addr-line><named-content content-type="city">Rehovot</named-content></addr-line><country>Israel</country></aff></contrib><contrib contrib-type="author"><name><surname>Shema</surname><given-names>Efrat</given-names></name><role specific-use="author">Author</role><aff><institution>Weizmann Institute of Science</institution><addr-line><named-content content-type="city">Rehovot</named-content></addr-line><country>Israel</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Public Reviews:</bold></p><p><bold>Reviewer #1 (Public Review):</bold></p><p>Summary:</p><p>This is an interesting study that utilizes a novel epigenome profiling technology (single molecule imaging) in order to demonstrate its utility as a readout of therapeutic response in multiple DIPG cell lines. Two different drugs were evaluated, singly and in combination. Sulfopin, an inhibitor of a component upstream of the MYC pathway, and Vorinostat, an HDAC inhibitor. Both drugs sensitized DIPG cells, but high (&gt;10 micromolar) concentrations were needed to achieve half-maximal effects. The combination seemed to have some efficacy in vivo, but also produced debilitating side-effects that precluded the measurement of any survival benefit.</p></disp-quote><p>We thank the reviewer for deeply evaluating our work and acknowledging the use of multiple experimental strategies to explore the effect of combination therapy on DMG cells. Of note, all mice in our experiment experienced deterioration (including the control mice and those treated with single agents). Thus, it is not the combination of drugs that led to the debilitating side-effects; the mice deteriorated due to the extremely aggressive tumor cells, forming relatively large tumors prior to the treatment onset, calling for further optimization of the therapeutic regime.</p><p>We modified the text in the results section to clarify this point (lines 238-241): “This rapid deterioration is likely a result of the aggressiveness of the transplanted tumors and does not represent side effects of the treatment, as mice from all groups, including the non-treated mice, showed similar signs of deterioration”.</p><p>We also elaborate on this in the discussion (lines 272-276): “Notably, despite a significant reduction in tumor size in-vivo, the combined treatment did not increase mice survival. This is perhaps due to the relatively large tumors already formed at the onset of treatment, leading to rapid deterioration of mice in all experimental groups. Thus, further optimization of the modeling system and therapeutic regime is needed.” We truly hope that further studies will allow better assessment of this drug combination in various models.</p><disp-quote content-type="editor-comment"><p>Strengths:</p><p>Interesting use of a novel epigenome profiling technology (single molecule imaging).</p><p>Weaknesses:</p><p>The use of this novel imaging technology ultimately makes up only a minor part of the study. The rest of the results, i.e. DIPG sensitivity to HDAC and MYC pathway inhibition, have already been demonstrated by others (Grasso Monje 2015; Pajovic Hawkins 2020, among others). The drugs have some interesting opposing effects at the level of the epigenome, demonstrated through CUT&amp;RUN, but this is not unexpected in any way. The drugs evaluated here also didn't have higher efficacy, or efficacy at especially low concentrations, than inhibitors used in previous reports. The combination therapy attempted here also caused severe side effects in mice (dehydration/deterioration), such that an effect on survival could not be determined. I'm not sure this study advances knowledge of targeted therapy approaches in DIPGs, or if it iterates on previous findings to deliver new, or more efficient, mechanistic or therapeutic/pharmaclogic insights. It is a translational report evaluating two drugs singly and in combination, finding that although they sensitise cells in vitro, efficacy in vivo is limited at best, as this particular combination cannot progress to human translation.</p></disp-quote><p>We thank the reviewer for pointing out the strengths and weaknesses of our work. As far as we know, while many studies demonstrated upregulation of the MYC pathway in DIPG, this is the first study that shows inhibition of this pathway (via PIN1) as a therapeutic strategy. While it is clear from the literature that MYC inhibition may pose therapeutic benefit, the development of potent MYC inhibitors is highly challenging due to its structure and cellular localization. Of note, in the 2020 paper, Pajovic and colleagues inhibited MYC by transfecting the cells with a plasmid expressing a specific inhibitory MYC peptide (Omomyc); while this strategy works well for cell cultures, the clinical translation requires different delivery strategies. Sulfopin is a small molecule inhibitor that can be used <italic>in-vivo</italic> and potentially in clinical studies. Thus, we believe that our study offers a novel strategy, as well as mechanistic insights, regarding the potential use of Sulfopin and Vorinostat to treat DIPG.</p><p>As noted above, the combination therapy did not cause side effects, but rather the aggressiveness of the tumors. We did not notice specific toxicity in the mice treated with Sulfopin alone, or the combined treatment. Furthermore, Dubiella et al. extensively examined toxicity issues and did not observe adverse effects or weight loss when administrating Sulfopin in a dose of 40 mg kg–1.</p><p>Optimization of the model and treatment regime (# of cells injected, treatment starting point, etc.) may have allowed us to reveal survival benefits. Yet, these are highly complicated and expensive experiments; unfortunately, we did not have the resources to perform them within the scope of this revision. Importantly, within the current manuscript, we show the effect of this drug combination in reducing the growth of DMG cells <italic>in-vitro</italic> and <italic>in-vivo</italic>, laying the framework for follow-up exploration in future studies. Furthermore, the epigenetic and transcriptomic profiling shed light on the molecular mechanisms that drive these aggressive tumors.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public Review):</bold></p><p>Summary:</p><p>The study by Algranati et al. introduces an exciting and promising therapeutic approach for the treatment of H3-K27M pediatric gliomas, a particularly aggressive brain cancer predominantly affecting children. By exploring the dual targeting of histone deacetylases (HDACs) and MYC activation, the research presents a novel strategy that significantly reduces cell viability and tumor growth in patient-derived glioma cells and xenograft mouse models. This approach, supported by transcriptomic and epigenomic profiling, unveils the potential of combining Sulfopin and Vorinostat to downregulate oncogenic pathways, including the mTOR signaling pathway. While the study offers valuable insights, it would benefit from additional clarification on several points, such as the rationale behind the dosing decisions for the compounds tested, the specific contributions of MYC amplification and H3K27me3 alterations to the observed therapeutic effects, and the details of the treatment protocols employed in both in-vitro and in-vivo experiments.</p></disp-quote><p>We thank the reviewer for evaluating our work and recognizing its potential for the DMG research field. We address in detail below the important comments regarding the treatment protocols and dosing decisions.</p><disp-quote content-type="editor-comment"><p>Clarification is needed on how doses were selected for the compounds in Figure S2A and throughout the study. Understanding the basis for these choices is crucial for interpreting the results and their potential clinical relevance. IC50s are calculated for specific patient derived lines, but it is not clear how these are used for selecting the dose.</p></disp-quote><p>We thank the reviewer for these important comments. For the epigenetic drugs shown in Figure S2A, we followed published experimental setups; for EPZ6438, GSKJ4, Vorinostat and MM-102 we chose the treating concentrations according to Mohammad et al. 2017, Grasso et al. 2015 and Furth et al. 2022, accordingly. For Sulfopin, we conducted a dedicated dose curve analysis (shown in Figure 1E), indicating only a mild effect on viability and relatively high IC-50 values as a single agent. Since we aimed to test the ability of a combined treatment to additively reduce viability, we used a sub-IC50 concentration for Sulfopin in these experiments. We added this information in lines 123 and 131-132.</p><p>Finally, following the results obtained in the experiment shown in Figure S2A, we conducted a full dose-curve analysis of the combined treatment in multiple DMG patient-derived cells (figure 2B and S2C), to identify a combination of concentrations that provides an additive effect (as indicated by BLISS index in figure 2C and S2E). Of note, for downstream analysis of the molecular mechanisms underlying the treatment response (RNAseq and Cut&amp;Run), we intentionally used concentrations that provide an additive BLISS index, but do not completely abolish the culture, to allow for cellular analysis (i.e. 10uM Sulfopin and 1uM Vorinostat).</p><disp-quote content-type="editor-comment"><p>The introduction mentions MYC amplification in high-grade gliomas. It would be beneficial if the authors could delineate whether the models used exhibit varying degrees of MYC amplification and how this factor, alongside differences in H3K27me3, contributes to the observed effects of the treatment.</p></disp-quote><p>The reviewer highlights an important part of our study relating to the MYC-dependent sensitivity of the proposed treatment combination. Since high expression of MYC can be mediated by different molecular mechanisms and not only genomic amplification, we directly quantified mRNA levels of MYC by qPCR (shown in figure S2G) in order to explore its relationship with cellular response to Sulfopin and Vorinostat. Indeed, cultures that express high levels of MYC mRNA were more sensitive to Sulfopin treatment alone (figure S1P) and to the combined treatment (figure 2D-E). We also relate to these findings in lines 103-106 and 142-147 of the results section. Importantly, in cultures that express high levels of MYC (SU-DIPG13 as an example), we see downregulation of MYC targets upon the combined treatment, supporting the notion that this treatment affects viability by attenuation of MYC signaling.</p><disp-quote content-type="editor-comment"><p>In Figure 2A, the authors outline an optimal treatment timing for their in vitro models, which appears to be used throughout the figure. It would be helpful to know how this treatment timing was selected and also why Sulfopin is dosed first (and twice) before the vorinostat. Was this optimized?</p></disp-quote><p>As PIN1 regulates the G2/M transition, its inhibition by Sulfopin delays cell cycle progression (Yeh et al. 2007). Thus, in order to observe a strong viability difference in culture, a prolonged treatment period of 8-9 days is required (Dubiella et al., 2021). To maintain an active concentration of the drug during this long time period, we added a Sulfopin pulse (2nd dose) to achieve a stronger effect on cell viability. We and others noticed that, unlike Sulfopin, the effect of Vorinostat on viability is rapid and can be clearly seen after 2-3 days of treatment. Thus, we added this drug only after the 2nd dose of Sulfopin. We now relate to the mode of action of Sulfopin in lines 79-81.</p><disp-quote content-type="editor-comment"><p>It should be clarified whether the dosing timeline for the combination drug experiments in Figure 3 aligns with that of Figure 2. This information is also important for interpreting the epigenetic and transcriptional profiling and the timing should be discussed if they are administered sequentially (also shown in Figure 2A).I have the same question for the mouse experiments in Figure 4.</p></disp-quote><p>The reviewer is correct that this information is critical for evaluating the results. In order to link the expression changes to the epigenetic changes, we kept the same experimental conditions in both the Cut&amp;Run and RNA-seq experiments (shown in figures 2-3). We added this information to the text in line 184.</p><p>For the <italic>in-vivo</italic> studies of HDAC inhibition (Figure 4), we followed published protocols (Ehteda et al. 2021). In these experiments both drugs were administrated simultaneously every day. We added this information to the text in line 231-232. It may be that changing the admission regime may improve the efficacy of the drug combination, which remains to be tested in future studies.</p><disp-quote content-type="editor-comment"><p>The authors mention that the mice all had severe dehydration and deterioration after 18 days. It would be helpful to know if there were differences in the side effects for different treatment groups? I would expect the combination to be the most severe. This is important in considering the combination treatment.</p></disp-quote><p>As noted in our response to Reviewer #1, all mice in our experiment experienced deterioration (including the control mice and those treated with single agents- we could not observe any differences between the groups). This is due to the extremely aggressive tumor cells, forming relatively large tumors prior to the treatment onset, calling for further optimization of the system and therapeutic regime (# of cell injected, treatment starting point, etc.). Unfortunately, this model is very challenging (especially the injection of cells to the pons of the mice brains, which requires unique expertise and is associated with mortality of some of the mice). Thus, these are highly complicated and expensive experiments; unfortunately, we did not have the resources to repeat and optimize the treatment protocol within the scope of this revision. Of note, Dubiella et al. extensively examined toxicity issues and did not observe adverse effects or weight loss when administrating Sulfopin in a dose of 40 mg kg–1. In our model, the side effects were caused by the tumors rather than the drugs.</p><disp-quote content-type="editor-comment"><p>Minor Points:</p><p>(1) For Figure 1F, reorganizing the bars to directly compare the K27M and KO cell lines at each dose would improve readability of this figure.</p></disp-quote><p>We have changed figure 1F as the reviewer suggested.</p><disp-quote content-type="editor-comment"><p>(2) In Figure 4D, it would be helpful to know how many cells were included (or a minimum included) to calculate the percentages.</p></disp-quote><p>We added the number of H3-K27M positive cells detected per FOV to the figure legend and method section (n=13-198 cells per FOV). Of note, while we analyzed similar-sized FOVs, the number of tumor cells varied between the groups, with the treated group presenting a lower number of H3-K27M cells (due to the effect of the treatment on tumor growth). To account for this difference, we calculated the portion of mTOR-positive cells out of the tumor cells.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Public Review):</bold></p><p>Summary:</p><p>The authors use in vitro grown cells and mouse xenografts to show that a combination of drugs, Sulfopin and Vorinostat, can impact the growth of cells derived from Diffuse midline gliomas, in particular the ones carrying the H3 K27M-mutations (clinically classified as DMG, H3 K27M-mutant). The authors use gene expression studies, and chromatin profiling to attempt to better understand how these drugs exert an effect on genome regulation. Their main findings are that the drugs reduce cell growth in vitro and in mouse xenografts of patient tumours, that DMG, H3 K27M-mutant tumours are particularly sensitive, identify potential markers of gene expression underlying this sensitivity, and broadly characterize the correlations between chromatin modification changes and gene expression upon treatment, identifying putative pathways that may be affected and underlie the sensitive (and thus how the drugs may affect the tumour cell biology).</p><p>Strengths:</p><p>It is a neat, mostly to-the-point work without exploring too many options and possibilities. The authors do a good job not overinterpreting data and speculating too much about the mechanisms, which is a very good thing since the causes and consequences of perturbing such broad epigenetic landscapes of chromatin may be very hard to disentangle. Instead, the authors go straight after testing the performance of the drugs, identifying potential markers and characterizing consequences.</p><p>Weaknesses:</p><p>If anything, the experiments done on Figure 3 could benefit from an additional replicate.</p></disp-quote><p>We thank the reviewer for evaluating our work, and for the positive and insightful comments.</p><disp-quote content-type="editor-comment"><p><bold>Recommendations for the authors:</bold></p><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><p>Perhaps a more substantial drug screen, or CRISPR screen, that utilises single molecule imaging as a readout would identify pharmacologic candidates that are either more effective, or novel.</p></disp-quote><p>While out of scope for the current study, this is a highly interesting suggestion, which will be considered in future studies. Here, we focused on the potential use of the novel MYC inhibitor, Sulfopin. While the dependency of DMG cells on MYC signaling has been documented, to the best of our knowledge, pharmacological inhibition of MYC has not been tested for this disease due to the severe lack of potent MYC inhibitors. We show preliminary evidence for the use of this inhibitor, in combination with HDAC inhibition, to attenuate DMG growth <italic>in-vitro</italic> and <italic>in-vivo</italic>.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>In Figure 1B, it is hard to tell if there are error bars for HSP90 and E2F2. Is there a potential error here? Seems unlikely to not have an error with a RT-qPCR?</p></disp-quote><p>We thank the reviewer for the careful evaluation of the figures. We included error bars for all genes shown in Figure 1B. We have now increased the line width with the hope of making this information more accessible. As stated in the figure legend, these error bars represent the standard deviation of two technical repeats.</p><disp-quote content-type="editor-comment"><p>I noticed that many experiments only had technical replicates. Incorporating biological (independent) replicates, where feasible, would strengthen the study's findings.</p><p>We agree with the reviewer regarding the importance of biological replicates. While some of the panels present error estimates based on technical repeats, the main results were repeated independently with complementary approaches or various biological systems for validation.</p></disp-quote><p>The RNAseq analysis presented in figure 1 was conducted in triplicates and then independently validated by qPCR (Figure 1A-B). Similarly, the transcriptomic analysis presented in figures 2G-I was verified by both western blot (figure 2J) and qPCR (figure S2O). Of note, this later validation was conducted for two different DMG-patient derived cultures.</p><p>To verify the robust effects on cellular viability, we analyzed the response to each drug and the combination on eight different DMG-patient-derived cultures, each representing a completely independent experiment. We show very similar trends in response to treatment between cultures that share the same H3-K27M variant. Thus, while for each culture technical repeats are shown, we provide multiple, independent repeats by examining the different cultures. Similarly, in figure 1F we examined the dependency of Sulfopin treatment on the expression of the H3-K27M oncohistone in two independent isogenic systems.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Recommendations For The Authors):</bold></p><p>A few questions and suggestions:</p><p>(1) To avoid confusion is important to state if the cells used in each experiment are or not K27M mutants (e.g. SU-DIPG13 on line 63).</p></disp-quote><p>We thank the reviewer for pointing this out and have now added this information when appropriate across the manuscript.</p><disp-quote content-type="editor-comment"><p>1. Line 72 - confirming epigenetic silencing of these genes upon PIN1 inhibition (Fig. 1C, S1D)</p><p>Considering that the mechanism of down regulation of MYC targets is likely H3K27me3-independent if it is also happening in DMG H3 K27M-mutants (high H3K27me3 here may rather be a consequence of less MYC binding?), I would strike this sentence out and just point out the correlation between lower expression and higher H3K27me3.</p></disp-quote><p>We agree with the reviewer that the exact molecular mechanism mediating the silencing is yet to be characterized. We have modified the text in line 72 accordingly.</p><disp-quote content-type="editor-comment"><p>1. (line 78) Are MYC targets also down regulated in Sulfopin treated DMG, H3 K27M-mutant lines? Any qPCR or previously done RNA-seq data to use?</p></disp-quote><p>In addition to the extensive analysis done on SU-DIPG13 cells (Figure 1 and S1), in light of the reviewer`s comment we examined specific MYC targets in an additional H3-K27M mutant DMG culture (SU-DIPG6) treated with Sulfopin, followed by qPCR. We observed a mild reduction in two prominent targets, E2F2 and mTOR (new figure S1D). Unfortunately, within this study, we only conducted full RNA-sequencing analysis on SU-DIPG13 cells treated with Sulfopin, and thus, we could not examine the global effect of Sulfopin on the transcriptome of other DMG cultures. This will, of course, be of high interest for future studies.</p></body></sub-article></article>